

Supplementary Information

α -Sulfinyl Benzoates as Precursors to Li- and Mg Carbenoids for the Stereoselective Iterative Homologation of Boronic Esters

Giorgia Casoni, Murat Kucukdisli, James M. Fordham, Matthew Burns, Eddie L. Myers* and
Varinder K. Aggarwal*

School of Chemistry, University of Bristol, Cantock's Close, Bristol BS8 1TS, UK

Contents

1. General Information.....	S2
2. Materials and reagents	S3
3. General Procedures	S3
4. Preparation of Triisopropylbenzoates	S7
5. Preparation of Boronic esters.....	S10
6. Preparation of α -Sulfinyl Benzoates	S10
7. Epimerization of <i>anti</i> -14a to <i>syn</i> -14b (Figure S1)	S42
8. Homologation of Boronic Esters	S44
9. Trapping Experiments.....	S77
10. Determination of Absolute Configuration of Benzoates	S78
11. References.....	S81
12. NMR Spectra	S83

1. General Information

All air- and water-sensitive reactions were carried out in oven-dried or flame-dried glassware under a N₂ atmosphere using standard Schlenk techniques. Analytical TLC was performed on aluminium backed plates pre-coated (0.25 mm) with Merck Silica Gel 60 F254. Compounds were visualized by exposure to UV-light or stained using KMnO₄, *p*-anisaldehyde or phosphomolybdic acid (PMA) followed by heating. Flash column chromatography was performed using Sigma Aldrich silica gel 60 (40-63 μm) or prepacked column (SNAP Ultra columns 10 g, 25 g, 100 g) with automated system (Biotage® Isolera™ One 3.0). All mixed solvent eluents are reported as v/v solutions.

¹H- and ¹³C- Nuclear Magnetic Resonance (NMR) spectra were acquired at various field strengths as indicated using JEOL ECS 300, JEOL ECS 400, Varian 400, Varian VNMR500, Bruker 400 and Bruker Cryo 500 MHz spectrometers. ¹H and ¹³C NMR spectra were referenced internally to the residual non-deuterated solvent signal. ¹H and ¹³C NMR coupling constants are reported in Hertz (Hz). Coupling constants are reported as follows: s = singlet, br. s = broad singlet, d = doublet, t = triplet, q = quartet, quin = quintet, sext = sextet, sept = septet, m = multiplet, dd = doublet of doublet, etc. Assignment of signals in ¹H- and ¹³C-spectra was performed using ¹H-¹H COSY, DEPT, HMQC and HMBC experiments where appropriate. ¹³C signals adjacent to boron are generally not observed due to quadrupolar relaxation.

High resolution mass spectra were recorded on Bruker Daltonics MicroTOF II by using Electronic Ionization (EI) and Electron Spray Ionization (ESI). GC-MS was performed on an Agilent 6890 apparatus. All IR data was obtained on a Perkin-Elmer Spectrum One FT-IR spectrometer. Optical rotations were obtained on a Bellingham and Stanley Ltd. ADP220 polarimeter. Melting point range were determined with a Kofler hot-stage microscope apparatus and are reported uncorrected.

Chiral HPLC was performed using Daicel Chiralpak IA and IB columns (4.6 mm × 250 mm, 5 μm) fitted with the respective guard (4 mm × 10 mm) and monitored by DAD (Diode Array Detector) on an Agilent 1100 system equipped with HP Chemstation/OpenLab software using. Waters HPLC system (Waters system fluidics organizer, Waters 2545 gradient module, and Waters 2998 photodiode array detector) was used for preparative reverse phase separation. Chiral gas chromatography (Chiral GC) was performed on an Agilent 7890A using a Chiraldex β-DP 120 column (30m x 0.25mm x 0.25μm) and a Chiraldex β-DM 120 column (30m x 0.25mm x 0.25μm)

2. Materials and reagents

All reagents were used as received unless otherwise stated. Anhydrous Et₂O, THF, and CH₂Cl₂ were dried using a purification column composed of activated alumina. Anhydrous Et₂O was stored over 3 Å mol sieves. TMEDA and PMDTA were distilled over CaH₂ and stored in a Young's tube under N₂. Diisopropylamine were dried over NaOH before distillation and stored in a Young's tube under N₂. Organolithiums (*n*BuLi, *s*BuLi, and *t*BuLi) reagents were periodically titrated using *N*-benzylbenzamide.¹ *i*PrMgCl•LiCl was titrated using I₂.² Lithium diisopropylamide (LDA) and lithium bis(trimethylsilyl)amide (LiHMDS) solutions were freshly prepared from the corresponding distilled amines and *n*BuLi immediately before use. Basic silica gel was prepared by adding trimethylamine (2 mL) to a slurry of SiO₂ (~100 g) in Et₂O.

(1*S*,2*R*,5*S*)-(+)-Menthyl (*R*)-*p*-toluenesulfinate, (1*R*,2*S*,5*R*)-(–)-menthyl (*S*)-*p*-toluenesulfinate, benzyl bromide, 4-benzyl bromide, 1-chloro-3-iodopropane, 3-bromo-1-(trimethylsilyl)-1-propyne, and ethyl trifluoromethanesulfonate were purchased from Sigma Aldrich.

The following compounds were prepared according to literature procedures and all spectroscopic data matched those previously reported: methyl *p*-toluenesulfinate,³ benzyl iodide,⁴ 1-azido-3-iodopropane,⁵ butyl trifluoromethanesulfonate,⁶ 3,3,3-trifluoropropyl trifluoromethanesulfonate,⁷ ethyl 6-(((trifluoromethyl)sulfonyl)oxy)hexanoate.⁸

3. General Procedures

3.1 General procedure 1 (GP1): Synthesis of *syn* and *anti* 1-(*p*-tolylsulfinyl) 2,4,6-triisopropylbenzoates by transmetalation

To a stirred solution of 2,4,6-triisopropylbenzoate (1.0 equiv) and TMEDA (1.2–1.5 equiv) in anhydrous Et₂O (0.3 M) was added *s*BuLi (1.3 M in cyclohexane/hexane, 1.2–1.5 equiv) dropwise at –78 °C. After stirring for the required time at –78 °C a solution of freshly prepared MgBr₂•Et₂O* (1.5 equiv in Et₂O – 0.8 M) was added at –78 °C and the reaction mixture was stirred for 2 h at that temperature. At this point a solution of (1*R*,2*S*,5*R*)-(–)-menthyl (*S*)-*p*-toluenesulfinate (1.5 equiv) in anhydrous THF (1.0 M) was added dropwise at –78 °C. The mixture was stirred for an additional hour at that temperature before being warmed to room temperature and stirred overnight. The reaction mixture was then diluted with EtOAc and sat. NH₄Cl, the phases were separated and the aqueous phase was extracted with EtOAc for 3 times. The combined organic layers were washed with brine, dried over MgSO₄ and the solvent was evaporated under reduced pressure. In many cases separation of the desired diastereoisomers from the menthol by-product was facilitated by silylation of the menthol:⁹ to a solution of the crude mixture in anhydrous DCM (0.5 M) was added Et₃N (1.5 equiv). TMSCl (1.3 equiv) was added dropwise at room temperature, the resulting mixture was stirred for 20 min, diluted with Et₂O and washed with H₂O. The organic layer was dried over MgSO₄ and the solvent was removed under

reduced pressure to give a crude residue, which was purified by flash column chromatography (hexane:EtOAc) to afford the *syn* (less polar) and the *anti* (more polar) diastereoisomers.

The racemates were synthesised as above but using racemic methyl 4-methylbenzenesulfinate³ as the starting material.

* A solution of MgBr₂•Et₂O was prepared as follows: Mg turnings (4.0 equiv) were put in a Schlenk tube in a N₂ atmosphere and anhydrous Et₂O (0.8 M with respect to dibromoethane) was added. The solution was cooled to 0 °C and dibromoethane (1.5 equiv) was added dropwise. The ice bath was removed and the reflux was initiated soon. After gas evolution ceased, the reaction mixture was stirred for additional 30 min.

3.2 General procedure 2 (GP2): Synthesis of *syn* and *anti* 1-(*p*-tolylsulfinyl) 2,4,6-triisopropylbenzoates by alkylation

((*R*)-*p*-Tolylsulfinyl)methyl 2,4,6-triisopropylbenzoate **19** (1.0 equiv) and alkylating agent (1.1–2.0 equiv) in an oven dried Schlenk tube was dissolved in anhydrous THF (0.2 M) under an atmosphere of nitrogen. For substrates **14k** and **14l**, HMPA (2.0 equiv) was added at this stage. The reaction mixture was cooled to –78 °C and base (2.0 equiv) was added dropwise. The mixture was stirred at –78 °C for 30 min and then the cooling bath was removed and the solution was stirred at room temperature for 30 min. The reaction mixture was quenched with sat. NH₄Cl and diluted with EtOAc. The layers were separated and the aqueous phase was extracted with EtOAc for 3 times. The combined organic layers were dried (MgSO₄), filtered and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography (hexane:EtOAc) to give the *syn* (less polar) and the *anti* (more polar) diastereoisomers. The racemates were synthesised as above but using racemic sulfoxide *rac*-**19** as the starting material.

3.3 General procedure 3 (GP3): Stereocontrolled homologation of boronic esters using α -sulfinyl benzoates: *in situ* procedure using *t*BuLi

*t*BuLi (1.7 M in pentane, 2.00 equiv) was added dropwise to a mixture of sulfoxide (1.05–1.10 equiv) and pinacol boronic ester (1.00 equiv) in anhydrous THF (0.1 M with respect to the boronic ester) at –78 °C and the resulting solution was stirred at this temperature for 1 h. After warming to room temperature, the reaction mixture was heated at 66 °C for 3 h, cooled to room temperature, diluted with Et₂O and sat. NH₄Cl was added. The phases were separated and the aqueous phase was extracted with Et₂O (3 times). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure. Purification of the crude reaction mixture by chromatography on silica gel (hexane:Et₂O) afforded the desired homologated boronic ester. A small portion of the boronic ester was oxidised to the corresponding alcohol following General Procedures **GP7** or **GP8** to determine the e.r.

In the presence of sensitive functional groups, after stirring the reaction mixture at $-78\text{ }^{\circ}\text{C}$ for 1 h, acetic acid (1.00 equiv) was added to quench the excess of the reactive organolithium and 1,2-metallate rearrangement was performed at room temperature for 16 h.

When the separation of the homologated boronic ester from the unreacted starting boronic ester was not possible the mixture was oxidised (see General Procedures 7 and 8 – **GP7** and **GP8**) and the corresponding alcohol was isolated clean.

The racemates were synthesised as above but using the corresponding racemic sulfoxides as the starting materials.

3.4 General procedure 4 (GP4): Stereocontrolled homologation of boronic esters using α -sulfinyl benzoates: *in situ* procedure using *i*PrMgCl•LiCl

*i*PrMgCl•LiCl (1.3 M in THF, 1.2 equiv) was added dropwise to a mixture of sulfoxide (1.3 equiv) and pinacol boronic ester (1.0 equiv) in anhydrous DCM (0.1 M with respect to the boronic ester) at $-78\text{ }^{\circ}\text{C}$ and the resulting solution was stirred at this temperature for 1 h. After warming to room temperature, the reaction mixture was heated at $40\text{ }^{\circ}\text{C}$ for 3 h, cooled to room temperature, diluted with Et₂O and sat. NH₄Cl was added. The phases were separated and the aqueous phase was extracted with Et₂O (3 times). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure. (Where specified the work-up procedure was modified and the crude reaction mixture was filtered through basic silica (see materials and reagents)(~10 mm depth of wetted (Et₂O) silica) and the solvent was removed under reduced pressure). The crude mixture was purified by chromatography on silica gel (hexane:Et₂O) to afford the desired homologated boronic ester. A small portion of the boronic ester was oxidised to the corresponding alcohol following General Procedures **GP7** or **GP8** to determine the e.r.

When the separation of the homologated boronic ester from the unreacted starting boronic ester was not possible the mixture was oxidised (see General Procedures 7 and 8 – **GP7** and **GP8**) and the corresponding alcohol was isolated clean.

The racemates were synthesised as above but using the corresponding racemic sulfoxides as the starting materials.

3.5 General procedure 5 (GP5): Stereocontrolled homologation of boronic esters using α -sulfinyl benzoates: *ex situ* procedure using *i*PrMgCl•LiCl

*i*PrMgCl•LiCl (1.3 M in THF, 1.2 equiv) was added dropwise to a solution of sulfoxide (1.3 equiv) in anhydrous DCM (0.13 M) at $-78\text{ }^{\circ}\text{C}$ and the resulting solution was stirred at this temperature for 30 min. A solution of the pinacol boronic ester (1.0 equiv) in DCM (0.5 M) was then added slowly and the resulting mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for additional 45 min. After warming to room temperature, the reaction mixture was heated at $40\text{ }^{\circ}\text{C}$ for 3 h, cooled to room temperature, diluted with Et₂O and sat. NH₄Cl was added. The phases were separated and the aqueous phase was extracted with Et₂O (3 times). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under

reduced pressure. (Where specified the work-up procedure was modified and the crude reaction mixture was filtered through basic silica (see materials and reagents)(~10 mm depth of wetted (Et₂O) silica) and the solvent was removed under reduced pressure). The crude mixture was purified by chromatography on silica gel (hexane:Et₂O) to afford the desired homologated boronic ester. A small portion of the boronic ester was oxidised to the corresponding alcohol following General Procedures **GP7** or **GP8** to determine the e.r.

When the separation of the homologated boronic ester from the unreacted starting boronic ester was not possible the mixture was oxidised (see General Procedures 7 and 8 – **GP7** and **GP8**) and the corresponding alcohol was isolated clean.

The racemates were synthesised as above but using the corresponding racemic sulfoxides as the starting materials.

3.6 General procedure 6 (GP 6): Stereocontrolled homologation of boronic esters using hindered α -sulfinyl benzoates: reverse addition procedure using *t*BuLi/PMDTA

To a solution of PMDTA (2.0–2.3 equiv) in anhydrous Et₂O (0.1 M with respect to the boronic ester) was added *t*BuLi (1.7 M in pentane, 2.0–2.3 equiv) dropwise at –78 °C. A solution of benzoate (1.05–1.3 equiv) in Et₂O (0.1 M with respect to the boronic ester) was added to the reaction mixture dropwise at –78 °C. After stirring 20 min at this temperature, a solution of boronic ester (1.0 equiv) in Et₂O (0.1 M with respect to the boronic ester) was introduced slowly. The mixture was stirred for 1 hour at –78 °C. After warming to room temperature, the reaction mixture was heated at 40 °C for 3 h, cooled to room temperature, diluted with Et₂O and sat. NH₄Cl was added. The phases were separated and the aqueous phase was extracted with Et₂O (3 times). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The crude mixture was purified by chromatography on silica gel (hexane:EtOAc) to afford the desired homologated boronic ester. A small portion of the boronic ester was oxidised to the corresponding alcohol following General Procedures **GP7** or **GP8** to determine the e.r.

When the separation of the homologated boronic ester from the unreacted starting boronic ester was not possible the mixture was oxidised (see General Procedures 7 and 8 – **GP7** and **GP8**) and the corresponding alcohol was isolated clean.

The racemates were synthesised as above but using the corresponding racemic sulfoxides as the starting materials.

3.7 General procedure 7 (GP7): Stereospecific oxidation of boronic esters using H₂O₂/NaOH

Pinacol boronic ester (1.0 equiv) was dissolved in THF (5.0 mL) and the solution was cooled to 0 °C. An aqueous solution of 2.0 M NaOH and 30% H₂O₂ (2:1 v/v, 3.0 mL) was added dropwise. The solution was stirred vigorously for 2 h at room temperature, then it was diluted with water (10 mL) and Et₂O (10 mL). The layers were separated and the aqueous layer was extracted with Et₂O (3 × 10 mL). The organic

layers were combined, dried over MgSO_4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (hexane:EtOAc) to afford the desired alcohol.


3.8 General procedure 8 (GP8): Stereospecific oxidation of boronic esters using sodium perborate tetrahydrate

To a solution of boronic ester/boronic ester mixture (0.2–0.3 mmol) in THF/water (3:2, 0.1 M) at room temperature was added $\text{NaBO}_3 \cdot 4\text{H}_2\text{O}$ (10 equiv) and the resulting suspension was stirred for 2–3 h. The mixture was filtered through silica [~10 mm depth of wetted (Et_2O) silica] and the filtrate was concentrated *in vacuo*. The crude product was purified by silica gel chromatography to afford the desired alcohol.

4. Preparation of Triisopropylbenzoates

Ethyl 2,4,6-triisopropylbenzoate,¹⁰ propyl 2,4,6-triisopropylbenzoate,¹¹ isobutyl 2,4,6-triisopropylbenzoate¹² and 3-phenylpropyl 2,4,6-triisopropylbenzoate¹³ were synthesised according to the literature reported procedures.

4.1 Preparation of methyl 2,4,6-triisopropylbenzoate (27)



A biphasic mixture of 2,4,6-triisopropylbenzoic acid (7.44 g, 30.0 mmol), tetrabutylammonium hydrogen sulfate (816 mg, 2.40 mmol), sodium hydroxide (3.60 g, 90.2 mmol) and methyl iodide (9.35 mL, 150 mmol) in chloroform:water (1.22:1, v/v, 282 mL) was stirred vigorously for 5 h at room temperature. The layers were separated and the aqueous phase was extracted with dichloromethane (3 × 50 mL). The combined organic layers were washed with brine (150 mL), dried (MgSO_4) and the solvent was removed under reduced pressure to give **27** as a crude pink solid (7.43 g, 95%) which was used without further purification.

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.01 (s, 2H, ArH), 3.89 (s, 3H, CH_3), 2.89 (sept, $J = 7.4$ Hz, 1H, CH), 2.82 (sept, $J = 7.4$ Hz, 2H, $\text{CH} \times 2$), 1.25 (d, $J = 7.4$ Hz, 18H, $\text{CH}_3 \times 6$) ppm


$^{13}\text{C NMR}$ (101 MHz, CDCl_3): δ 170.9 (CO), 150.2 (C), 144.8 ($2 \times$ C), 130.8 (C), 120.9 ($2 \times$ CH), 60.8 (CH_3), 30.6 (CH), 31.5 ($2 \times$ CH), 24.2 ($4 \times$ CH_3), 24.0 ($2 \times$ CH_3) ppm

IR (neat): 2957, 2869, 1719, 1254, 1080, 877

HRMS (ESI): calculated for $\text{C}_{17}\text{H}_{26}\text{ONa}$ [$\text{M}+\text{Na}^+$] 285.1825, found 285.1837

M.P. 40–42 °C

4.2 Preparation of but-3-en-1-yl 2,4,6-triisopropylbenzoate (**28**)¹⁴



To a solution of 2,4,6-triisopropylbenzoic acid (5.00 g, 20.1 mmol) in chloroform (50 mL) was added a solution of NaOH (2.42 g, 60.4 mmol) and *n*Bu₄NHSO₄ (0.55 g, 1.61 mmol) in distilled H₂O (50 mL). 4-Bromo-1-butene (6.13 mL, 60.4 mmol) was added to the biphasic mixture under vigorous stirring and the resulting reaction mixture was stirred at room temperature for 16 h. The phases were separated, the organic phase was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The resulting oil was dissolved in pentane:EtOAc = 90:10 and filtered through a plug of silica. The solution was concentrated under reduced pressure to afford the pure benzoate **28** (4.93 g, 81%) as a colourless oil.


¹H NMR (CDCl₃, 400 MHz) δ: 7.03 (s, 2H, Ar-H), 5.86 (m, 1H, 2-H), 5.17 (dq, *J*₁ = 17.2 Hz, *J*₂ = 1.6 Hz, 1H, 1-H_{trans}), 5.11 (dq, *J*₁ = 10.3 Hz, *J*₂ = 1.2 Hz, 1H, 1-H_{cis}), 4.40 (t, *J* = 6.8 Hz, 2H, 4-H), 2.89 (sept, *J* = 6.8 Hz, 3H, CH(CH₃)₂ × 3), 2.52 (qt, *J*₁ = 6.7 Hz, *J*₂ = 1.4 Hz, 2H, 3-H), 1.26 (d, *J* = 6.9 Hz, 18H, CH₃ × 6) ppm

¹³C NMR (CDCl₃, 101 MHz) δ: 170.8 (CO), 150.1 (Ar-C), 144.7 (2C, Ar-C × 2), 134.0 (2-C), 130.5 (Ar-C), 120.8 (2C, Ar-C × 2), 117.3 (1-C), 64.0 (4-C), 34.4 (CH-(CH₃)₂), 33.1 (3-C), 31.4 (2C, CH-(CH₃)₂ × 2), 24.1 (2C, CH₃ × 2), 23.9 (4C, CH₃ × 4) ppm

HRMS (ESI) calculated for C₂₀H₃₁O₂: 303.2319, found: 303.2319

IR (neat): 2961, 2930, 2871, 1725, 1607, 1461, 1248, 1134, 1102, 1074, 917, 876 cm⁻¹

4.3 Preparation of 3-(2-methyl-1,3-dioxolan-2-yl)propyl 2,4,6-triisopropylbenzoate (**29**)



Following a modified literature reported procedure,¹⁵ to a solution of 2,4,6-triisopropylbenzoic acid (2.20 g, 8.70 mmol) and Cs₂CO₃ (3.70 g, 11.9 mmol) in acetonitrile (90.0 mL) was added 5-chloro-2-pentanone ethylene ketal (1.30 g, 7.90 mmol) and the resulting reaction mixture was stirred at 82 °C for 24 h. After cooling to room temperature, the precipitate was filtrated off and the filtrate was concentrated under reduced pressure. The residue was dissolved in chloroform (50 mL) and washed with 20% aq. NaHCO₃ solution (3 × 30 mL). The organic phases were combined, dried over MgSO₄,

filtered and the solvent was removed under reduced pressure. Purification by flash column chromatography (SiO₂, hexane:EtOAc = 80:20) afforded the pure benzoate **29** (2.51 g, 85%) as a colourless oil.


¹H NMR (CDCl₃, 400 MHz) δ: 7.01 (s, 2H, Ar-H), 4.33 (t, *J* = 6.2 Hz, 2H, 1-H), 3.94 (m, 4H, O-CH₂ × 2), 2.87 (sept, *J* = 6.7 Hz, 3H, CH(CH₃)₂ × 3), 1.89–1.81 (m, 2H, 2-H), 1.79–1.75 (m, 2H, 3-H), 1.33 (s, 3H, 4-H), 1.25 (d, *J* = 6.8 Hz, 18H, CH₃ × 6) ppm

¹³C NMR (CDCl₃, 101 MHz) δ: 171.0 (CO), 150.0 (Ar-C), 144.7 (2C, Ar-C × 2), 130.6 (Ar-C), 120.8 (2C, Ar-C × 2), 109.6 (O-C-O), 65.0 (1-C), 64.7 (2C, O-CH₂ × 2), 35.7 (3-C), 34.4 (CH-(CH₃)₂), 31.5 (2C, CH-(CH₃)₂ × 2), 24.1 (4C, CH₃ × 4), 23.9 (2C, CH₃ × 2), 23.9 (2-C), 23.4 (4-C) ppm

IR (neat): 2961, 1722, 1462, 1250, 1137, 1068, 877, 754 cm⁻¹

HRMS (ESI) calculated for C₂₃H₃₆NaO₄: 399.2506, found: 399.2503

4.4 Preparation of neopentyl 2,4,6-triisopropylbenzoate (**30**)



To a solution of 2,4,6-triisopropylbenzoic acid (20 g, 80.0 mmol), triphenyl phosphine (20 g, 76.0 mmol) and neopentyl alcohol (7.1 g, 80.0 mmol) in anhydrous THF (152 mL) was added diisopropyl azodicarboxylate (16 mL, 80.0 mmol) dropwise at 0 °C. The mixture was stirred for 20 min at 0 °C, then warmed to rt and stirred overnight. It was quenched with NaHCO₃ (120 mL) and H₂O (120 mL). The layers were separated and the aqueous layer was extracted with Et₂O (3 × 60 mL). The combined organic phase was dried over MgSO₄, filtered and concentrated *in vacuo* to give a yellow solid. Pentane (300 mL) was added to the solid and the resulting suspension was passed through a plug of SiO₂. The filtrate was concentrated under reduced pressure to give a pale oil. Purification by flash column chromatography (pentane:Et₂O = 98:2) gave the product benzoate **30** (23 g, 70 mmol, 93%) as a colourless oil.

¹H NMR (CDCl₃, 500 MHz): δ 7.01 (s, 2H, Ar-H), 3.98 (s, 2H, CH₂), 2.94–2.81 (m, 3H, CH), 1.26 (d, *J* = 7.0 Hz, 6H, CH₃ × 2), 1.25 (d, *J* = 6.8 Hz, 12H, CH₃ × 4), 0.99 (s, 9H, CH₃ × 3) ppm

¹³C NMR (CDCl₃, 125 MHz): δ 171.5 (CO), 150.0 (Ar-C), 144.8 (2C, Ar-C), 131.0 (Ar-C), 120.9 (2C, Ar-C), 74.9 (CH₂), 34.5 (CH), 31.7 (CH), 31.2 (C(CH₃)₃), 26.7 (3C, (CH₃)₃C), 24.3 (4C, CH₃ × 4), 24.1 (2C, CH₃ × 2) ppm


IR (neat): 2959, 2870, 1725, 1606 cm⁻¹

HRMS (ESI) calculated for C₂₁H₃₄O₂Na: 341.2451, found: 341.2452

5. Preparation of Boronic esters

Boronic esters **15**,¹⁶ **17a**,¹⁷ 2-(3-azidopropyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**17c**),¹⁸ (*E*)-*tert*-butyldimethyl((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-2-en-1-yl)oxy)silane (**17d**),¹⁹ 2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**17e**),²⁰ *tert*-butyl(((2*R*,4*S*)-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentyl)oxy)diphenylsilane (**17f**),²¹ 2-cyclohexyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**17g**),¹⁶ and 2-cyclohexyl-5,5-dimethyl-1,3,2-dioxaborinane (**17h**)²² were prepared according to literature procedures and all spectroscopic data matched those previously reported.

5.1 Preparation of *tert*-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanoate (**17b**)



Boronic ester **17b** was prepared by a hydroboration of the corresponding terminal alkene using Miyaura's procedure.²³ A Schlenk flask was charged with [Ir(cod)Cl]₂ (58 mg, 0.086 mmol, 1.5 mol%) and dppe (68 mg, 3 mol%). *tert*-Butyl pent-4-enoate (893 mg, 5.72 mmol) in DCM (3 mL) was added to the flask. To the orange solution was added pinacolborane (1.08 mL, 7.44 mmol) dropwise at rt. The mixture was stirred overnight and quenched with H₂O (20 mL). The product was extracted with Et₂O (3 × 20 mL). Combined organic extracts were dried over MgSO₄ and concentrated. The crude was dissolved in pentane:Et₂O (90:10, 30 mL) and the white precipitate was removed by filtration. The product **17b** (1.13 g, 70% yield) was obtained as a yellow oil after column chromatography (pentane:Et₂O = 85:15).

¹H NMR (CDCl₃, 400 MHz) δ: 2.19 (t, *J* = 7.6 Hz, 2H), 1.58 (quint, *J* = 7.6 Hz, 2H), 1.46–1.38 (m, 2H), 1.43 (s, 9H), 1.23 (s, 12H), 0.78 (t, *J* = 7.8 Hz, 2H) ppm

¹³C NMR (CDCl₃, 101 MHz) δ: 173.4 (3-C), 83.1 (2C, 8-C), 80.0 (2-C), 35.7, 28.3 (3C, 1-C), 27.9, 25.0 (4C, 9-C), 23.7 ppm (carbon attached to boron not observed due to quadrupolar relaxation)


¹¹B NMR (CDCl₃, 128 MHz) δ: 33.4 ppm

IR (neat): 2978, 2934, 2865, 1730, 1368, 1319, 1145, 1142, 847 cm⁻¹


HRMS (ESI) calculated for C₁₅H₂₉BNaO₄: 307.2054, found: 307.2059

6. Preparation of α -Sulfinyl Benzoates

6.1 Preparation of α -sulfinyl benzoates by transmetalation




6.1.1 Preparation of (*S*)-(*p*-Tolylsulfinyl)methyl 2,4,6-triisopropylbenzoate (**19**)



19

Following **GP1**, methyl benzoate **27** (5.00 g, 19.1 mmol), TMEDA (3.71 mL, 24.8 mmol), *s*BuLi (1.30 M in cyclohexane/hexane, 19.1 mL, 24.8 mmol – lithiation time = 30 min), Mg turnings (1.37 g, 57.2 mmol), dibromoethane (2.46 mL, 28.6 mmol) and (1*R*,2*S*,5*R*)-(-)-menthyl (*S*)-*p*-toluenesulfinate (8.15 g, 28.6 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 100:0→80:20) sulfoxide **19** (5.09 g, 67%) as a colourless solid.



$[\alpha]_D^{24}$: +134 (*c* 1.0, CHCl₃)

¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, *J* = 8.2 Hz, 2H, ArH), 7.37 (d, *J* = 8.2 Hz, 2H, ArH), 7.02 (s, 2H, ArH), 5.28 (d, *J* = 10.4 Hz, 1H, CHH), 5.00 (d, *J* = 10.4 Hz, 1H, CHH), 2.90 (sept, *J* = 7.5 Hz, 1H, CH), 2.90 (sept, *J* = 6.9 Hz, 2H, CH × 2), 2.44 (s, 3H, CH₃), 1.25 (d, *J* = 6.9 Hz, 12H, CH₃ × 2), 1.23 (d, *J* = 6.9 Hz, 6H, CH₃ × 2) ppm

¹³C NMR (101 MHz, CDCl₃): 169.8 (CO), 151.1 (C), 145.4 (2 × C), 142.5 (C), 137.4 (C), 130.3 (2 × CH), 128.6 (C), 124.8 (2 × CH), 121.1 (2 × CH), 83.4 (CH₂), 34.6 (CH), 31.8 (2 × CH), 24.4 (2 × CH₃), 24.3 (2 × CH₃), 24.1 (2 × CH₃), 21.6 (CH₃) ppm

IR (neat): 2961, 1745, 1227, 1035, 816 cm⁻¹

HRMS (ESI) calculated for C₂₄H₃₂O₃SNa: 423.1964, found 423.1974

M.P. 90–92 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm) with guard, hexane:isopropanol = 95:5, 1.0 mL/min, room temperature, 210.8 nm): t_R = 10.05 minutes (major), 12.02 minutes (minor), e.r. = 99:1




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.05	MM	4487.7	316.5	0.2363	49.768	0.853
2	12.023	MM	4529.7	264.4	0.2855	50.232	0.873




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.048	MM	17885.1	1255.6	0.2374	98.779	0.822
2	12.019	MM	221	13.5	0.273	1.221	1.051

6.1.2 Preparation of (*S*)-3-phenyl-1-((*S*)-*p*-tolylsulfinyl)propyl 2,4,6-triisopropylbenzoate (*syn*-14a) and (*R*)-3-phenyl-1-((*S*)-*p*-tolylsulfinyl)propyl 2,4,6-triisopropylbenzoate (*anti*-14a)



Following **GPI**, 3-phenylpropyl 2,4,6-triisopropylbenzoate (1.00 g, 2.70 mmol), TMEDA (485 μ L, 3.24 mmol), *s*BuLi (1.30 M in cyclohexane/hexane, 2.50 mL, 3.24 mmol – lithiation time = 2 h), Mg turnings (263 mg, 10.8 mmol), dibromoethane (350 μ L, 4.05 mmol), (1*R*,2*S*,5*R*)-(-)-menthyl (*S*)-*p*-toluenesulfinate (1.19 g, 4.05 mmol), Et₃N (560 μ L, 4.05 mmol) and TMSCl (450 μ L, 3.51 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 95:5) the *syn* diastereoisomer *syn*-14a (less polar, 500 mg, 37%) as a colourless solid and the *anti* diastereoisomer *anti*-14a (more polar, 581 mg, 43%) as a colourless solid.



***syn*-14a**

[α]_D²²: +123 (*c* 0.9, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.60 (d, *J* = 8.2 Hz, 2H, Ar-H), 7.34 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.21–7.15 (m, 3H, Ar-H), 7.07 (s, 2H, 14-H), 6.94 (d, *J* = 6.3 Hz, 2H, Ar-H), 5.64 (dd, *J*₁ = 9.7 Hz, *J*₂ = 2.9 Hz, 1H, 5-H), 2.96 (m, 3H, 11-H × 2 + 15-H), 2.78 (m, 1H, 7-H), 2.51 (m, 1H, 7-H), 2.45 (s, 3H, 1-H), 2.29 (m, 1H, 6-H), 1.99 (m, 1H, 6-H), 1.33–1.27 (m, 18H, CH₃ × 6) ppm


¹³C NMR (CDCl₃, 101 MHz) δ: 170.4 (CO), 150.9 (Ar-C), 145.2 (2C, Ar-C × 2), 141.5 (Ar-C), 139.9 (Ar-C), 137.4 (Ar-C), 130.0 (2C, Ar-C × 2), 128.8 (Ar-C), 128.4 (2C, Ar-C × 2), 128.1 (2C, Ar-C × 2), 126.2 (Ar-C), 124.2 (2C, Ar-C × 2), 121.0 (2C, Ar-C × 2), 92.0 (5-C), 34.5 (15-C), 31.7 (2C, 11-C), 30.8 (7-C), 24.6 (6-C), 24.4 (2C, CH-CH₃ × 2), 24.3 (2C, CH-CH₃ × 2), 23.9 (2C, CH-CH₃ × 2), 21.4 (1-C) ppm

IR (neat): 2960, 1731, 1239, 1060, 1048, 1027, 813, 756 cm⁻¹

HRMS (ESI) calculated for C₃₂H₄₀NaO₃S: 527.2590, found: 527.2574

M.P. 99–101 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): t_R = 13.8 minutes (minor), 16.2 minutes (major), e.r. > 99:1



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	13.758	MM	3753.1	211.7	0.2955	42.546	0.778
2	16.247	MM	8068.3	207.9	0.4064	57.454	1.045



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	16.121	SM	2697.5	129.3	0.3176	100.000	0.76

anti-14a

[α]²²_D: +11 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.53 (d, *J* = 8.1 Hz, 2H, Ar-H), 7.31–7.26 (m, 4H, Ar-H), 7.21 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.09 (d, *J* = 7.2 Hz, 2H, Ar-H), 7.07 (s, 2H, 14-H), 6.08 (dd, *J*₁ = 8.8 Hz, *J*₂ = 3.4 Hz, 1H, 5-H), 2.96 (app sept, *J* = 6.8 Hz, 3H, 11-H × 2 + 15-H), 2.78 (m, 2H, 7-H), 2.41 (s, 3H, 1-H), 2.21 (m, 1H, 6-H), 1.71 (m, 1H, 6-H), 1.30–1.25 (m, 18H, CH₃ × 6) ppm


¹³C NMR (CDCl₃, 101 MHz) δ: 169.2 (CO), 150.8 (Ar-C), 145.2 (2C, Ar-C × 2), 142.1 (Ar-C), 139.9 (Ar-C), 136.1 (Ar-C), 129.9 (2C, Ar-C × 2), 128.9 (Ar-C), 128.6 (2C, Ar-C × 2), 128.2 (2C, Ar-C × 2), 126.4 (Ar-C), 125.5 (2C, Ar-C × 2), 121.0 (2C, Ar-C × 2), 87.8 (5-C), 34.4 (15-C), 31.7 (2C, 11-C × 2), 31.6 (7-C), 29.2 (6-C), 24.7 (2C, CH-CH₃ × 2), 24.1 (2C, CH-CH₃ × 2), 23.9 (2C, CH-CH₃ × 2), 21.5 (1-C) ppm

IR (neat): 2962, 1734, 1460, 1229, 1067, 1042, 880, 815 cm⁻¹


HRMS (ESI) calculated for C₃₂H₄₀NaO₃S: 527.2590, found: 527.2574

M.P. 91-93 °C.


Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.7 mL/min, room temperature, 210.8 nm): tR = 14.4 minutes (minor), 30.8 minutes (major), e.r. > 99:1



6.1.3 Preparation of (*S*)-1-((*S*)-*p*-tolylsulfinyl)ethyl 2,4,6-triisopropylbenzoate (*syn*-14b) and (*R*)-1-((*S*)-*p*-tolylsulfinyl)ethyl 2,4,6-triisopropylbenzoate (*anti*-14b)



Following **GP1**, ethyl benzoate **1** (2.45 g, 8.86 mmol), TMEDA (1.59 mL, 10.64 mmol), *s*BuLi (1.3 M in cyclohexane/hexane, 8.18 mL, 10.6 mmol – lithiation time = 1 h), Mg turnings (869 mg, 36.2 mmol), dibromoethane (1.17 mL, 13.3 mmol), (1*R*,2*S*,5*R*)-(–)-menthyl (*S*)-*p*-toluenesulfinate (3.91 g, 13.3 mmol), Et₃N (1.85 mL, 13.3 mmol) and TMSCl (1.46 mL, 11.6 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 95:5) the *syn* diastereoisomer *syn*-**14b** (less polar, 1.49 g, 41%) as a colourless solid and the *anti* diastereoisomer *anti*-**14b** (more polar, 1.48 g, 40%) as a colourless solid.



syn-14b

$[\alpha]_D^{24}$: +86 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.63 (d, *J* = 8.2 Hz, 2H, Ar-H), 7.37 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.04 (s, 2H, 13-H), 5.79 (q, *J* = 6.4 Hz, 1H, 6-H), 2.90 (app sept, *J* = 6.8 Hz, 3H, 15-H + 11-H), 2.44 (s, 3H, 1-H), 1.40 (d, *J* = 6.4 Hz, 3H, 7-H), 1.29–1.24 (m, 18H, CH₃ × 6) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 169.9 (CO), 150.9 (Ar-C), 145.2 (2C, Ar-C × 2), 141.7 (Ar-C), 137.5 (Ar-C), 130.0 (2C, Ar-C × 2), 128.7 (Ar-C), 124.4 (2C, Ar-C × 2), 121.0 (2C, Ar-C × 2), 89.0 (6-C), 34.5 (15-C), 31.6 (2C, 11-C), 24.2 (2C, CH-CH₃ × 2), 24.1 (2C, CH-CH₃ × 2), 23.9 (2C, CH-CH₃ × 2), 21.4 (1-C), 9.1 (7-C) ppm

IR (neat): 2962, 1735, 1228, 1087, 1060, 1041, 874, 811 cm⁻¹


HRMS (ESI) calculated for C₂₅H₃₄NaOS: 437.212087, found: 437.210910

M.P. 117–119 °C.

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 96:4, 0.5 mL/min, room temperature, 210.8 nm): tR = 13.4 minutes (minor), 15.8 minutes (major), e.r. > 99:1



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	13.371	BB	4170.1	246.7	0.2569	52.406	0.754
2	15.788	VB	3787.2	190.2	0.3037	47.594	0.76



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	13.434	MM	52.9	2.5	0.3529	0.263	1.502
2	15.849	BB	20277.3	994.3	0.3122	99.740	0.719

anti-14b

$[\alpha]_D^{21}$: +30 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.54 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.32 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.01 (s, 2H, 13-H), 6.07 (q, *J* = 6.4 Hz, 1H, 6-H), 2.90 (sept, *J* = 6.8 Hz, 1H, 15-H), 2.78 (sept, *J* = 6.8 Hz, 2H, 11-H), 2.41 (s, 3H, 1-H), 1.39 (d, *J* = 6.4 Hz, 3H, 7-H), 1.26–1.24 (m, 12H, 12-H), 1.19 (d, *J* = 6.0 Hz, 6H, 16-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 169.0 (CO), 150.7 (Ar-C), 145.1 (2C, Ar-C × 2), 142.1 (Ar-C), 136.0 (Ar-C), 129.8 (2C, Ar-C × 2), 128.8 (Ar-C), 125.6 (2C, Ar-C × 2), 120.9 (2C, Ar-C × 2), 85.0 (6-C), 34.4 (15-C), 31.5 (2C, 11-C), 24.5 (2C, CH-CH₃ × 2), 23.9 (2C, CH-CH₃ × 2), 23.9 (2C, CH-CH₃ × 2), 21.4 (1-C), 13.1 (7-C) ppm

IR (neat): 2962, 1735, 1228, 1087, 1060, 1041, 874, 811 cm⁻¹


HRMS (ESI) calculated for C₂₅H₃₄NaOS: 437.212087, found: 437.210910

M.P. 95–97 °C.


Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 96:4, 0.5 mL/min, room temperature, 210.8 nm): t_R = 19.3 minutes (minor), 32.5 minutes (major), e.r. = 99:1



6.1.4 Preparation of (*S*)-1-((*S*)-*p*-tolylsulfinyl)propyl 2,4,6-triisopropylbenzoate (*syn*-14c) and (*R*)-1-((*S*)-*p*-tolylsulfinyl)propyl 2,4,6-triisopropylbenzoate (*anti*-14c)



Following **GP1**, propyl 2,4,6-triisopropylbenzoate (2.90 g, 10.0 mmol), TMEDA (1.80 mL, 12.0 mmol), *s*BuLi (1.30 M in cyclohexane/hexane, 9.20 mL, 12.0 mmol – lithiation time = 1 h), Mg turnings (972 mg, 40.0 mmol), dibromoethane (1.30 mL, 15.0 mmol) and (1*R*,2*S*,5*R*)-(-)-menthyl (*S*)-*p*-toluenesulfinate (4.40 g, 15.0 mmol), afforded after purification by flash column chromatography (hexane:EtOAc = 95:5 → 90:10) the *syn* diastereoisomer *syn*-14c (less polar, 1.10 g, 26%) as a colourless solid and the *anti* diastereoisomer *anti*-14c (more polar, 1.37 g, 32%) as a colourless oil that turned into a waxy colourless solid upon standing at room temperature.



syn-14c

[α]²²_D: +92 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.66 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.36 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.04 (s, 2H, 13-H), 5.62 (dd, *J*₁ = 9.8 Hz, *J*₂ = 3.2 Hz, 1H, 5-H), 2.92 (app s, *J* = 6.7 Hz, 3H, 11-H × 2 + 15-

H), 2.44 (s, 3H, 1-H), 2.01 (sept, $J = 7.6$ Hz, 1H, 6-H), 1.71 (m, 1H, 6-H), 1.29 (d, $J = 6.8$ Hz, 6H, $\text{CH}_3 \times 2$), 1.26 (d, $J = 6.9$ Hz, 6H, $\text{CH}_3 \times 2$), 1.25 (d, $J = 6.6$ Hz, 6H, $\text{CH}_3 \times 2$), 0.95 (t, $J = 7.4$ Hz, 3H, 7-H) ppm



^{13}C NMR (CDCl_3 , 101 MHz) δ : 170.5 (CO), 150.8 (Ar-C), 145.2 (2C, Ar-C $\times 2$), 141.5 (Ar-C), 137.6 (Ar-C), 130.0 (2C, Ar-C $\times 2$), 128.9 (Ar-C), 124.4 (2C, Ar-C $\times 2$), 121.0 (2C, Ar-C $\times 2$), 93.8 (5-C), 34.4 (15-C), 31.6 (2C, 11-C $\times 2$), 24.4 (2C, CH- $\text{CH}_3 \times 2$), 24.2 (2C, CH- $\text{CH}_3 \times 2$), 23.9 (2C, CH- $\text{CH}_3 \times 2$), 21.5 (1-C), 16.7 (6-C), 9.4 (7-C) ppm

IR (neat): 3675, 2988, 2972, 2901, 1394, 1057, 892 cm^{-1}

HRMS (ESI) calculated for $\text{C}_{26}\text{H}_{36}\text{NaO}_3\text{S}$: 451.2277, found: 451.2278

M.P. 87-89 $^\circ\text{C}$

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): tR = 12.6 minutes (minor), 14.9 minutes (major), e.r. > 99:1



anti-14c

$[\alpha]_D^{22}$: +20 (c 1.0, CHCl_3)


^1H NMR (CDCl_3 , 400 MHz) δ : 7.55 (d, $J = 8.1$ Hz, 2H, Ar-H), 7.31 (d, $J = 8.0$ Hz, 2H, Ar-H), 7.02 (s, 2H, 13-H), 5.93 (dd, $J_1 = 8.5$ Hz, $J_2 = 4.1$ Hz, 1H, 5-H), 2.90 (sept, $J = 6.9$ Hz, 1H, 15-H), 2.84 (sept, $J = 6.8$ Hz, 2H, 11-H $\times 2$), 2.41 (s, 3H, 1-H), 1.94 (m, 1H, 6-H), 1.45 (sept, $J = 8.0$ Hz, 1H, 6-H), 1.25 (d, $J = 6.9$ Hz, 6H, $\text{CH}_3 \times 2$), 1.25 (d, $J = 6.8$ Hz, 6H, $\text{CH}_3 \times 2$), 1.20 (d, $J = 6.8$ Hz, 6H, $\text{CH}_3 \times 2$), 1.06 (t, $J = 7.4$ Hz, 3H, 7-H) ppm

^{13}C NMR (CDCl_3 , 101 MHz) δ : 169.4 (CO), 150.6 (Ar-C), 145.1 (2C, Ar-C $\times 2$), 142.0 (Ar-C), 136.4 (Ar-C), 129.8 (2C, Ar-C $\times 2$), 129.0 (Ar-C), 125.5 (2C, Ar-C $\times 2$), 121.0 (2C, Ar-C $\times 2$), 89.9 (5-C), 34.4 (15-C), 31.6 (2C, 11-C $\times 2$), 24.6 (2C, CH- $\text{CH}_3 \times 2$), 24.1 (2C, CH- $\text{CH}_3 \times 2$), 23.9 (2C, CH- $\text{CH}_3 \times 2$), 21.5 (1-C), 21.0 (6-C), 9.8 (7-C) ppm


IR (neat): 3675, 2968, 1742, 1231, 1065, 752 cm^{-1}

HRMS (ESI) calculated for $\text{C}_{26}\text{H}_{36}\text{NaO}_3\text{S}$: 451.2277, found: 451.2278


Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): t_R = 18.3 minutes (minor), 27.8 minutes (major), e.r. = 98:2



6.1.5 Preparation of (*S*)-2-methyl-1-((*S*)-*p*-tolylsulfinyl)propyl 2,4,6-triisopropylbenzoate (*syn*-14d) and (*R*)-2-methyl-1-((*S*)-*p*-tolylsulfinyl)propyl 2,4,6-triisopropylbenzoate (*anti*-14d)



Following **GP1**, isobutyl 2,4,6-triisopropylbenzoate (0.51 g, 1.68 mmol), TMEDA (300 μ L, 2.01 mmol), *s*BuLi (1.30 M in cyclohexane/hexane, 1.50 mL, 2.01 mmol – lithiation time = 1.5 h), Mg turnings (163 mg, 6.72 mmol), dibromoethane (220 μ L, 2.52 mmol), (1*R*,2*S*,5*R*)-(–)-menthyl (*S*)-*p*-toluenesulfinate (0.74 g, 2.52 mmol), Et₃N (350 μ L, 2.52 mmol) and TMSCl (280 μ L, 2.18 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 90:10) a 1.8:1 mixture of the *syn* diastereoisomer *syn*-**14d** and the *anti* diastereoisomer *anti*-**14d** (488 mg, 66% overall yield). A portion of the mixture (450 mg) was further purified by reverse phase HPLC (acetonitrile:water = 85:15, isocratic) to afford the *syn* diastereoisomer *syn*-**14d** (less polar, 112 mg, 15%) as a colourless solid and the *anti* diastereoisomer *anti*-**14d** (more polar, 215 mg, 29%) as a thick colourless oil.



syn-14d

$[\alpha]^{22}_D$: +41 (*c* 0.9, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.73 (d, *J* = 7.8 Hz, 2H, Ar-H), 7.35 (d, *J* = 7.8 Hz, 2H, Ar-H), 7.04 (s, 2H, 13-H), 5.72 (d, *J* = 4.9 Hz, 1H, 5-H), 2.94–2.81 (m, 3H, 11-H \times 2 + 15-H), 2.54 (app sept, *J* = 6.8 Hz, 1H, 6-H), 2.43 (s, 3H, 1-H), 1.26 (d, *J* = 6.9 Hz, 12H, CH₃ \times 4), 1.22 (d, *J* = 6.8 Hz, 6H, CH₃ \times 2), 1.14 (d, *J* = 6.8 Hz, 3H, 7-H), 0.96 (d, *J* = 6.9 Hz, 3H, 7-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 170.1 (CO), 150.7 (Ar-C), 145.2 (2C, Ar-C \times 2), 141.7 (Ar-C), 138.2 (Ar-C), 129.9 (2C, Ar-C \times 2), 128.7 (Ar-C), 125.3 (2C, Ar-C \times 2), 121.0 (2C, Ar-C \times 2), 95.8 (5-C), 34.4 (15-C), 31.4 (2C, 11-C \times 2), 26.5 (6-C), 24.4 (2C, CH-CH₃ \times 2), 24.3 (2C, CH-CH₃ \times 2), 23.9 (2C, CH-CH₃ \times 2), 21.4 (1-C), 20.1 (7-C), 17.5 (7-C) ppm

IR (neat): 2961, 1729, 1236, 1060, 1042, 812 cm⁻¹

HRMS (ESI) calculated for C₂₇H₃₈NaO₃S: 465.2434, found: 465.2439

M.P. 87–89 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): tR = 12.3 minutes (minor), 13.6 minutes (major), e.r. = >99:1



anti-14d

$[\alpha]^{22}_D$: +173 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.66 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.35 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.04 (s, 2H, 13-H), 5.89 (d, *J* = 3.5 Hz, 1H, 5-H), 3.03 (sept, *J* = 6.7 Hz, 2H, 11-H \times 2), 2.90 (sept, *J* = 6.9 Hz, 1H, 15-H), 2.43 (s, 3H, 1-H), 1.95 (m, 1H, 6-H), 1.26 (d, *J* = 6.9 Hz, 12H, CH₃ \times 4), 1.23 (d, *J* = 6.8 Hz, 6H, CH₃ \times 2), 1.06 (app t, *J* = 6.4 Hz, 6H, 7-H \times 2) ppm

¹³C NMR (CDCl₃, 101 MHz) δ : 169.6 (CO), 150.5 (Ar-C), 145.5 (2C, Ar-C \times 2), 142.3 (Ar-C), 138.3 (Ar-C), 130.1 (2C, Ar-C \times 2), 129.2 (Ar-C), 125.7 (2C, Ar-C \times 2), 121.0 (2C, Ar-C \times 2), 94.5 (5-C), 34.4 (15-C), 31.3 (2C, 11-C \times 2), 28.6 (6-C), 24.5 (4C, CH-CH₃ \times 4), 23.9 (2C, CH-CH₃ \times 2), 21.5 (1-C), 19.5 (7-C), 17.3 (7-C) ppm

IR (neat): 2962, 1740, 1461, 1230, 1063, 1048, 877, 810 cm⁻¹

HRMS (ESI) calculated for C₂₇H₃₈NaO₃S: 465.2434, found: 465.2439

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): tR = 17.3 minutes (minor), 24.7 minutes (major), e.r. = 98:2




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	17.284	VB	36487	1588.4	0.351	49.768	0.707
2	24.658	VB R	36827.8	1131.6	0.4988	50.232	0.731



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	17.305	BB	1813.8	81.7	0.3414	1.396	0.763
2	25.004	BB	129499.8	3085.6	0.6577	98.604	0.532

6.1.6 Preparation of (*S*)-2,2-dimethyl-1-((*S*)-*p*-tolylsulfinyl)propyl 2,4,6-triisopropylbenzoate (*syn*-14e) and (*R*)-2,2-dimethyl-1-((*S*)-*p*-tolylsulfinyl)propyl 2,4,6-triisopropylbenzoate (*anti*-14e)



Following **GPI**, neopentyl benzoate **30** (1.00 g, 3.14 mmol), TMEDA (610 μ L, 4.08 mmol), *s*BuLi (1.30 M in cyclohexane/hexane, 3.14 mL, 4.08 mmol – lithiation time = 2 h), Mg turnings (303 mg, 12.6 mmol), dibromoethane (410 μ L, 4.71 mmol) and (1*R*,2*S*,5*R*)-(-)-menthyl (*S*)-*p*-toluenesulfinate (1.39 g, 4.71 mmol), afforded after purification by flash column chromatography (hexane:EtOAc = 90:10 \rightarrow 80:20) the *syn* diastereoisomer *syn*-14e (less polar, 557 mg, 39%) as a colourless solid and the *anti* diastereoisomer *anti*-14e (more polar, 654 mg, 46%) as a colourless solid.



syn-14e

$[\alpha]_{\text{D}}^{20}$: +50 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.78 (d, *J* = 8.0 Hz, 2H, 4-H), 7.33 (d, *J* = 8.0 Hz, 2H, 3-H), 7.05 (s, 2H, 15-H), 5.61 (s, 1H, 6-H), 3.00–2.87 (m, 3H, 12-H + 17-H), 2.42 (s, 3H, 1-H), 1.29 (d, *J* = 7.5 Hz, 6H, 13-H), 1.28 (d, *J* = 7.3 Hz, 6H, 18-H), 1.24 (d, *J* = 6.8 Hz, 6H, 14-H), 1.12 (s, 9H, 8-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ: 170.4 (9-C), 150.9 (16-C), 145.7 (2C, 11-C), 141.3 (2-C), 139.6 (5-C), 129.8 (2C, 3-C), 128.8 (10-C), 125.4 (2C, 4-C), 121.2 (2C, 15-C), 98.6 (6-C), 38.2 (7-C), 34.5 (17-C), 31.6 (2C, 12-C), 26.6 (3C, 8-C), 24.8 (2C, 13-C), 24.3 (2C, 14-C), 24.0 (2C, 18-C), 21.6 (1-C) ppm

IR (neat): 2962, 2929, 2871, 1730, 1606, 1461, 1235, 1058, 1040, 814 cm⁻¹

HRMS (ESI) calculated for C₂₈H₄₀NaO₃S: 479.2590, found: 479.2594

M.P. 90–92 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 97:3, 0.5 mL/min, room temperature, 210.8 nm): t_R = 10.8 minutes (minor), 11.9 minutes (major), e.r. > 99:1



anti-14e

[α]_D²⁰: +180 (*c* 0.7, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.63 (d, *J* = 8.0 Hz, 2H, 4-H), 7.33 (d, *J* = 8.0 Hz, 2H, 3-H), 7.02 (s, 2H, 15-H), 5.66 (s, 1H, 6-H), 3.12 (sept, *J* = 6.8 Hz, 2H, 12-H), 2.89 (sept, *J* = 7.0 Hz, 1H, 17-H), 2.41 (s, 3H, 1-H), 1.25 (d, *J* = 7.0 Hz, 6H, 18-H), 1.24 (d, *J* = 6.8 Hz, 6H, 13-H), 1.21–1.19 (m, 15H, 14-H + 8-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ: 169.3 (9-C), 150.6 (16-C), 146.1 (2C, 11-C), 141.5 (2-C), 140.5 (5-C), 129.9 (2C, 3-C), 128.9 (10-C), 125.6 (2C, 4-C), 121.3 (2C, 15-C), 95.7 (6-C), 35.7 (7-C), 34.5 (17-C), 31.3 (2C, 12-C), 26.6 (3C, 8-C), 24.9 (2C, 13-C), 24.5 (2C, 14-C), 24.0 (18-C), 21.6 (1-C) ppm

IR (neat): 2962, 2870, 1738, 1607, 1461, 1230, 1066, 1036, 878, 810 cm⁻¹


HRMS (ESI) calculated for C₂₈H₄₀NaO₃S: 479.2590, found: 479.2594

M.P. 84–86 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.7 mL/min, room temperature, 210.8 nm): t_R = 9.8 minutes (minor), 11.2 minutes (major), e.r. = 98:2




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.509	MM	6008.2	445.1	0.226	45.711	0.812
2	12.081	MM	6078.2	388.6	0.2607	50.289	0.841




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	9.752	MM	28774.5	2202.4	0.2178	97.957	0.782
2	11.223	MM	800.2	41.7	0.2398	2.043	0.888

6.1.7 Preparation of (*S*)-1-((*S*)-*p*-tolylsulfinyl)but-3-en-1-yl 2,4,6-triisopropylbenzoate (*syn*-14f) and (*R*)-1-((*S*)-*p*-tolylsulfinyl)but-3-en-1-yl 2,4,6-triisopropylbenzoate (*anti*-14f)



Following **GPI**, homoallylic benzoate **28** (700 mg, 2.31 mmol), TMEDA (417 μ L, 2.78 mmol), *s*BuLi (1.35 M in cyclohexane/hexane, 2.0 mL, 2.78 mmol – lithiation time = 1 h), Mg turnings (225 mg, 9.24 mmol), dibromoethane (300 μ L, 3.47 mmol), (1*R*,2*S*,5*R*)-(–)-menthyl (*S*)-*p*-toluenesulfinate (1.36 g, 4.62 mmol), Et₃N (485 μ L, 3.47 mmol) and TMSCl (380 μ L, 3.00 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 95:5) the *syn* diastereoisomer *syn*-14f (less polar, 285 mg, 28%) as a colourless solid and the *anti* diastereoisomer *anti*-14f (more polar, 395 mg, 39%) as a dense colourless oil.



syn-14f

$[\alpha]_D^{22}$: +163 (*c* 0.3, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.67 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.38 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.04 (s, 2H, 14-H), 5.75 (dd, *J*₁ = 10.0 Hz, *J*₂ = 3.0 Hz, 1H, 5-H), 5.67 (m, 1H, 7-H), 5.11–5.06 (m, 2H, 7-H + 8-H), 2.91 (app sept, *J* = 6.6 Hz, 3H, 12-H + 16-H), 2.72 (m, 1H, 6-H), 2.44 (s, 3H, 1-H), 2.42 (m, 1H, 6-H), 1.28–1.23 (m, 18H, CH₃ × 6) ppm


¹³C NMR (CDCl₃, 101 MHz) δ: 170.1 (CO), 150.7 (Ar-C), 145.1 (2C, Ar-C × 2), 141.6 (Ar-C), 137.2 (Ar-C), 131.3 (Ar-C), 130.0 (2C, Ar-C × 2), 128.7 (7-C), 124.3 (2C, Ar-C × 2), 120.9 (2C, Ar-C × 2), 119.2 (8-C), 91.3 (5-C), 34.3 (16-C), 31.4 (6-C), 27.7 (2C, 12-C), 24.3 (2C, CH-CH₃ × 2), 24.1 (2C, CH-CH₃ × 2), 23.8 (2C, CH-CH₃ × 2), 21.3 (1-C) ppm

IR (neat): 2961, 1740, 1230, 1056, 1038, 877, 809 cm⁻¹


HRMS (ESI) calculated for C₂₇H₃₆NaO₃S: 463.2277, found: 463.2276

M.P. 85–87 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): tR = 12.8 minutes (minor), 14.0 minutes (major), e.r. > 99:1



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	12.809	MM	4376.4	271.8	0.2684	49.986	0.774
2	14.026	MM	4378.8	248.4	0.2938	50.014	0.785



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	13.995	MM	48434	2553.6	0.3161	100.000	0.715

anti-14f

[α]_D²⁵: -8 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.55 (d, *J* = 8.1 Hz, 2H, Ar-H), 7.32 (d, *J* = 8.1 Hz, 2H, Ar-H), 7.02 (s, 2H, 14-H), 6.07 (dd, *J*₁ = 8.9 Hz, *J*₂ = 3.6 Hz, 1H, 5-H), 5.78 (m, 1H, 7-H), 5.15 (m, 2H, 7-H + 8-H), 2.90 (sept, *J* = 7.0 Hz, 1H, 16-H), 2.83 (sept, *J* = 6.7 Hz, 2H, 12-H × 2), 2.70 (m, 1H, 6-H), 2.42 (s, 3H, 1-H), 2.08 (m, 1H, 6-H), 1.26–1.18 (m, 18H, CH₃ × 6) ppm

¹³C NMR (CDCl₃, 101 MHz) δ: 169.1 (CO), 150.6 (Ar-C), 145.2 (2C, Ar-C × 2), 142.1 (Ar-C), 136.0 (Ar-C), 131.3 (Ar-C), 129.8 (2C, Ar-C × 2), 128.8 (7-C), 125.4 (2C, Ar-C × 2), 120.9 (2C, Ar-C × 2), 119.5 (8-C), 87.2 (5-C), 34.3 (16-C), 31.8 (6-C), 31.3 (2C, 12-C), 24.4 (2C, CH-CH₃ × 2), 24.0 (2C, CH-CH₃ × 2), 23.8 (2C, CH-CH₃ × 2), 21.4 (1-C) ppm

IR (neat): 2961, 1740, 1230, 1056, 1038, 877, 809 cm⁻¹

HRMS (ESI) calculated for C₂₇H₃₆NaO₃S: 463.2277, found: 463.2276

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): tR = 16.7 minutes (minor), 24.2 minutes (major), e.r. = 98:2




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	16.723	BB	15799.6	740.3	0.3262	49.915	0.753
2	24.206	MM	15853.2	509	0.5191	50.085	0.775




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	17.222	BB	3126.2	138.3	0.3452	1.901	0.798
2	25.057	MM	161568.1	3304.9	0.6138	98.099	0.46

6.1.8 Preparation of (*S*)-3-(2-methyl-1,3-dioxolan-2-yl)-1-((*S*)-*p*-tolylsulfinyl)propyl 2,4,6-triisopropylbenzoate (*syn*-14g) and (*R*)-3-(2-methyl-1,3-dioxolan-2-yl)-1-((*S*)-*p*-tolylsulfinyl)propyl 2,4,6-triisopropylbenzoate (*anti*-14g)



Following **GP1**, ketal benzoate **29** (1.45 g, 3.85 mmol), TMEDA (870 μ L, 5.78 mmol), *s*BuLi (1.30 M in cyclohexane/hexane, 4.40 mL, 5.78 mmol – lithiation time = 2 h), Mg turnings (374 mg, 15.5 mmol), dibromoethane (500 μ L, 5.78 mmol) and (1*R*,2*S*,5*R*)-(-)-menthyl (*S*)-*p*-toluenesulfinate (1.70 g, 5.78 mmol), afforded after purification by flash column chromatography (hexane:EtOAc = 75:25 \rightarrow 70:30) the *syn* diastereoisomer *syn*-**14g** (less polar, 367 mg, 19%) as a colourless solid and the *anti* diastereoisomer *anti*-**14g** (more polar, 659 mg, 33%) as a colourless oil that turned into a waxy colourless solid upon standing at room temperature.



syn-14g

$[\alpha]_D^{22}$: +64 (*c* 0.7, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.66 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.36 (d, *J* = 7.9 Hz, 2H, Ar-H), 7.04 (s, 2H, 13-H), 5.78 (dd, *J*₁ = 10.2 Hz, *J*₂ = 2.1 Hz, 1H, 5-H), 3.83 (m, 2H, 10-H), 3.72–3.60 (m, 2H, 10-H), 2.99–2.88 (m, 3H, 14-H × 2 and 18-H), 2.43 (s, 3H, 1-H), 2.05 (m, 1H, 6-H), 1.83–1.73 (m, 2H, 7-H), 1.64 (m, 1H, 6-H), 1.29 (d, *J* = 6.8 Hz, 6H, CH₃ × 2), 1.26 (d, *J* = 6.9 Hz, 12H, CH₃ × 4), 1.16 (s, 3H, 9-H) ppm



¹³C NMR (CDCl₃, 101 MHz) δ: 170.4 (CO), 150.8 (Ar-C), 145.2 (2C, Ar-C × 2), 141.4 (Ar-C), 137.6 (Ar-C), 129.9 (2C, Ar-C × 2), 128.9 (Ar-C), 124.3 (2C, Ar-C × 2), 121.0 (2C, Ar-C × 2), 109.3 (8-C), 92.5 (5-C), 64.7 (10-C), 64.4 (10-C), 34.4 (18-C), 33.6 (7-C), 31.5 (2C, 14-C × 2), 24.4 (2C, CH-CH₃ × 2), 24.2 (2C, CH-CH₃ × 2), 23.9 (9-C), 23.9 (CH-CH₃), 23.9 (CH-CH₃), 21.4 (1-C), 17.6 (6-C) ppm

IR (neat): 3675, 2988, 2901, 1394, 1250, 1066, 1057, 892 cm⁻¹

HRMS (ESI) calculated for C₃₀H₄₂NaO₅S: 537.2645, found: 537.2641

M.P. 71–73 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): t_R = 19.7 minutes (minor), 27.8 minutes (major), e.r. > 99:1



anti-14g

[α]_D²²: +47 (*c* 1.0, CHCl₃)


¹H NMR (CDCl₃, 400 MHz) δ: 7.56 (d, *J* = 7.8 Hz, 2H, Ar-H), 7.31 (d, *J* = 7.9 Hz, 2H, Ar-H), 7.01 (s, 2H, 13-H), 6.09 (dd, *J*₁ = 8.2 Hz, *J*₂ = 4.2 Hz, 1H, 5-H), 3.92 (m, 2H, 10-H), 3.84 (m, 2H, 10-H), 2.90 (sept, *J* = 6.9 Hz, 1H, 18-H), 2.82 (sept, *J* = 6.8 Hz, 2H, 14-H × 2), 2.41 (s, 3H, 1-H), 2.04 (m, 1H, 6-H), 1.84 (m, 2H, 7-H), 1.58 (m, 1H, 6-H), 1.26–1.20 (m, 21H, CH₃ × 6 + 9-H) ppm

¹³C NMR (CDCl₃, 101 MHz) δ: 169.20 (CO), 150.6 (Ar-C), 145.1 (2C, Ar-C × 2), 142.0 (Ar-C), 136.4 (Ar-C), 129.8 (2C, Ar-C × 2), 128.9 (Ar-C), 125.5 (2C, Ar-C × 2), 120.9 (2C, Ar-C × 2), 109.2 (8-C), 88.4 (5-C), 64.7 (10-C), 64.7 (10-C), 34.4 (14-C), 34.3 (7-C), 31.5 (2C, 18-C × 2), 24.6 (2C, CH-CH₃ × 2), 24.1 (2C, CH-CH₃ × 2), 23.9 (CH₃), 23.9 (CH₃), 23.9 (CH₃), 22.5 (6-C), 21.4 (1-C) ppm

IR (neat): 3675, 2962, 1736, 1230, 1040, 812 cm⁻¹

HRMS (ESI) calculated for C₃₀H₄₂NaO₅S: 537.2645, found: 537.2641


Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): tR = 28.7 minutes (minor), 37.5 minutes (major), e.r. = 98:2




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	28.743	PB	0.5717	4.04683e4	1078.54944	49.3256
2	37.517	VB	0.7090	4.15750e4	852.47467	50.6744

#	Time	Type	Area	Height	Width	Area%	Symmetry
1	31.037	NM	2946.1	78.9	0.6226	2.354	0.842
2	41.446	NM	127195.8	1604.6	1.3212	97.756	0.364

6.2 Preparation of α -sulfinyl benzoates by alkylation



6.2.1 Preparation of (*S*)-2-phenyl-1-((*R*)-*p*-tolylsulfinyl)ethyl 2,4,6-triisopropylbenzoate (*anti*-14h)



According to **GP 2** using ((*R*)-*p*-tolylsulfinyl)methyl 2,4,6-triisopropylbenzoate **19** (400 mg, 1.00 mmol), LiHMDS (1.0 M in THF, 2.00 mL, 2.00 mmol) and benzyl bromide (140 μ L, 1.10 mmol). The crude residue (d.r. = 10:1) was purified by silica gel chromatography (pentane:EtOAc = 100:0 \rightarrow 91:9) which gave *anti*-**14h** (311 mg, 63%) as a colourless oil.

$[\alpha]_D^{22}$: +45 (*c* 1.0, CHCl₃)

¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, *J* = 8.0 Hz, 2H, ArH), 7.36–7.20 (m, 7H, ArH), 6.97 (s, 2H, ArH), 6.37 (dd, *J*₁ = 10.0 Hz, *J*₂ = 4.0 Hz, 1H, CH), 3.32 (d, *J* = 14.6 Hz, 1H, CHH), 2.88 (sept, *J* = 6.8 Hz, 1H, CH), 2.59 (dd, *J*₁ = 14.8 Hz, *J*₂ = 10.0 Hz, 1H, CHH), 2.47 (sept, *J* = 6.8 Hz, 2H, CH \times 2), 2.43 (s, 3H, CH₃), 1.24 (d, *J* = 6.8 Hz, 6H, CH₃ \times 2), 1.08 (app. t, *J* = 6.8 Hz, 12H, CH₃ \times 4) ppm

^{13}C NMR (101 MHz, CDCl_3): 169.2 (CO), 150.8 (C), 145.3 (2 \times C), 142.3 (C), 136.2 (C), 135.1 (C), 130.1 (2 \times CH), 129.3 (2 \times CH), 128.9 (C), 128.8 (2 \times CH), 127.3 (CH), 125.6 (2 \times CH), 121.0 (2 \times CH), 88.3 (CH), 34.5 (CH), 33.4 (CH_2), 31.4 (2 \times CH), 24.5 (2 \times CH_3), 24.3 (2 \times CH_3), 24.0 (2 \times CH_3), 21.6 (CH_3) ppm


IR (neat): 2965, 2233, 1734, 1233, 1031, 730 cm^{-1}

HRMS (ESI) calculated for $\text{C}_{31}\text{H}_{38}\text{O}_3\text{SNa}$: 513.2434, found 513.2442

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm) with guard, hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): tR = 22.30 minutes (minor), 25.57 minutes (major), e.r. = 99:1




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	22.261	MM	49923.4	1687.2	0.4932	49.613	0.733
2	25.495	MM	50701.4	1488.9	0.5676	50.387	0.723



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	22.299	MM	415.9	14.8	0.4674	1.224	0.981
2	25.567	MM	33553.2	1007.7	0.555	98.776	0.761

6.2.2 Preparation of (*R*)-2-(4-bromophenyl)-1-((*S*)-*p*-tolylsulfinyl)ethyl 2,4,6-triisopropylbenzoate (*anti*-14i)



According to **GP 2** using ((*S*)-*p*-tolylsulfinyl)methyl 2,4,6-triisopropylbenzoate **19** (1.00 g, 2.50 mmol), LiHMDS (1.0 M in THF, 5.00 mL, 5.00 mmol) and 4-bromobenzyl bromide (929 mg, 3.75 mmol). The crude residue (d.r. = 15:1) was purified by silica gel chromatography (pentane:EtOAc = 100:0 \rightarrow 91:9) which gave *anti*-14i (568 mg, 40%) as a colourless crystalline solid.

TLC conditions:
Pentane:EtOAc = 85:15



decomposition
Syn-14i
Anti-14i

$[\alpha]_D^{22}$: -82 (*c* 1.0, CHCl_3)

¹H NMR (400 MHz, CDCl₃): δ 7.56 (d, *J* = 8.1 Hz, 2H, ArH), 7.42 (d, *J* = 8.3 Hz, 2H, ArH), 7.34 (d, *J* = 8.1 Hz, 2H, ArH), 7.08 (d, *J* = 8.3 Hz, 2H, ArH), 6.96 (s, 2H, ArH), 6.31 (dd, *J*₁ = 10.2 Hz, *J*₂ = 3.8 Hz, 1H, CH), 3.25 (dd, *J*₁ = 14.4 Hz, *J*₂ = 3.8 Hz, 1H, CHH), 2.87 (sept, *J* = 6.8 Hz, 1H, CH), 2.50 (dd, *J*₁ = 14.4 Hz, *J*₂ = 10.2 Hz, 1H, CHH), 2.43 (s, 3H, CH₃), 2.41 (sept, *J* = 6.8 Hz, 2H, CH × 2), 1.23 (d, *J* = 6.8 Hz, 6H, CH₃ × 2), 1.10 (d, *J* = 6.8 Hz, 6H, CH₃ × 2) 1.08 (d, *J* = 6.8 Hz, 6H, CH₃ × 2) ppm


¹³C NMR (101 MHz, CDCl₃): 169.1 (CO), 150.9 (C), 145.3 (C), 142.4 (C), 136.0 (C), 134.2 (C), 131.9 (2 × CH), 131.1 (2 × CH), 130.2 (2 × CH), 128.7 (C), 125.6 (2 × CH), 127.3 (CH), 121.3 (C), 121.0 (2 × CH), 87.9 (CH), 34.5 (CH), 32.8 (CH₂), 31.5 (2 × CH), 24.4 (2 × CH₃), 24.3 (2 × CH₃), 24.0 (2 × CH₃), 21.6 (CH₃) ppm

IR (neat): 2962, 1736, 1229, 1039, 810 cm⁻¹


HRMS (ESI) calculated for C₃₁H₃₇BrO₃SNa: 591.1539, found 591.1541

M.P. 114–116 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm) with guard, hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): t_R = 32.70 minutes (minor), 35.80 minutes (major), e.r. >99:1




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	A
1	32.658	BB	0.6374	1.84946e4	451.94720	50
2	35.886	BP	0.6962	1.83782e4	408.99823	49




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	32.690	BV	0.4772	398.13724	9.98506	0.7056
2	35.800	VB	0.6425	5.60285e4	1183.17224	99.2944

6.2.3 Preparation of (*R*)-1-((*R*)-*p*-tolylsulfinyl)-4-(trimethylsilyl)but-3-yn-1-yl 2,4,6-triisopropylbenzoate (*syn*-14j) and (*S*)-1-((*R*)-*p*-tolylsulfinyl)-4-(trimethylsilyl)but-3-yn-1-yl 2,4,6-triisopropylbenzoate (*anti*-14j)



(*R*)-*p*-Tolylsulfinyl)methyl 2,4,6-triisopropylbenzoate **19** (400 mg, 1.00 mmol) in an oven dried Schlenk tube was dissolved in anhydrous THF (4.00 mL). The solution was cooled to −78 °C and 2,2,6,6-tetramethylpiperidinylmagnesium chloride lithium chloride complex (1.0 M in THF/toluene, 1.05 mL, 1.05 mmol) was added dropwise. The solution was stirred for 20 min, at which point a solution

of 3-bromo-1-(trimethylsilyl)-1-propyne (495 μL , 3.00 mmol) in THF (1.0 mL) was added dropwise. The reaction mixture was stirred at $-78\text{ }^\circ\text{C}$ for a further 2 h and then the cooling bath was removed and the solution was stirred at room temperature for 30 min. The reaction mixture was quenched with sat. NH_4Cl solution (5 mL) and diluted with EtOAc (5 mL). The layers were separated and the aqueous phase was extracted with EtOAc ($3 \times 5\text{ mL}$). The combined organic layers were dried (MgSO_4), filtered and the solvent was removed under reduced pressure. The crude residue (d.r. = 2.5:1) was purified by silica gel chromatography (pentane:EtOAc = 100:0 \rightarrow 93:7) which gave *syn*-**14j** (less polar, 160 mg, 31%) and *anti*-**14j** (more polar, 70.0 mg, 14%) as colourless amorphous solids. Further elution (pentane:EtOAc = 93:7 \rightarrow 75:25) gave recovered starting material (154 mg, 39%) as a colourless crystalline solid.



syn-**14j**

$[\alpha]_D^{22}$: -40 (c 1.0, CHCl_3)

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.65 (d, $J = 8.8\text{ Hz}$, 2H, ArH), 7.37 (d, $J = 8.8\text{ Hz}$, 2H, ArH), 7.05 (s, 2H, ArH), 5.84 (dd, $J_1 = 8.7\text{ Hz}$, $J_2 = 3.8\text{ Hz}$, 1H, CH), 3.02-2.82 (m, 4H, CHH and $\text{CH} \times 3$), 2.72 (dd, $J_1 = 18.0\text{ Hz}$, $J_2 = 3.8\text{ Hz}$, 1H, CHH), 2.45 (s, 3H, CH_3), 1.30-1.25 (m, 18H, $\text{CH}_3 \times 6$), 0.08 (s, 9H, $\text{Si}(\text{CH}_3)_3$) ppm


$^{13}\text{C NMR}$ (101 MHz, CDCl_3): δ 170.1 (CO), 151.2 (C), 145.6 ($2 \times \text{C}$), 142.1 (C), 137.0 (C), 130.3 ($2 \times \text{CH}$), 128.6 (C), 124.7 ($2 \times \text{CH}$), 121.2 ($2 \times \text{CH}$), 100.0 (C), 90.3 (CH), 88.1 (C), 34.6 (CH), 31.6 ($2 \times \text{CH}$), 24.6 ($2 \times \text{CH}_3$), 24.4 ($2 \times \text{CH}_3$), 24.0 ($2 \times \text{CH}_3$), 21.6 (CH_3), 16.4 (CH_2), 0.0 ($3 \times \text{CH}_3$) ppm

IR (neat): 2961, 2182, 1736, 1041, 837 cm^{-1}


HRMS (ESI) calculated for $\text{C}_{30}\text{H}_{42}\text{O}_3\text{SSiNa}$: 533.2516, found 533.2504

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm) with guard, hexane:isopropanol = 95:5, 1.0 mL/min, room temperature, 210.8 nm): $t_R = 4.60$ minutes (major), 5.20 minutes (minor), e.r. > 99:1

Note: *Syn* Diastereomer **14j** decomposes in its neat form at room temperature and should be stored in a freezer where it is stable for over several months.



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	4.383	MMT	1895.4	229.1	0.1374	49.616	0.716
2	5.025	MMT	1918.7	210.7	0.1518	50.384	0.724



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	4.606	MMT	17788.4	2455.8	0.1207	99.098	0.739
2	5.203	MMT	161.9	22.3	0.1209	0.902	0.901

***anti*-14j**

$[\alpha]^{22}_D$: +29 (*c* 1.0, CHCl₃)


¹H NMR (400 MHz, CDCl₃): δ 7.54 (d, *J* = 8.4 Hz, 2H, ArH), 7.31 (d, *J* = 8.4 Hz, 2H, ArH), 7.02 (s, 2H, ArH), 6.06 (dd, *J*₁ = 7.4 Hz, *J*₂ = 4.4 Hz, 1H, CH), 2.96 (dd, *J*₁ = 17.5 Hz, *J*₂ = 4.4 Hz, 1H, CHH), 2.92–2.78 (m, 3H, CH × 3), 2.41 (s, 3H, CH₃), 2.31 (dd, *J*₁ = 17.5 Hz, *J*₂ = 7.4 Hz, 1H, CHH), 1.27–1.18 (m, 18H, CH₃ × 6), 0.15 (s, 9H, Si(CH₃)₃) ppm

¹³C NMR (101 MHz, CDCl₃): δ 169.0 (CO), 151.0 (C), 145.5 (2 × C), 142.4 (C), 136.0 (C), 130.1 (2 × CH), 128.6 (C), 125.5 (2 × CH), 121.1 (2 × CH), 99.5 (C), 89.0 (C), 86.5 (CH), 34.6 (CH), 31.7 (2 × CH), 25.0 (2 × CH₃), 24.0 (4 × CH₃), 21.6 (CH₃), 20.2 (CH₂), 0.0 (3 × CH₃) ppm


IR (neat): 2967, 2181, 1746, 1054, 839 cm⁻¹

HRMS (ESI) calculated for C₃₀H₄₂O₃SSiNa: 533.2516, found 533.2510

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm) with guard, hexane:isopropanol = 95:5, 1.0 mL/min, room temperature, 210.8 nm): t_R = 5.47 minutes (major), 6.46 minutes (minor), e.r. > 99:1




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	5.591	MMT	1277.9	156.6	0.136	49.113	0.79
2	6.663	MMT	1324	131.6	0.1676	50.887	0.802




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	5.474	MMT	20800	2416.8	0.1434	99.176	0.75
2	6.455	MMT	172.8	19.8	0.1523	0.824	0

6.2.4 Preparation of (*R*)-4-chloro-((*S*)-*p*-tolylsulfinyl)butyl 2,4,6-triisopropylbenzoate (*anti*-14k)



Following **GP2**, ((*S*)-*p*-tolylsulfinyl)methyl 2,4,6-triisopropylbenzoate **19** (1.00 g, 2.50 mmol), 1-chloro-3-iodopropane (1.00 g, 5.00 mmol), *i*Pr₂NH (700 μL, 5.00 mmol), *n*BuLi (1.6 M in hexane, 3.10

mL, 5.00 mmol) and HMPA (870 μ L, 5.00 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 90:10) the *syn* diastereoisomer *syn*-**14k** (less polar, mixed with impurity) and the *anti* diastereoisomer *anti*-**14k** (more polar, 482 mg, 40%) as a colourless solid.



$[\alpha]_D^{22}$: -15 (*c* 1.0, CHCl_3)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ : 7.56 (d, $J = 8.0$ Hz, 2H, Ar-H), 7.32 (d, $J = 8.0$ Hz, 2H, Ar-H), 7.03 (s, 2H, 14-H), 6.02 (dd, $J_1 = 8.4$ Hz, $J_2 = 3.4$ Hz, 1H, 5-H), 3.49 (m, 2H, 8-H), 2.91 (sept, $J = 6.9$ Hz, 1H, 16-H), 2.84 (sept, $J = 6.8$ Hz, 2H, 12-H $\times 2$), 2.42 (s, 3H, 1-H), 2.06–1.90 (m, 3H, 7-H $\times 2$ + 6-H), 1.60 (m, 1H, 6-H), 1.26 (d, $J = 6.8$ Hz, 12H, $\text{CH}_3 \times 4$), 1.21 (d, $J = 6.8$ Hz, 6H, $\text{CH}_3 \times 2$) ppm



$^{13}\text{C NMR}$ (CDCl_3 , 101 MHz) δ : 169.2 (CO), 150.8 (Ar-C), 145.2 (2C, Ar-C $\times 2$), 142.3 (Ar-C), 136.1 (Ar-C), 130.0 (2C, Ar-C $\times 2$), 128.7 (Ar-C), 125.5 (2C, Ar-C $\times 2$), 121.0 (2C, Ar-C $\times 2$), 87.6 (5-C), 43.8 (8-C), 34.4 (16-C), 31.6 (2C, 12-C $\times 2$), 28.3 (7-C), 25.2 (6-C), 24.5 (2C, $\text{CH-CH}_3 \times 2$), 24.1 (2C, $\text{CH-CH}_3 \times 2$), 23.9 (2C, $\text{CH-CH}_3 \times 2$), 21.5 (1-C) ppm

IR (neat): 3675, 2965, 1741, 1229, 1073, 1040 cm^{-1}


HRMS (ESI) calculated for $\text{C}_{27}\text{H}_{37}\text{ClNaO}_3\text{S}$: 499.2044, found: 499.2044

M.P. 95–97 $^\circ\text{C}$

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.7 mL/min, room temperature, 210.8 nm): $t_R = 15.8$ minutes (major), 31.8 minutes (minor), e.r. = 99:1



6.2.5 Preparation of (*S*)-4-azido-1-((*S*)-*p*-tolylsulfinyl)butyl 2,4,6-triisopropylbenzoate (*syn*-14I) and (*R*)-4-azido-1-((*S*)-*p*-tolylsulfinyl)butyl 2,4,6-triisopropylbenzoate (*anti*-14I)



Following **GP2**, ((*S*)-*p*-tolylsulfinyl)methyl 2,4,6-triisopropylbenzoate **19** (400 mg, 1.00 mmol), 1-azido-3-iodopropane (421 mg, 2.00 mmol), *i*Pr₂NH (280 μ L, 2.00 mmol), *n*BuLi (1.6 M in hexane, 1.25 mL, 2.00 mmol) and HMPA (350 μ L, 2.00 mmol) afforded after purification by flash column chromatography (petroleum ether:EtOAc = 10:1) the *syn* diastereoisomer *syn*-**14I** (less polar, 54 mg, 11%) as a colourless oil and the *anti* diastereoisomer *anti*-**14I** (more polar, 122 mg, 25%) as a colourless solid.



syn-14I

$[\alpha]_D^{24}$: -47 (*c* 1.0, CHCl₃)


¹H NMR (CDCl₃, 400 MHz) δ : 7.66 (d, *J* = 8.2 Hz, 2H, Ar-H), 7.38 (d, *J* = 8.2 Hz, 2H, Ar-H), 7.05 (s, 2H, Ar-H), 5.67 (dd, *J*₁ = 9.8 Hz, *J*₂ = 2.8 Hz, 1H, CH), 3.25–3.18 (m, 2H, CH₂), 2.91 (sept, *J* = 6.9 Hz, 3H, CH \times 3), 2.45 (s, 3H, CH₃), 2.10–2.01 (m, 1H), 1.77–1.68 (m, 2H, CH₂), 1.55–1.50 (m, 1H), 1.30 (d, *J* = 6.9 Hz, 6H, CH₃ \times 2), 1.26 (d, *J* = 6.9 Hz, 12H, CH₃ \times 4) ppm

¹³C NMR (CDCl₃, 101 MHz) δ : 170.5 (CO), 151.2 (Ar-C), 145.4 (2C, Ar-C), 142.0 (Ar-C), 137.4 (Ar-C), 130.3 (2C, Ar-C), 128.7 (Ar-C), 124.4 (2C, Ar-C), 121.2 (2C, Ar-C), 92.1 (CH), 50.9 (CH₂), 34.6 (CH), 31.9 (2C, CH \times 2), 24.5 (3C, CH₃ \times 2 + CH₂), 24.3 (2C, CH₃ \times 2), 24.0 (2C, CH₃ \times 2), 21.6 (CH₃), 20.7 (CH₂) ppm


IR (neat): 2962, 2871, 2097, 1732, 1606, 1234, 1045, 845, 812 cm⁻¹

HRMS (ESI) calculated for C₂₇H₃₇N₃NaO₃S: 506.2448, found: 506.2445

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 96:4, 0.8 mL/min, room temperature, 210.8 nm): tR = 10.9 minutes (minor), 12.4 minutes (major), e.r. = 99:1



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.88	MM	27.1	2.7	0.1673	0.607	0.947
2	12.363	MM	4429.8	258.4	0.3857	99.393	0.841



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	11.039	MM	369.3	23.2	0.2831	49.760	0.861
2	12.265	MM	373.1	21.1	0.2945	50.240	0.905

anti-14l

$[\alpha]_D^{23}$: +46 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.55 (d, *J* = 7.9 Hz, 2H, Ar-H), 7.33 (d, *J* = 7.9 Hz, 2H, Ar-H), 7.03 (s, 2H, Ar-H), 6.01 (dd, *J*₁ = 8.7 Hz, *J*₂ = 3.8 Hz, 1H, CH), 3.39–3.16 (m, 2H, CH₂), 2.97–2.73 (m, 3H, CH × 3), 2.42 (s, 3H, CH₃), 1.99–1.89 (m, 1H), 1.78–1.69 (m, 2H, CH₂), 1.54–1.43 (m, 1H), 1.26 (d, *J* = 6.8 Hz, 12H, CH₃ × 4), 1.21 (d, *J* = 6.8 Hz, 6H, CH₃ × 2) ppm

¹³C NMR (CDCl₃, 101 MHz) δ: 169.4 (CO), 151.0 (Ar-C), 145.3 (2C, Ar-C), 142.5 (Ar-C), 136.2 (Ar-C), 130.1 (2C, Ar-C), 128.8 (Ar-C), 125.6 (2C, Ar-C), 121.2 (2C, Ar-C), 87.8 (CH), 50.9 (CH₂), 34.6 (CH), 31.8 (2C, CH × 2), 25.1 (CH₂), 25.0 (CH₂), 24.7 (2C, CH₃ × 2), 24.2 (2C, CH₃ × 2), 24.1 (2C, CH₃ × 2), 21.7 (CH₃) ppm

IR (neat): 2962, 2099, 1041 cm⁻¹


HRMS (ESI) calculated for C₂₇H₃₇N₃NaO₃S: 506.2448, found: 506.2445

M.P. 120–122 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 96:4, 0.8 mL/min, room temperature, 210.8 nm): t_R = 15.7 minutes (minor), 35.9 minutes (major), e.r. > 99:1




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	15.699	MM	1416.1	66.8	0.3531	49.570	0.872
2	35.406	MM	1440.7	29.2	0.8234	50.430	0.866




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	15.693	MM	30.9	1.6	0.3247	0.323	0.994
2	35.864	MM	5857.6	114	0.8567	99.477	0.804

6.2.6 Preparation of (*R*)-1-((*R*)-*p*-tolylsulfinyl)pentyl 2,4,6-triisopropylbenzoate (*syn*-14m) and (*S*)-1-((*R*)-*p*-tolylsulfinyl)pentyl 2,4,6-triisopropylbenzoate (*anti*-14m)



Following **GP2**, ((*S*)-*p*-tolylsulfinyl)methyl 2,4,6-triisopropylbenzoate **19** (601 mg, 1.50 mmol), butyl trifluoromethanesulfonate (260 μ L, 1.65 mmol), NaHMDS (1.0 M in THF, 1.60 mL, 1.58 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 95:5) the *syn* diastereoisomer *syn*-**14m** (less polar, 290 mg, 42%) as a colourless solid and the *anti* diastereoisomer *anti*-**14m** (more polar, 246 mg, 36%) as a colourless solid.



***syn*-14m**

$[\alpha]_D^{22}$: -126 (*c* 1.3, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.65 (d, *J* = 8.1 Hz, 2H, Ar-H), 7.37 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.05 (s, 2H, 13-H), 5.67 (dd, *J*₁ = 10.2 Hz, *J*₂ = 2.8 Hz, 1H, 5-H), 2.93 (app sept, *J* = 7.0 Hz, 3H, 13-H \times 2 + 17-H), 2.44 (s, 3H, 1-H), 2.00 (m, 1H, 6-H), 1.61 (m, 1H, 6-H), 1.41 (m, 1H, 7-H), 1.34–1.16 (m, 3H, 7-H + 8-H), 1.29 (d, *J* = 6.8 Hz, 6H, CH₃ \times 2), 1.26 (d, *J* = 6.7 Hz, 12H, CH₃ \times 4), 0.80 (t, *J* = 7.4 Hz, 3H, 9-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 170.5 (CO), 150.8 (Ar-C), 145.2 (2C, Ar-C \times 2), 141.5 (Ar-C), 137.5 (Ar-C), 130.0 (2C, Ar-C \times 2), 128.9 (Ar-C), 124.4 (2C, Ar-C \times 2), 120.9 (2C, Ar-C \times 2), 92.5 (5-C), 34.4 (17-C), 31.6 (2C, 13-C \times 2), 26.9 (7-C), 24.4 (2C, CH-CH₃ \times 2), 24.2 (2C, CH-CH₃ \times 2), 23.9 (CH-CH₃), 23.9 (CH-CH₃), 22.6 (6-C), 22.2 (8-C), 21.4 (1-C), 13.7 (9-C) ppm

IR (neat): 2960, 1735, 1461, 1232, 1046, 753 cm⁻¹


HRMS (ESI) calculated for C₂₈H₄₀NaO₃S: 479.259037, found: 479.258003

M.P. 104–106 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): t_R = 11.2 minutes (major), 12.9 minutes (minor), e.r. = 98:2



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	11.208	BB	4710	341.9	0.2384	49.354	0.796
2	12.87	BB/R	4718.6	295	0.2397	50.046	0.769



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	11.121	VV R	20929.9	1507.5	0.2112	98.281	0.74
2	12.75	VB E	366.1	22.8	0.2386	1.719	0.88

anti-14m

[α]²²_D: -14 (*c* 1.3, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.55 (d, *J* = 8.2 Hz, 2H, Ar-H), 7.31 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.03 (s, 2H, 13-H), 6.00 (m, 1H, 5-H), 2.94–2.82 (m, 3H, 13-H \times 2 + 17-H), 2.42 (s, 3H, 1-H), 1.85 (m, 1H, 6-H), 1.47–1.39 (m, 3H, 6-H + 7-H), 1.35–1.29 (m, 2H, 8-H), 1.25 (d, *J* = 6.9 Hz, 12H, CH₃ \times 4), 1.21 (d, *J* = 6.8 Hz, 6H, CH₃ \times 2), 0.85 (t, *J* = 7.4 Hz, 3H, 9-H) ppm

¹³C NMR (CDCl₃, 101 MHz) δ : 169.3 (CO), 150.6 (Ar-C), 145.1 (2C, Ar-C \times 2), 142.0 (Ar-C), 136.5 (Ar-C), 129.8 (2C, Ar-C \times 2), 129.0 (Ar-C), 125.5 (2C, Ar-C \times 2), 121.0 (2C, Ar-C \times 2), 88.5 (5-C), 34.4 (17-C), 31.5 (2C, 13-C \times 2), 27.3 (7-C), 27.1 (6-C), 24.6 (2C, CH-CH₃ \times 2), 24.1 (2C, CH-CH₃ \times 2), 23.9 (CH-CH₃), 23.9 (CH-CH₃), 22.2 (8-C), 21.5 (1-C), 13.7 (9-C) ppm

IR (neat): 3675, 2968, 2901, 1736, 1394, 1230, 1066, 1044, 879 cm⁻¹

HRMS (ESI) calculated for C₂₈H₄₀NaO₃S: 479.259037, found: 479.258003

M.P. 112–114 °C

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): t_R = 15.4 minutes (major), 21.5 minutes (minor), e.r. = 98:2




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	15.389	BB	6718.7	356.7	0.2867	50.042	0.801
2	21.503	BB	6707.5	252.4	0.4062	49.958	0.823



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	15.305	UV S	4950.7	229.3	0.3074	98.355	0.717
2	21.422	UV S	867.8	30.9	0.4038	1.895	0.774

6.2.7 Preparation of (*R*)-7-ethoxy-7-oxo-1-((*R*)-*p*-tolylsulfinyl)heptyl 2,4,6-triisopropylbenzoate (*syn*-**14n**) and (*S*)-7-ethoxy-7-oxo-1-((*R*)-*p*-tolylsulfinyl)heptyl 2,4,6-triisopropylbenzoate (*anti*-**14n**)



Following **GP2**, ((*S*)-*p*-tolylsulfinyl)methyl 2,4,6-triisopropylbenzoate **19** (600 mg, 1.50 mmol), ethyl hexanoate trifluoromethanesulfonate (575 mg, 1.95 mmol), NaHMDS (1.0 M in THF, 2.25 mL, 2.25 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 85:15) the *syn* diastereoisomer *syn*-**14n** (less polar, 239 mg, 29%) as a thick colourless oil and the *anti* diastereoisomer *anti*-**14n** (more polar, 217 mg, 27%) as a thick colourless oil which was found to contain 5% of *syn*-**14n**. Further subsequent purification by reverse phase HPLC (acetonitrile:water = 30:70 → 85:15) afforded pure *anti*-**14n**.

syn-**14n**

$[\alpha]_D^{22}$: -93 (c 0.7, CHCl_3)


$^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ : 7.64 (d, $J = 7.8$ Hz, 2H, Ar-H), 7.37 (d, $J = 7.6$ Hz, 2H, Ar-H), 7.04 (s, 2H, Ar-H), 5.66 (dd, $J_1 = 9.6$ Hz, $J_2 = 2.2$ Hz, 1H, 5-H), 4.09 (q, $J = 7.0$ Hz, 2H, 12-H), 2.92 (quint, $J = 6.4$ Hz, 3H, 17-H \times 2 + 21-H), 2.44 (s, 3H, 1-H), 2.20 (t, $J = 7.4$ Hz, 2H, 10-H), 1.99 (m, 1H, 6-H), 1.64–1.41 (m, 5H, 6-H + 7-H \times 2 + 9-H \times 2), 1.30–1.21 (m, 23H, $\text{CH}_3 \times 7$ + 8-H \times 2) ppm

$^{13}\text{C NMR}$ (CDCl_3 , 101 MHz) δ : 173.4 (11-C), 170.4 (14-C), 150.8 (Ar-C), 145.1 (2C, Ar-C \times 2), 141.6 (Ar-C), 137.5 (Ar-C), 130.0 (2C, Ar-C \times 2), 128.8 (Ar-C), 124.3 (2C, Ar-C \times 2), 121.0 (2C, Ar-C \times 2), 92.5 (5-C), 60.2 (12-C), 34.4 (21-C), 34.0 (10-C), 31.6 (2C, 17-C \times 2), 28.6 (8-C), 24.6 (9-C), 24.5 (7-C), 24.4 (2C, $\text{CH-CH}_3 \times 2$), 24.2 (2C, $\text{CH-CH}_3 \times 2$), 23.9 (2C, $\text{CH-CH}_3 \times 2$), 22.8 (6-C), 21.4 (1-C), 14.2 (13-C) ppm


IR (neat): 2960, 1731, 1461, 1233, 1044, 811 cm^{-1}

HRMS (ESI) calculated for $\text{C}_{32}\text{H}_{46}\text{NaO}_5\text{S}$: 565.295816, found: 565.295522

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 90:10, 0.5 mL/min, room temperature, 210.8 nm): t_R = 14.9 minutes (major), 16.5 minutes (minor), e.r. = 99:1



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	14.894	UV R	36553.7	1923.7	0.2964	99.880	0.753
2	16.499	UV	37931.4	1747.2	0.3266	50.120	0.771



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	14.881	UV R	43441.2	2235.5	0.2995	98.746	0.74
2	16.486	UV E	551.9	27.1	0.3079	1.254	0.924

anti-14n

[α]²²_D: -9 (c 0.8, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.53 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.31 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.02 (s, 2H, Ar-H), 5.99 (dd, *J*₁ = 8.5 Hz, *J*₂ = 4.1 Hz, 1H, 5-H), 4.11 (q, *J* = 7.2 Hz, 2H, 12-H), 2.90 (sept, *J* = 6.9 Hz, 1H, 21-H), 2.84 (sept, *J* = 6.8 Hz, 2H, 17-H × 2), 2.42 (s, 3H, 1-H), 2.25 (t, *J* = 7.5 Hz, 2H, 10-H), 1.85 (m, 1H, 6-H), 1.56 (quint, *J* = 7.5 Hz, 2H, 9-H), 1.50–1.31 (m, 5H, 6-H + 7-H × 2 + 8-H × 2), 1.26–1.20 (m, 21H, CH₃ × 7) ppm

¹³C NMR (CDCl₃, 101 MHz) δ: 173.4 (11-C), 169.3 (14-C), 150.7 (Ar-C), 145.1 (2C, Ar-C × 2), 142.1 (Ar-C), 136.3 (Ar-C), 129.9 (2C, Ar-C × 2), 128.9 (Ar-C), 125.5 (2C, Ar-C × 2), 121.0 (2C, Ar-C × 2), 88.7 (5-C), 60.2 (12-C), 34.4 (21-C), 34.1 (10-C), 31.6 (2C, 17-C × 2), 28.7 (8-C), 27.2 (6-C), 25.1 (7-C), 24.6 (9-C), 24.6 (2C, CH-CH₃ × 2), 24.1 (2C, CH-CH₃ × 2), 23.9 (2C, CH-CH₃ × 2), 21.5 (1-C), 14.2 (13-C) ppm

IR (neat): 2961, 1733, 1230, 1088, 1038, 810 cm⁻¹

HRMS (ESI) calculated for C₃₂H₄₆NaO₅S: 565.295816, found: 565.295522

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): t_R = 26.3 minutes (major), 46.0 minutes (minor), e.r. = 99:1




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	26.246	UV R	12879.4	372.5	0.5147	99.479	0.784
2	46.007	UV	12624.9	214.2	0.8056	49.521	0.936



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	26.224	UV R	48832.7	1124.3	0.5379	98.654	0.664
2	46.139	UV R	629.8	35.2	0.794	1.346	0.903

6.2.8 Preparation of (*S*)-4,4,4-trifluoro-1-((*S*)-*p*-tolylsulfinyl)butyl 2,4,6-triisopropylbenzoate (*syn*-**14o**)



((*S*)-*p*-Tolylsulfinyl)methyl 2,4,6-triisopropylbenzoate **19** (240 mg, 0.60 mmol) in an oven dried Schlenk tube was dissolved in anhydrous THF (3.00 mL). The solution was cooled to $-78\text{ }^{\circ}\text{C}$ and 2,2,6,6-tetramethylpiperidinylmagnesium chloride lithium chloride complex (1.0 M in THF/toluene, 0.66 mL, 0.66 mmol) was added dropwise. The solution was stirred for 20 min, at which point a solution of 3,3,3-trifluoropropyl trifluoromethanesulfonate (442 mg, 1.80 mmol) in THF (1 mL) was added dropwise. The reaction mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for a further 2 h and then the cooling bath was removed and the solution was stirred at room temperature overnight. The reaction mixture was quenched with sat. NH_4Cl solution (5 mL) and diluted with Et_2O (5 mL). The layers were separated and the aqueous phase was extracted with Et_2O ($3 \times 5\text{ mL}$). The combined organic layers were dried (MgSO_4), filtered and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (petroleum ether:EtOAc = 98:2 \rightarrow 85:15) which gave *syn*-**14o** (84 mg, 28%) as a colourless solid. *Anti*-**14o** (17 mg, 6%) could not be separated from impurities. Further elution (petroleum ether:EtOAc = 85:15 \rightarrow 75:25) gave recovered starting material **19** (146 mg, 61%) as a colourless solid.



syn-**14o**

$[\alpha]_D^{24}$: +69 (*c* 1.0, CHCl_3)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ : 7.68–7.66 (m, 2H, 4-H), 7.41–7.39 (m, 2H, 3-H), 7.06 (s, 2H, 15-H), 5.68 (dd, $J_1 = 9.1\text{ Hz}$, $J_2 = 3.6\text{ Hz}$, 1H, 6-H), 2.97–2.84 (m, 3H, 17-H + 13-H \times 2), 2.45 (s, 3H, 1-H), 2.36–2.21 (m, 2H, 7-H_a, 8-H_a), 2.18–2.06 (m, 1H, 8-H_b), 1.93–1.85 (m, 1H, 7-H_b), 1.30 (d, $J = 6.8\text{ Hz}$, 6H, 18-H), 1.28–1.26 (m, 12H, 14-H) ppm

^{13}C NMR (CDCl_3 , 101 MHz) δ : 170.2 (10-C), 151.3 (16-C), 145.4 (2C, 12-C), 142.2 (2-C), 137.1 (5-C), 130.4 (2C, 3-C), 128.4 (11-C), 126.6 (q, $^1J_{\text{CF}} = 276.4$ Hz, 9-C), 124.3 (2C, 4-C), 121.3 (2C, 15-C), 90.7 (6-C), 34.6 (17-C), 31.9 (2C, 13-C), 29.3 (q, $^2J_{\text{CF}} = 29.6$ Hz, 8-C), 24.5 (2C, CH_3), 24.3 (2C, CH_3), 24.1 (CH_3), 24.0 (CH_3), 21.6 (1-C), 16.6 (q, $^3J_{\text{CF}} = 3.1$ Hz, 7-C) ppm

^{19}F NMR (CDCl_3 , 377 MHz) δ : -66.5 (t, $J = 10.4$ Hz, CF_3) ppm

IR (neat): 2963, 2929, 2871, 1736, 1232, 1141, 1039, 1013, 812 cm^{-1}

HRMS (ESI) calculated for $\text{C}_{27}\text{H}_{35}\text{F}_3\text{NaO}_3\text{S}$: 519.2151, found: 519.2146

M.P. 143–144 $^\circ\text{C}$

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 96:4, 0.7 mL/min, room temperature, 210.8 nm): $t_R = 7.7$ minutes (minor), 9.5 minutes (major), e.r. > 99:1




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	7.688	MM	6093	619.6	0.1639	50.279	0.75
2	9.527	MM	6025.4	498.9	0.2013	49.721	0.789




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	7.649	MM	72.3	6.9	0.1724	0.373	0.759
2	9.452	MM	19307.4	1561.3	0.2061	99.627	0.777

6.2.9 Preparation of (*R*)-1-phenyl-2-((*S*)-*p*-tolylsulfinyl)propan-2-yl 2,4,6-triisopropylbenzoate (**20a**)



Following **GP2**, sulfoxide *anti*-**14b** (800 mg, 1.93 mmol), benzyl iodide (505 mg, 2.32 mmol), $i\text{Pr}_2\text{NH}$ (490 μL , 3.47 mmol), $n\text{BuLi}$ (1.6 M in hexane, 2.17 mL, 3.47 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 90:10) sulfoxide **20a** (736 mg, 76%, $dr >95:5$) as a colourless oil.



$[\alpha]_D^{25}$: +27 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.55 (d, *J* = 7.9 Hz, 2H, 4-H), 7.34–7.33 (m, 2H, 10-H), 7.32–7.27 (m, 3H, 11-H + 12H), 7.22 (d, *J* = 7.9 Hz, 2H, 3-H), 6.96 (s, 2H, 19-H), 3.62 (d, ²*J* = 13.9 Hz, 1H, 8-H_a), 3.40 (d, ²*J* = 13.9 Hz, 1H, 8-H_b), 2.88 (sept, *J* = 6.9 Hz, 1H, 21-H), 2.67 (sept, *J* = 6.8 Hz, 2H, 16-H × 2), 2.38 (s, 3H, 1-H), 1.68 (s, 3H, 7-H), 1.25 (d, *J* = 6.9 Hz, 6H, 22-H), 1.16 (d, *J* = 6.8 Hz, 6H, 17-H), 1.05 (d, *J* = 6.8 Hz, 6H, 18-H) ppm

¹³C NMR (CDCl₃, 101 MHz) δ: 169.6 (13-C), 150.5 (20-C), 145.2 (2C, 15-C), 142.3 (2-C), 136.3 (5-C), 134.7 (9-C), 131.2 (2C, 10-C), 129.6 (14-C), 129.5 (2C, 3-C), 128.5 (2C, 11-C), 127.3 (12-C), 127.2 (2C, 4-C), 120.9 (2C, 19-C), 99.0 (6-C), 38.1 (8-C), 34.5 (21-C), 31.1 (2C, 16-C), 24.4 (2C, 17-C), 24.2 (2C, 18-C), 24.1 (2C, 22-C), 21.6 (1-C), 18.3 (7-C) ppm

IR (neat): 2961, 2870, 1730, 1458, 1236, 1042, 811, 738, 703 cm⁻¹

HRMS (ESI) calculated for C₃₂H₄₀NaO₃S: 527.2590, found: 527.2592

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): t_R = 17.3 minutes (major), 20.9 minutes (minor), e.r. = 98:2




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	17.337	MM	46142.4	2003.2	0.3839	49.252	0.727
2	20.867	MM	47543.8	1725.1	0.4593	50.748	0.743




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	17.337	MM	19541.5	870.6	0.2741	98.180	0.753
2	20.867	MM	366.3	13.8	0.4435	1.820	0.887

6.2.10 Preparation of (*R*)-2-((*S*)-*p*-tolylsulfinyl)pent-4-en-2-yl 2,4,6-triisopropylbenzoate (**20b**)



Following **GP2**, sulfoxide *anti*-**14a** (414 mg, 1.00 mmol), allyl iodide (140 μ L, 1.50 mmol), *i*Pr₂NH (250 μ L, 1.80 mmol), *n*BuLi (1.6 M in hexane, 1.12 mL, 1.80 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 90:10) sulfoxide **20b** (348 mg, 77%, *dr* >95:5) as a colourless oil.



$[\alpha]_D^{23}$: +49 (*c* 1.0, CHCl₃)


¹H NMR (CDCl₃, 400 MHz) δ : 7.54 (d, *J* = 7.9 Hz, 2H, 4-H), 7.25 (d, *J* = 7.9 Hz, 2H, 3-H), 7.00 (s, 2H, 17-H), 5.83 (ddt, *J*_{trans} = 17.1 Hz, *J*_{cis} = 10.1 Hz, *J* = 7.1 Hz, 1H, 9-H), 5.24–5.17 (m, 2H, 10-H), 3.03 (dd, ²*J* = 14.6 Hz, ³*J* = 6.9 Hz, 1H, 8-H_a), 2.94–2.86 (m, 3H, 14-H + 19-H), 2.68 (dd, ²*J* = 14.6 Hz, ³*J* = 7.3 Hz, 1H, 8-H_b), 2.40 (s, 3H, 1-H), 1.74 (s, 3H, 7-H), 1.26 (d, *J* = 6.9 Hz, 6H, 20-H), 1.22 (d, *J* = 6.8 Hz, 6H, 15-H), 1.17 (d, *J* = 6.8 Hz, 6H, 16-H) ppm

¹³C NMR (CDCl₃, 101 MHz) δ : 169.3 (11-C), 150.6 (18-C), 145.3 (2C, 13-C), 142.3 (2-C), 136.4 (5-C), 131.1 (9-C), 129.7 (12-C), 129.5 (2C, 3-C), 126.8 (2C, 4-C), 121.0 (2C, 17-C), 120.4 (10-C), 98.9 (6-C), 37.3 (8-C), 34.6 (19-C), 31.2 (2C, 14-C), 24.4 (2C, CH₃ × 2), 24.3 (2C, CH₃ × 2), 24.1 (2C, 20-C), 21.6 (1-C), 17.7 (7-C) ppm

IR (neat): 2962, 1733, 1607, 1460, 1236, 1047, 810 cm⁻¹

HRMS (ESI) calculated for C₂₈H₃₈NaO₃S: 477.2434, found: 477.2425

Chiral HPLC: (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 96:4, 1.0 mL/min, room temperature, 210.8 nm): t_R = 7.7 minutes (minor), 9.2 minutes (major), e.r. = 99:1



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	7.701	MM	1936.9	177.5	0.1819	51.004	0.786
2	9.203	MM	1860.6	147	0.2111	48.996	0.853



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	7.707	MM	18.4	2.2	0.137	0.575	0.879
2	9.19	MM	3187.7	253.1	0.2099	99.425	0.855

7. Epimerization of *anti*-14a to *syn*-14b (Figure S1)

In many cases, standard flash chromatography was sufficient for separating mixtures of *syn*- and *anti* diastereomers. Diastereomeric pairs showed differences in retention factors (R_f values) of up to 0.2, the *anti* diastereomer always proving to be the more polar. However, in some cases, separation was more challenging; for example, the isopropyl-substituted benzoates, *syn*- and *anti*-14d, could only be separated using preparative HPLC. Therefore, we investigated the base-mediated epimerization of a diastereomeric mixture of the α -sulfinyl benzoates, *syn* and *anti*-14b, under both kinetic and thermodynamic conditions, hoping to enrich the mixture heavily towards one diastereomer, thus facilitating chromatographic separation. The Knochel–Hauser base, $\text{TMPMgCl}\cdot\text{LiCl}$, was found to be the optimal reagent to affect the deprotonation, LiHMDS and NaHMDS being ineffective and LDA leading to complete decomposition. A 50:50 mixture of *syn* and *anti*-14b in THF was exposed to $\text{TMPMgCl}\cdot\text{LiCl}$ at $-78\text{ }^\circ\text{C}$ for 30 minutes followed by a quench with excess *i*-PrOH at the same temperature; the process resulted in a mixture more enriched in the *syn* diastereomer (*syn*-14b/*anti*-14b 72:28; Figure 1, entry 1). The origin of the selectivity for the *syn* diastereomer presumably is the favored approach of the proton source from the less hindered *Re* face of the carbanion center presented by the more thermodynamically stable conformer, that is, the one that places the large OTIB group gauche to the small substituent (the lone pair) of the vicinal sulfur center (Figure S1). Surmising that the minor *anti* isomer was formed through approach of the proton source from the *Si* face of this conformer, the increased steric hindrance of this face being mitigated by a favorable interaction between the magnesium ion and the oxygen atom of the proton source, we explored other proton sources where such an interaction might be diminished or absent. Indeed, the use of less coordinating proton sources proved to be beneficial, with the use of indene exhibiting the highest d.r. value (*syn*-14b/*anti*-14b 86:14; Figure 1, entry 4). We also explored epimerization under conditions that would be expected to permit equilibration of the mixture, namely, $\text{KO}t\text{Bu}/t\text{BuOH}$ and $\text{dmsyl sodium}/\text{DMSO}$; however, resulting mixtures were only very slightly enriched in favor of the *syn* diastereomer. Unfortunately, when we subjected a mixture of the isopropyl-substituted benzoates, *syn*- and *anti*-14d, to the optimized conditions ($\text{TMPMgCl}\cdot\text{LiCl}$, THF, $-78\text{ }^\circ\text{C}$; indene), the d.r. value did not change, suggesting that deprotonation did not occur, presumably owing to steric hindrance.




Figure S1: Optimization of reaction conditions for the epimerization of methyl-substituted α -sulfinyl benzoate. Reactions performed on 0.05 mmol scale; d.r. values were measured by ¹H NMR analysis of the crude reaction mixture.

7.1 Representative Procedure Using TMPMgCl•LiCl

A stirred solution of a 50:50 mixture of *syn*- and *anti*-**14b** (20.70 mg, 0.050 mmol) in dry THF (0.500 mL) under nitrogen was treated with TMPMgCl•LiCl (1.0 M in THF/toluene, 0.750 mL, 0.075 mmol) at -78 °C. The resulting mixture was stirred for 30 min at that temperature before the proton source (0.500 mmol, 10 equiv) was added. The quenched reaction mixture was warmed to room temperature, H₂O (5 mL) and Et₂O (5 mL) were added, the phases were separated and the aqueous phase was extracted with Et₂O (5 mL \times 3). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The d.r. and the yield of each diastereoisomer were determined by ¹H NMR using 1,4-dimethoxybenzene as internal standard.

7.2 Procedure Using *t*-BuOK/*t*-BuOH


A stirred solution of a 50:50 mixture of *syn*- and *anti*-**14b** (20.70 mg, 0.050 mmol) in dry THF (0.500 mL) under nitrogen was treated with *t*-BuOK (1.0 M in *t*-BuOH, 0.750 mL, 0.075 mmol) at -78 °C. The resulting mixture was stirred for 30 min at that temperature before it was warmed to room temperature. H₂O (5 mL) and Et₂O (5 mL) were added, the phases were separated and the aqueous phase was extracted with Et₂O (5 mL \times 3). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The d.r. and the yield of each diastereoisomer were determined by ¹H NMR using 1,4-dimethoxybenzene as internal standard.

7.3 Procedure Using NaDMSO/DMSO


NaDMSO was freshly prepared according to a modified literature procedure.²⁴ A dry schlenk tube was charged with NaH (60% dispersion in mineral oil, 8.0 mg, 0.2 mmol). Pentane (1.0 mL) was added, the suspension was swirled for few minutes, decanted and the solvent was removed with a syringe. The

procedure was repeated for three times to remove all the mineral oil, then NaH was dried in high vacuum before suspending in dry DMSO (1.0 mL). The resulting suspension was heated at 60 °C for 40 minutes. Completion of the reaction was shown by disappearance of solid NaH and cessation of gas evolution to give a pale yellow solution. The flask was cooled to room temperature and a 50:50 mixture of *syn*- and *anti*-**14b** (42 mg, 0.1 mmol) in DMSO:THF (2:1 v/v, 1.0 mL in total) under nitrogen was added slowly. The resulting mixture was stirred for 1 hour at room temperature before H₂O (5 mL) and Et₂O (5 mL) were added. The phases were separated and the aqueous phase was extracted with Et₂O (5 mL × 3). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The d.r. and the yield of each diastereoisomer were determined by ¹H NMR using 1,4-dimethoxybenzene as internal standard.

8. Homologation of Boronic Esters



8.1 Preparation of (*R*)-2-(1-(4-methoxyphenyl)-5-phenylpentan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**18a**)



Following **GP3**, phenyl ethyl sulfoxide *syn*-**14a** (106 mg, 0.21 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) the homologated boronic ester **18a** (61.7 mg, 81%) as a colourless oil.

Following **GP4**, phenyl ethyl sulfoxide *syn*-**14a** (131 mg, 0.26 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *i*PrMgCl·LiCl (1.14 M in THF, 210 μ L, 0.24 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) the homologated boronic ester **18a** (61.7 mg, 71%) as a colourless oil.

$[\alpha]_D^{23}$: -6 (*c* 0.5, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.30–7.26 (m, 2H, Ar-H), 7.21–7.17 (m, 3H, Ar-H), 7.11 (d, *J* = 8.6 Hz, 2H, Ar-H), 6.83 (d, *J* = 8.6 Hz, 2H, Ar-H), 3.80 (s, 3H, O-CH₃), 2.70–2.51 (m, 4H, 1-H + 5-H), 1.86–1.64 (m, 4H, 2-H + 4-H), 1.30 (s, 12H, C-CH₃ × 4), 1.14 (m, 1H, 3-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ: 157.6 (Ar-C), 143.0 (Ar-C), 135.0 (Ar-C), 129.2 (2C, Ar-C × 2), 128.4 (2C, Ar-C × 2), 128.2 (2C, Ar-C × 2), 125.5 (Ar-C), 113.6 (2C, Ar-C × 2), 83.0 (2C, B-O-C × 2), 55.2 (O-CH₃), 35.6 (5-C), 34.6 (1-C), 33.6 (2-C), 33.4 (4-C), 24.9 (4C, C-CH₃ × 4) ppm (*carbon attached to boron not observed due to quadrupolar relaxation*)

¹¹B NMR (CDCl₃, 128 MHz) δ: 33.5 ppm


IR (neat): 2977, 2926, 1511, 1379, 1316, 1243, 1142, 1037, 821 cm⁻¹

HRMS (ESI) calculated for C₂₄H₃₃BNaO₃: 403.2419, found: 403.2412


Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 90:10, 0.7 mL/min, room temperature, 210.8 nm): t_R = 13.5 minutes (major), 15.3 minutes (minor), e.r. = 98:2 (Li), e.r. > 99:1 (Mg)



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	13.529	BB	10227.8	586.2	0.2647	49.976	0.679
2	15.372	BB	10237.6	505.4	0.3077	50.024	0.637




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	13.398	BB	426.3	26	0.2497	1.897	0.775
2	15.111	BB	22040.9	1085.9	0.3067	98.103	0.577



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	15.41	BB	6947.7	343.1	0.309	100.000	0.668

8.2 Preparation of (*R*)-2-(4-(4-methoxyphenyl)butan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**18b**)



Following **GP3**, methyl sulfoxide *syn*-**14b** (87.1 mg, 0.21 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *t*BuLi (1.7 M in pentane, 235 μL, 0.40 mmol) afforded after purification by flash column

chromatography (hexane:Et₂O = 95:5) the homologated boronic ester **18b** (45.4 mg, 78%) as a colourless oil.

Following **GP4**, methyl sulfoxide *syn*-**14b** (108 mg, 0.26 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.14 M in THF, 210 μL, 0.24 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) the homologated boronic ester **18b** (33.6 mg, 58%) as a colourless oil.

Spectral data matched that previously reported.²⁵

[α]²³_D: −19 (*c* 0.7, CHCl₃). Lit. for (*R*):²⁶ −8.2 (*c* 0.98, CHCl₃); for (*S*):²⁵ +7.6 (*c* 1.7, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.10 (dt, *J*₁ = 8.7 Hz, *J*₂ = 2.9 Hz, 2H, Ar-H), 6.81 (dt, *J*₁ = 8.6 Hz, *J*₂ = 3.0 Hz, 2H, Ar-H), 3.78 (s, 3H, O-CH₃), 2.60–2.53 (m, 2H, 1-H), 1.75 (m, 1H, 2-H), 1.56 (m, 1H, 2-H), 1.25 (s, 12H, C-CH₃ × 4), 1.10–1.00 (m, 4H, 3-H + 4-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ: 157.5 (Ar-C), 135.2 (Ar-C), 129.3 (2C, Ar-C × 2), 113.6 (2C, Ar-C × 2), 82.8 (2C, B-O-C × 2), 55.2 (O-CH₃), 35.5 (1-C), 34.4 (2-C), 24.8 (2C, C-CH₃ × 2), 24.8 (2C, C-CH₃ × 2), 15.4 (4-C) ppm (*carbon attached to boron not observed due to quadrupolar relaxation*)

¹¹B NMR (CDCl₃, 128 MHz) δ: 34.3 ppm


IR (neat): 2977, 2931, 1612, 1512, 1463, 1380, 1370, 1314, 1243, 1142, 1112, 1038, 967, 863, 848, 822, 687, 670, 561 cm^{−1}

HRMS (ESI) calculated for C₁₇H₂₇BO₃: 291.2132, found: 291.2123


Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 95:5, 0.5 mL/min, room temperature, 210.8 nm): t_R = 17.6 minutes (major), 18.6 minutes (minor), e.r. = 99:1 (Li), >99:1 (Mg)



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	17.561	VV R	14130.3	681.3	0.3133	49.783	0.695
2	18.575	VB	14253.7	640.7	0.3352	50.217	0.668




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	17.993	EV R	32696.8	1506.2	0.3304	98.366	0.658
2	18.981	VB E	475.7	20.4	0.3442	1.434	0.702



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	18.157	EV R	39056.7	1736.5	0.3439	99.666	0.617
2	19.923	VV E	131	6.6	0.3132	0.334	0.901

8.3 Preparation of (*R*)-2-(1-(4-methoxyphenyl)pentan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane **18c**



Following **GP3**, ethyl sulfoxide *syn*-**14c** (90.0 mg, 0.21 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) the homologated boronic ester **18c** (37.1 mg, 61%) as a colourless oil.

Following **GP4**, ethyl sulfoxide *syn*-**14c** (111 mg, 0.26 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.3 M in THF, 210 μ L, 0.24 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) the homologated boronic ester **18c** (29.8 mg, 49%) as a colourless oil.

Spectral data matched that previously reported.²⁵

[α]²³_D: -9 (*c* 0.7, CHCl₃). Lit. for (*R*):²⁶ -9.6 (*c* 1.05, CHCl₃); for (*S*):²⁵ +9.4 (*c* 1.6, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.10 (d, *J* = 8.6 Hz, 2H, Ar-H), 6.82 (d, *J* = 8.5 Hz, 2H, Ar-H), 3.78 (s, 3H, O-CH₃), 2.61–2.48 (m, 2H, 1-H), 1.72 (m, 1H, 2-H), 1.62 (m, 1H, 2-H), 1.51–1.43 (m, 2H, 4-H), 1.27 (s, 12H, C-CH₃ \times 4), 0.98 (m, 1H, 3-H), 0.22 (t, *J* = 7.4 Hz, 3H, 5-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 157.6 (Ar-C), 135.2 (Ar-C), 129.2 (2C, Ar-C \times 2), 113.6 (2C, Ar-C \times 2), 82.9 (2C, B-O-C \times 2), 55.2 (O-CH₃), 34.7 (1-C), 33.4 (2-C), 24.8 (2C, C-CH₃ \times 2), 24.8 (2C, C-CH₃ \times 2), 24.1 (4-C), 13.6 (5-C) ppm (carbon attached to boron not observed due to quadrupolar relaxation)

¹¹B NMR (CDCl₃, 128 MHz) δ : 33.6 ppm

IR (neat): 2976, 2927, 1511, 1371, 1313, 1244, 1142, 1038, 966, 852, 824 cm⁻¹

HRMS (ESI) calculated for C₁₈H₂₉BNaO₃: 327.2105, found: 327.2099


Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 97:3, 0.7 mL/min, room temperature, 210.8 nm): the racemate was previously analysed (see reference 16) with retention times tR = 16.0 minutes, 19.1 minutes, e.r. > 99:1 (Li), e.r. > 99:1 (Mg)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.212	VV	0.0972	8.73743	1.11776	0.0506
2	19.237	VV	0.3579	1.72745e4	741.09216	99.9494

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.800	VV	0.1758	15.85568	1.12918	0.3029
2	18.504	VB	0.3288	5218.14941	238.96301	99.6971

8.4 Preparation of (*R*)-2-(1-(4-methoxyphenyl)-4-methylpentan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**18d**)



Following **GP3**, isopropyl sulfoxide *anti*-**14d** (93.0 mg, 0.21 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 97:3) the homologated boronic ester **18d** (34.1 mg, 54%) as a colourless solid.

Following **GP4**, isopropyl sulfoxide *syn*-**14d** (95.0 mg, 0.22 mmol), boronic ester **17a** (43.3 mg, 0.17 mmol) and *i*PrMgCl•LiCl (1.14 M in THF, 170 μ L, 0.20 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 97:3) the homologated boronic ester **18d** (4.00 mg, 8%) as a colourless solid.

[α]²³_D: +3 (*c* 1.1, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.12 (d, *J* = 8.5 Hz, 2H, Ar-H), 6.82 (d, *J* = 8.5 Hz, 2H, Ar-H), 3.79 (s, 3H, O-CH₃), 2.58 (m, 1H, 1-H), 2.46 (m, 1H, 1-H), 1.80–1.59 (m, 3H, 2-H + 4-H), 1.28 (s, 12H, C-CH₃ \times 4), 0.93 (d, *J* = 6.8 Hz, 6H, 5-H \times 2), 0.91 (m, 1H, 3-H) ppm

¹³C NMR (CDCl₃, 101 MHz) δ : 157.68 (Ar-C), 135.4 (Ar-C), 129.3 (2C, Ar-C \times 2), 113.8 (2C, Ar-C \times 2), 83.0 (2C, B-O-C \times 2), 55.3 (O-CH₃), 35.2 (1-C), 31.8 (2-C), 29.7 (4-C), 25.2 (2C, C-CH₃ \times 2), 25.0 (2C, C-CH₃ \times 2), 22.4 (5-C), 21.8 (5-C) ppm (*carbon attached to boron not observed due to quadrupolar relaxation*)


¹¹B NMR (CDCl₃, 128 MHz) δ : 33.7 ppm

IR (neat): 2952, 2857, 1512, 1312, 1297, 1235, 1141, 1041, 874, 824, 515 cm⁻¹


HRMS (ESI) calculated for C₁₉H₃₁BNaO₃: 341.2262, found: 341.2261

M.P. 35–37 °C


Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 90:10, 0.5 mL/min, room temperature, 210.8 nm): t_R = 10.7 minutes (minor), 12.1 minutes (major), e.r. = 95:5 (Li), e.r. = 98:2 (Mg)



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.664	BB	13086.7	1001.5	0.1976	49.961	0.675
2	12.108	BB	13107.1	894	0.222	50.039	0.677




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.655	BB	1130.7	87.1	0.1967	4.720	0.689
2	12.086	MM	22825.5	1535.5	0.2478	95.280	0.668



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.621	BV	298.9	18.4	0.2313	1.526	0.497
2	12.006	MM	19291.1	1336.4	0.2406	98.474	0.687

8.5 Preparation of (S)-2-(1-(4-methoxyphenyl)-4,4-dimethylpentan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**18e**)



Following **GP6**, sulfoxide *syn*-**14e** (177 mg, 0.39 mmol), boronic ester **17a** (78.0 mg, 0.30 mmol), *t*BuLi (1.6 M in pentane, 370 μ L, 0.60 mmol) and PMDTA (120 μ L, 0.60 mmol) afforded after purification by flash column chromatography (petroleum ether:EtOAc = 98:2 \rightarrow 90:10) the homologated boronic ester **18e** (53.0 mg, 54%) as a colourless oil.

$[\alpha]_D^{24}$: +12 (*c* 0.25, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.11 (d, *J* = 8.5 Hz, 2H, 4-H), 6.82 (d, *J* = 8.5 Hz, 2H, 3-H), 3.78 (s, 3H, 1-H), 2.57 (ddd, ²*J*₁ = 13.6 Hz, *J*₂ = 9.9 Hz, *J*₃ = 5.7 Hz 1H, 6-H_a), 2.36 (ddd, ²*J*₁ = 13.6 Hz, *J*₂ = 9.8 Hz, *J*₃ = 7.1 Hz, 1H, 6-H_b), 1.76–1.61 (m, 2H, 7-H), 1.29 (s, 12H, 12-H + 13-H), 0.93 (s, 9H, 10-H), 0.87 (dd, *J*₁ = 11.2 Hz, *J*₂ = 4.6 Hz, 1H, 8-H_b) ppm

¹³C NMR (CDCl₃, 101 MHz) δ : 157.8 (2-C), 135.5 (5-C), 129.4 (2C, 4-C), 113.8 (2C, 3-C), 83.1 (2C, 11-C), 55.4 (1-C), 36.0 (6-C), 32.2 (9-C), 29.9 (7-C), 29.7 (3C, 10-C), 25.3 (2C, 12-C), 25.2 (2C, 13-C) ppm (carbon attached to boron (8-C) not observed due to quadrupolar relaxation) in ¹³C NMR but it correlates with 10-H at 37.0 ppm in HMBC)

¹¹B NMR (CDCl₃, 96 MHz) δ : 32.4 ppm


IR (neat): 2953, 2866, 1512, 1371, 1245, 1144, 1040, 826 cm⁻¹

HRMS (ESI) calculated for C₂₀H₃₃BNaO₃: 355.2419, found: 355.2420

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 97:3, 0.8 mL/min, room temperature, 210.8 nm): t_R = 10.7 minutes (major), 15.3 minutes (minor), e.r. = 76:24




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.669	MM	928.5	70.6	0.2191	51.685	0.745
2	15.402	MM	868	49.5	0.2921	48.315	0.816



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.652	MM	1541.4	118.2	0.2173	76.382	0.745
2	15.29	MM	476.6	27.1	0.2036	23.618	0.799

8.6 Preparation of (S)-2-(1-(4-methoxyphenyl)hex-5-en-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**18f**)



Following **GP3**, allylic sulfoxide *syn*-**14f** (92.5 mg, 0.21 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) the homologated boronic ester **18f** (53.6 mg, 85%) as a colourless oil.

Following **GP4**, allylic sulfoxide *syn*-**14f** (115 mg, 0.26 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.14 M in THF, 210 μ L, 0.24 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) the homologated boronic ester **18f** (43.9 mg, 69%) as a colourless oil.

Spectral data matched that previously reported.²⁵

$[\alpha]_D^{23}$: -16 (*c* 0.8, CHCl₃). Lit. for (*R*):²⁵ +0.12 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.09 (dt, $J_1 = 8.6$ Hz, $J_2 = 2.9$ Hz, 2H, Ar-H), 6.81 (dt, $J_1 = 8.6$ Hz, $J_2 = 2.9$ Hz, 2H, Ar-H), 5.80 (m, 1H, 5-H), 5.03 (dq, $J_1 = 17.1$ Hz, $J_2 = 2.0$ Hz, 1H, 6-H_{trans}), 4.95 (dq, $J_1 = 10.1$ Hz, $J_2 = 1.0$ Hz, 1H, 6-H_{cis}), 3.78 (s, 3H, O-CH₃), 2.55 (m, 2H, 1-H), 2.19 (m, 2H, 4-H), 1.68 (m, 2H, 2-H), 1.25 (s, 12H, C-CH₃ \times 4), 1.13 (m, 1H, 3-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 157.6 (Ar-C), 138.4 (5-C), 135.0 (Ar-C), 129.2 (2C, Ar-C \times 2), 114.9 (6-C), 113.7 (2C, Ar-C \times 2), 83.0 (2C, B-O-C \times 2), 55.2 (O-CH₃), 35.4 (1-C), 34.5 (3-C), 33.2 (2-C), 24.9 (2C, C-CH₃ \times 2), 24.8 (2C, C-CH₃ \times 2) ppm (*carbon attached to boron not observed due to quadrupolar relaxation*)

^{11}B NMR (CDCl_3 , 128 MHz) δ : 33.3 ppm


IR (neat): 2977, 2924, 1511, 1318, 1142, 1038, 823 cm^{-1}

HRMS (ESI) calculated for $\text{C}_{19}\text{H}_{29}\text{BNaO}_3$: 339.2105, found: 339.2109

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 90:10, 0.8 mL/min, room temperature, 210.8 nm): t_R = 7.3 minutes, 7.8, e.r. = 99:1 (Li), e.r. >99:1 (Mg)



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	7.278	SV	8222.7	878.2	0.1413	50.349	0.685
2	7.832	VB	8108.8	799.8	0.1532	49.651	0.679




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	7.286	VB R	2887.9	310.3	0.1392	99.000	0.701
2	7.838	VB E	25.2	1.8	0.2201	1.000	2.73



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	7.119	VB R	54.6	4.8	0.1639	0.219	1.068
2	8.237	VB R	24854.8	2182.2	0.1751	99.781	0.64

8.7 Preparation of (S)-2-(1-(4-methoxyphenyl)-5-(2-methyl-1,3-dioxolan-2-yl)pentan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (18g)



Following **GP3**, ketal sulfoxide *syn*-**14g** (108 mg, 0.21 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *t*BuLi (1.7 M in pentane, 235 μL , 0.40 mmol) afforded after purification by flash column chromatography (hexane: Et_2O = 75:25) the homologated boronic ester **18g** (54.3 mg, 70%) as a colourless oil.

Following **GP4**, ketal sulfoxide *syn*-**14g** (134 mg, 0.26 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *i*PrMgCl \cdot LiCl (1.14 M in THF, 210 μL , 0.24 mmol) afforded after purification by flash column chromatography (hexane: Et_2O = 75:25) the homologated boronic ester **18g** (48.9 mg, 63%) as a colourless oil.

$[\alpha]_D^{23}$: -3 (c 0.6, CHCl_3)

¹H NMR (CDCl₃, 400 MHz) δ: 7.09 (d, *J* = 8.5 Hz, 2H, Ar-H), 6.81 (d, *J* = 8.5 Hz, 2H, Ar-H), 3.95–3.87 (m, 4H, 7-H × 2), 3.77 (s, 3H, O-CH₃), 2.61–2.47 (m, 2H, 1-H), 1.77–1.46 (m, 6H, 2-H + 4-H + 5-H), 1.31 (s, 3H, 6-H), 1.25 (s, 12H, C-CH₃ × 4), 1.00 (m, 1H, 3-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ: 157.6 (Ar-C), 135.1 (Ar-C), 129.2 (2C, Ar-C × 2), 113.6 (2C, Ar-C × 2), 110.1 (O-C-O), 82.9 (2C, B-O-C × 2), 64.5 (2C, 7-C × 2), 55.2 (O-CH₃), 38.3 (5-C), 34.6 (1-C), 33.6 (2-C), 25.5 (4-C), 24.8 (2C, C-CH₃ × 2), 24.8 (2C, C-CH₃ × 2), 23.6 (6-C) ppm (*carbon attached to boron not observed due to quadrupolar relaxation*)

¹¹B NMR (CDCl₃, 128 MHz) δ: 33.7 ppm


IR (neat): 2978, 2932, 1511, 1372, 1316, 1244, 1142, 1037, 848, 825 cm⁻¹

HRMS (ESI) calculated for C₂₂H₃₅BNaO₅: 413.2474, found: 413.2475

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 95:5, 0.7 mL/min, room temperature, 210.8 nm): t_R = 23.6 minutes (major), 25.1 minutes (minor), e.r. = 99:1 (Li), e.r. = 99:1 (Mg)



8.8 Preparation of (*R*)-tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)heptanoate (**18h**)



Following **GP4**, sulfoxide *ent-anti-14b* (108 mg, 0.26 mmol), boronic ester **17b** (57 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.3 M in THF, 170 μ L, 0.22 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 95:5) the homologated boronic ester **18h** (43 mg, 69%) as a colourless oil.

$[\alpha]_D^{23}$: -4 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 2.19 (t, *J* = 7.4 Hz, 2H, 4-H), 1.63–1.52 (m, 2H, 5-H), 1.48–1.41 (m, 1H), 1.43 (s, 9H, 1-H), 1.36–1.25 (m, 3H), 1.22 (s, 12H, 11-H), 1.03–0.92 (m, 4H, 8-H + 9-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 173.4 (3-C), 83.0 (2C, 10-C), 80.0 (2-C), 35.8 (4-C), 33.0 (CH₂), 28.6 (CH₂), 28.3 (3C, 1-C), 25.5 (5-C), 24.9 (4C, 11-C), 15.6 (9-C) ppm (*carbon attached to boron not observed due to quadrupolar relaxation*)

¹¹B NMR (CDCl₃, 128 MHz) δ : 33.8 ppm


IR (neat): 2977, 2930, 1730, 1462, 1367, 1314, 1142, 859 cm⁻¹

HRMS (ESI) calculated for C₁₇H₃₃BNaO₄: 335.2367, found: 335.2382

Chiral HPLC: A small portion of the product was oxidized and the corresponding alcohol was converted to the benzoate using benzoyl chloride²⁷ for HPLC analysis. (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 98:2, 0.3 mL/min, room temperature, 230 nm): tR = 18.9 minutes (major), 20.1 minutes (minor), e.r. > 99:1 (Mg)



8.9 Preparation of (*R*)-2-(5-azidopentan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**18i**)



Following **GP4**, sulfoxide *syn*-**14b** (135.3 mg, 0.33 mmol), boronic ester **17c** (53 mg, 0.25 mmol) and *i*PrMgCl•LiCl (1.30 M in THF, 230 μ L, 0.30 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 95:5) the homologated boronic ester **18i** (46 mg, 77%) as a colourless oil.

$[\alpha]_D^{24}$: -9 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 3.24 (t, 2H, 1-H), 1.68–1.56 (m, 2H, 2-H), 1.56–1.45 (m, 1H, 3-H_a), 1.40–1.29 (m, 1H, 3-H_b), 1.24 (s, 12H, 7-H), 1.09–0.94 (m, 4H, 4-H + 5-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 83.1 (2C, 6-C), 51.8 (1-C), 30.4 (3-C), 28.3 (2-C), 24.9 (4C, 7-C), 15.6 (5-C) ppm (carbon attached to boron not observed due to quadrupolar relaxation)

¹¹B NMR (CDCl₃, 128 MHz) δ : 34.0 ppm


IR (neat): 2978, 2934, 2869, 2093, 1464, 1372, 1257, 1144, 967 cm⁻¹

HRMS (ESI) calculated for C₁₁H₂₂BN₃NaO₂: 262.1699, found: 262.1696

Chiral HPLC: A small portion of the product was oxidized and the corresponding alcohol was converted to the benzoate using benzoyl chloride²⁷ for HPLC analysis. (Daicel Chiralcel-IA column (25 cm), hexane:isopropanol = 98:2, 0.3 mL/min, room temperature, 230 nm): tR = 18.4 minutes (minor), 19.5 minutes (major), e.r. > 99:1 (Mg)



8.10 Preparation of (*S,E*)-*tert*-butyldimethyl((3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-2-en-1-yl)oxy)silane (**18j**)



Following **GP3**, methyl sulfoxide *anti*-**14b** (87 mg, 0.21 mmol), boronic ester **17d** (63 mg, 0.20 mmol) and *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 97:3) the homologated boronic ester **18j** (20.8 mg, 31%) as a colourless oil.

Following **GP4**, methyl sulfoxide *anti*-**14b** (108 mg, 0.26 mmol), boronic ester **17d** (63 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.25 M in THF, 190 μ L, 0.24 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 97:3) the homologated boronic ester **18j** (49 mg, 73%) as a colourless oil.

$[\alpha]_D^{23}$: -95 (*c* 0.8, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 5.27 (t, *J* = 6.4 Hz, 1H, 2-H), 4.21 (d, *J* = 6.3 Hz, 2H, 1-H), 1.80 (q, *J* = 7.3 Hz, 1H, 5-H), 1.65 (s, 3H, CH₃), 1.22 (s, 12H, C-CH₃ x 4), 1.09 (d, *J* = 7.4 Hz, 3H, 6-H), 0.89 (s, 9H, Si-C-(CH₃)₃), 0.06 (s, 6H, Si-(CH₃)₂) ppm



¹³C NMR (CDCl₃, 101 MHz) δ : 139.2 (2-C), 122.7 (3-C), 83.1 (2C, B-O-C x 2), 60.6 (1-C), 26.0 (Si-C-CH₃)₃, 24.7 (2C, C-CH₃ x 2), 24.6 (2C, C-CH₃ x 2), 18.4 (Si-C), 16.7 (4-C), 14.1 (6-C), -5.0 (Si-CH₃)₂ ppm (carbon attached to boron not observed due to quadrupolar relaxation)


¹¹B NMR (CDCl₃, 128 MHz) δ : 32.8 ppm

IR (neat): 2956, 2929, 1462, 1347, 1317, 1253, 1144, 834, 774 cm⁻¹


HRMS (ESI) calculated for C₁₈H₃₇BNaO₃Si: 363.2501, found: 363.2512

Chiral GC: (Chiraldex β -DM column, injector T = 250 $^{\circ}$ C, detector T = 300 $^{\circ}$ C. Oven conditions: Inject at T = 70 $^{\circ}$ C for 3 min then ramp (1 $^{\circ}$ C min⁻¹) until 180 $^{\circ}$ C then hold for 5 min. He carrier gas at 1.0 mL min⁻¹. tR (minor) = 61.9 min, tR (major) = 62.5 min, total analysis time 120 min; e.r. = 99:1 (Li), e.r. >99:1 (Mg).





8.11 Preparation of (*R*)-2-(1-(4-methoxyphenyl)ethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**18k**)



Following **GP3**, methyl sulfoxide *ent-anti*-**14b** (87 mg, 0.21 mmol), 4-methoxyphenyl pinacol boronic ester (**17e**, 47 mg, 0.20 mmol), and *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) the homologated boronic ester **18k** (23.1 mg, 44%) as a colourless oil. A solution of MgBr₂•MeOH* (1.0 M, 300 μ L, 0.3 mmol) was added prior to warm the reaction mixture to 66 °C.

* 1.0 M MgBr₂•MeOH solution was prepared in advance by adding anhydrous MeOH to MgBr₂ solid. Reaction without addition of MgBr₂•MeOH gave the desired homologated alcohol in 56% yield but only 85:15 er due to reversible “ate” complex formation.²⁸

Following **GP4**, methyl sulfoxide *ent-anti*-**14b** (108 mg, 0.26 mmol), boronic ester **17e** (47 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.25 M in THF, 190 μ L, 0.24 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) the homologated boronic ester **18k** (37 mg, 71%) as a colourless oil.

Spectral data matched that previously reported.²⁹

[α]²³_D: -10 (*c* 0.1, CHCl₃). Lit. for (*R*)³⁰: -120.3 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.14 (d, *J* = 8.6 Hz, 2H, Ar-H), 6.82 (d, *J* = 8.6 Hz, 2H, Ar-H), 3.78 (s, 3H, O-CH₃), 2.38 (q, *J* = 7.6 Hz, 1H, CH-CH₃), 1.30 (d, *J* = 7.5 Hz, 3H, CH-CH₃), 1.22 (s, 6H, C-CH₃ x 2), 1.20 (s, 6H, C-CH₃ x 2) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 157.2 (Ar-C), 137.0 (Ar-C), 128.6 (Ar-C x 2), 113.7 (Ar-C x 2), 83.2 (2C, B-O-C x 2), 55.2 (O-CH₃), 24.6 (2C, C-CH₃ x 2), 24.6 (2C, C-CH₃ x 2), 17.3 (CH-CH₃) ppm (carbon attached to boron not observed due to quadrupolar relaxation)

¹¹B NMR (CDCl₃, 128 MHz) δ : 32.8 ppm


IR (neat): 2977, 1509, 1353, 1318, 1242, 1141, 1038, 845, 828 cm⁻¹

HRMS (ESI) calculated for C₁₅H₂₄BO₃: 263.1816, found: 263.1822

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 99:1, 0.7 mL/min, room temperature, 210.8 nm): t_R = 34.5 minutes (major), 36.0 minutes (minor), e.r. = 99:1 (Li), e.r. = 97:3 (Mg)



8.12 Preparation of (*tert*-butyl(((2*R*,4*R*,6*R*)-2,4-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)heptyl)oxy)diphenylsilane (**181**)



181

Following **GP3**, methyl sulfoxide *syn*-**14b** (87.1 mg, 0.21 mmol), boronic ester **17f** (96 mg, 0.20 mmol) and *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol) afforded after purification by flash column chromatography (hexane:dichloromethane = 100:0 \rightarrow 80:20) the homologated boronic ester **181** (86 mg, 85%, >95:5 d.r.) as a colourless oil.

Following **GP4**, methyl sulfoxide *syn*-**14b** (108 mg, 0.26 mmol), boronic ester **17f** (96 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.14 M in THF, 210 μ L, 0.24 mmol) afforded after purification by flash column chromatography (hexane:dichloromethane = 100:0 \rightarrow 80:20) the homologated boronic ester **181** (34 mg, 33%, >95:5 d.r.) as a colourless oil.

$[\alpha]_D^{23}$: +10 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.66 (d, *J* = 7.8 Hz, 4H, Ar-H), 7.44–7.34 (m, 6 H, Ar-H), 3.53 (dd, *J*₁ = 9.6 Hz, *J*₂ = 5.1 Hz, 1H, CHH) 3.36 (dd, *J*₁ = 9.6 Hz, *J*₂ = 7.0 Hz, 1H, CHH), 1.77 (dq, *J*₁ = 7.0 Hz, *J*₂ = 6.7 Hz, 1H, CH), 1.56–1.45 (m, 1H, CH), 1.33–1.12 (m, 15H, CHH, CH₂ and 4 \times CH₃), 1.08 (m, 1H, CH), 1.05 (s, 9H, 3 \times CH₃), 0.93 (d, *J* = 6.7 Hz, 3H, CH₃), 0.92 (m, 1H, CHH), 0.90 (d, *J* = 7.5 Hz, 3H, CH₃), 0.78 (d, *J* = 6.6 Hz, 3H, CH₃) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 135.8 (4 \times CH), 134.3 (2 \times C), 129.6 (2 \times CH), 127.7 (4 \times CH), 82.9 (2 \times C), 69.2 (CH₂), 41.9 (CH₂), 40.0 (CH₂), 33.3 (CH), 28.5 (CH), 27.0 (3 \times CH₃), 24.9 (4 \times CH₃), 20.0 (CH₃), 19.5 (CH), 18.0 (CH₃), 15.2 (CH₃) ppm (carbon attached to boron not observed due to quadrupolar relaxation)

¹¹B NMR (CDCl₃, 128 MHz) δ : 35.9 ppm

IR (neat): 2955, 2929, 1427, 1378, 1143, 1110, 823, 739 cm⁻¹

HRMS (ESI) calculated for C₃₁H₄₉BNaO₃Si: 531.3442, found: 531.3442

8.13 Preparation (*R*)-1-cyclohexylethanol (**18n**)



Following **GP3**, methyl sulfoxide *ent-anti-14b* (87.1 mg, 0.21 mmol), pinacol boronic ester **17g** (42 mg, 0.20 mmol), *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol), afforded a crude mixture. Following **GP8**, oxidation of the mixture using NaBO₃·4H₂O (308 mg, 2.00 mmol) afforded after purification by flash column chromatography (pentane:dichloromethane = 100:0 \rightarrow 30:70) a mixture of the alcohol **18n** and 2,4,6-triisopropylbenzoic acid. The residue was dissolved in Et₂O (ca. 5 mL) and filtered through a pad of basic silica (~20 mm depth, contents of flask washed with Et₂O ca. 30 mL) and the solvent was removed under reduced pressure to give alcohol **18n** (15.2 mg, 59%) as a colourless oil.

Following **GP4**, methyl sulfoxide *ent-anti-14b* (108 mg, 0.26 mmol), pinacol boronic ester **17g** (42 mg, 0.20 mmol) and *i*PrMgCl·LiCl (1.14 M in THF, 210 μ L, 0.24 mmol) afforded a crude mixture. Following **GP8**, oxidation of the mixture using NaBO₃·4H₂O (308 mg, 2.00 mmol) afforded after purification by flash column chromatography (pentane:dichloromethane = 100:0 \rightarrow 30:70) a mixture of the alcohol **18n** and 2,4,6-triisopropylbenzoic acid. The residue was dissolved in Et₂O (ca. 5 mL) and filtered through a pad of basic silica (~20 mm depth, contents of flask washed with Et₂O ca. 30 mL) and the solvent was removed under reduced pressure to give alcohol **18n** (9.3 mg, 36%) as a colourless oil.

Following **GP3**, methyl sulfoxide *ent-anti-14b* (87.1 mg, 0.21 mmol), neopentyl boronic ester **17h** (38 mg, 0.20 mmol), *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol), afforded a crude mixture. Following **GP8**, oxidation of the mixture using NaBO₃•4H₂O (308 mg, 2.00 mmol) afforded after purification by flash column chromatography (pentane:dichloromethane = 100:0 \rightarrow 30:70) a mixture of the alcohol **18n** and 2,4,6-triisopropylbenzoic acid. The residue was dissolved in Et₂O (ca. 5 mL) and filtered through a pad of basic silica (~20 mm depth, contents of flask washed with Et₂O ca. 30 mL) and the solvent was removed under reduced pressure to give alcohol **18n** (9.2 mg, 36%) as a colourless oil.

Following **GP4**, methyl sulfoxide *ent-anti-14b* (108 mg, 0.26 mmol), neopentyl boronic ester **17h** (38 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.14 M in THF, 210 μ L, 0.24 mmol) afforded a crude mixture. Following **GP8**, oxidation of the mixture using NaBO₃•4H₂O (308 mg, 2.00 mmol) afforded after purification by flash column chromatography (pentane:dichloromethane = 100:0 \rightarrow 30:70) a mixture of the alcohol **18n** and 2,4,6-triisopropylbenzoic acid. The residue was dissolved in Et₂O (ca. 5 mL) and filtered through a pad of basic silica (~20 mm depth, contents of flask washed with Et₂O ca. 30 mL) and the solvent was removed under reduced pressure to give alcohol **18n** (12.4 mg, 48%) as a colourless oil.

Spectral data matched that previously reported.³¹

[α]_D²⁴: -1.8 (c 0.4, CHCl₃). Lit.:³¹ -3.8 (c 1.2, CHCl₃, 87% ee)


¹H NMR (400 MHz, CDCl₃): δ 3.55 (p, *J* = 6.2 Hz, 1H, CH), 1.85 (app. br. d, *J* = 13.0 Hz, 1H, CHH), 1.80–1.72 (m, 2H, CH₂), 1.67 (app. br. d, *J* = 13.0 Hz, 2H, 2 \times CHH), 1.48 (br. s, 1H, OH), 1.33–1.17 (m, 4H, CH, CH₂ and CHH), 1.16 (d, *J* = 6.2, 3H, CH₃), 1.07–0.90 (m, 2H, CHH) ppm

¹³C NMR (101 MHz, CDCl₃): 72.4 (CH), 45.3 (CH), 28.9 (CH₂), 28.5 (CH₂), 26.7 (CH₂), 26.4 (CH₂), 26.3 (CH₂), 20.6 (CH₃) ppm


IR (neat): 3362 (br.), 2922, 2852, 1702, 1448, 1062, 938 cm⁻¹

GC-MS (EI) calculated for C₈H₁₆O: 128.1, found 128.0


Chiral GC: Chiraldex β -DP, injector T = 250 °C, detector T = 300 °C. Oven conditions: Inject at T = 70 °C then ramp (10 °C min⁻¹) until 87 °C, then ramp (1 °C min⁻¹) until 102 °C, and ramp (10 °C min⁻¹) until 180 °C. He carrier gas at 3.0 mL min⁻¹. tR (minor) = 15.3 min, tR (major) = 16.4 min, total analysis time 28 min; e.r. = 99:1 (Bpin, Li), e.r. >99:1 (Bpin, Mg), e.r. = 98:2 (Bneo, Li), e.r. >99:1 (Bneo, Mg) .




#	Time	Area	Height	Width	Symmetry
1	15.322	241.2	19.9	0.2023	0.264
2	16.418	252.8	16.7	0.2525	0.172




#	Time	Area	Height	Width	Symmetry
1	15.527	6	5.3E-1	0.1881	0.35
2	16.324	425.7	25.5	0.2782	0.114



#	Time	Area	Height	Width	Symmetry
1	15.59	1.4	1.4E-1	0.1655	0.671
2	16.405	263.4	17.8	0.2526	0.162




#	Time	Area	Height	Width	Symmetry
1	15.444	18.6	1.9	0.1671	0.318
2	16.166	945.5	45.3	0.3482	0.115



#	Time	Area	Height	Width	Symmetry
1	15.516	4.9	4.2E-1	0.1969	0.274
2	16.265	605	32.8	0.3077	0.117

8.14 Preparation of (*S*)-2-(4-(4-methoxyphenyl)-1-phenylbutan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**18p**) and (*S*)-4-(4-methoxyphenyl)-1-phenylbutan-2-ol (**31**)



Following **GP3**, benzyl sulfoxide *anti*-**14h** (108 mg, 0.22 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol), filtered through basic silica, afforded after purification by flash column chromatography (pentane:Et₂O = 95:5) the homologated boronic ester **18p** (58 mg, 79%) as a colourless oil.

Following **GP4**, benzyl sulfoxide *anti*-**14h** (128 mg, 0.26 mmol), boronic ester **17a** (52.4 mg, 0.2 mmol) and *i*PrMgCl•LiCl (1.14 M in THF, 210 μ L, 0.24 mmol), filtered through basic silica, afforded after purification by flash column chromatography (pentane:Et₂O = 95:5) a mixture of the homologated boronic ester **18p** and starting boronic ester **17a**. Following **GP8**, oxidation of the mixture using NaBO₃•4H₂O (308 mg, 2.00 mmol), afforded after purification by flash column chromatography (pentane:EtOAc = 80:20) the corresponding alcohol **31** (33 mg, 58%) as a colourless oil.

$[\alpha]_D^{24}$: -31 (*c* 0.9, CHCl₃)


¹H NMR (400 MHz, CDCl₃): δ 7.26–7.17 (m, 4H, Ar-H), 7.14 (app. tt, 1H, $J_1 = 6.9$ Hz, $J_2 = 2.6$ Hz, Ar-H), 7.07 (d, $J = 8.5$ Hz, 2H, Ar-H), 6.82 (d, $J = 8.5$ Hz, 2H, Ar-H), 3.78 (s, 3H, OCH₃), 2.78–2.68 (m, 2H, CH₂), 2.65–2.50 (m, 2H, CH₂), 1.78–1.61 (m, 2H, CH₂), 1.44 (quint, $J = 6.0$ Hz, 1H, CH), 1.18 (s, 6H, CH₃ × 2), 1.15 (s, 6H, CH₃ × 2) ppm

¹³C NMR (101 MHz, CDCl₃): 157.5 (C), 141.9 (C), 134.7 (C), 129.1 (2 × CH), 128.7 (2 × CH), 127.9 (2 × CH), 125.4 (CH), 113.5 (2 × CH), 82.9 (2 × C), 55.1 (CH₃), 37.0 (CH₂), 34.4 (CH₂), 33.2 (CH₂), 25.4 (CH), 24.7 (2 × CH₃), 24.6 (2 × CH₃) ppm

¹¹B NMR (96 MHz, CDCl₃): 32.9 ppm

IR (neat): 2977, 2924, 1511, 1370, 1244, 1143, 1037 cm⁻¹

HRMS (ESI) calculated for C₂₃H₃₁BO₃Na: 389.2263, found 389.2264



$[\alpha]_D^{24}$: -17 (*c* 1.0, CHCl₃)


¹H NMR (400 MHz, CDCl₃): δ 7.34–7.29 (m, 2H, Ar-H), 7.27–7.18 (m, 3H, Ar-H), 7.12 (d, $J = 8.3$ Hz, 2H, Ar-H), 6.84 (d, $J = 8.3$ Hz, 2H, Ar-H), 3.84 (app. sept, $J = 4.2$ Hz, 1H, CH), 3.79 (s, 3H, OCH₃), 2.85 (dd, $J_1 = 13.8$ Hz, $J_2 = 4.2$ Hz, 1H, CHH), 2.82–2.75 (m, 1H, CHH), 2.73–2.62 (m, 2H, 2 × CHH), 1.85–1.78 (m, 2H, CH₂), 1.57 (br. s, 1H, OH) ppm

¹³C NMR (101 MHz, CDCl₃): 157.9 (C), 138.5 (C), 134.2 (C), 129.6 (2 × CH), 129.5 (2 × CH), 128.7 (2 × CH), 126.6 (CH), 114.0 (2 × CH), 72.1 (CH), 55.4 (CH₃), 44.3 (CH₂), 38.8 (CH₂), 31.3 (CH₂) ppm

IR (neat): 3407 (br), 2933, 1511, 1243, 1034, 823 cm⁻¹

HRMS (ESI) calculated for C₁₇H₂₀O₂Na: 279.1356, found 279.1351

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm) with guard, hexane:isopropanol = 98:2, 0.5 mL/min, room temperature, 210.8 nm): t_R = 32.7 minutes (major), 42.4 minutes (minor), e.r. = 98:2 (Li), e.r. = 98:2 (Mg)




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	32.749	MM	10556.5	265	0.6638	49.814	0.566
2	42.424	MM	10635.3	209.5	0.8462	50.186	0.644

#	Time	Type	Area	Height	Width	Area%	Symmetry
1	32.641	MM	25797.6	629.7	0.6828	97.626	0.561
2	42.952	MM	627.2	13	0.8014	2.374	0.849

#	Time	Type	Area	Height	Width	Area%	Symmetry
1	33.247	MM	19965.9	468.4	0.7104	98.055	0.589
2	43.757	MM	396.1	7.1	0.9349	1.945	0.884

8.15 Preparation of (*R*)-2-(1-(4-bromophenyl)-4-(4-methoxyphenyl)butan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**18q**) and (*R*)-1-(4-bromophenyl)-4-(4-methoxyphenyl)butan-2-ol (**32**)



Following modified **GP3**, *p*-bromobenzyl sulfoxide *anti*-**14i** (125 mg, 0.22 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol), and *t*BuLi (1.7 M in pentane, 142 μ L, 0.24 mmol), filtered through basic silica, afforded after purification by flash column chromatography (pentane:Et₂O = 95:5) a mixture of the homologated boronic ester **18q** and starting boronic ester **17a**. Following **GP8**, oxidation of the mixture using NaBO₃·4H₂O (308 mg, 2.00 mmol), afforded after purification by flash column chromatography (pentane:EtOAc = 80:20) the alcohol **32** (24.0 mg, 36%) as a colourless solid.

Following **GP4**, *p*-bromobenzyl sulfoxide *anti*-**14i** (148 mg, 0.26 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *i*PrMgCl·LiCl (1.14 M in THF, 210 μ L, 0.24 mmol), filtered through basic silica, afforded after purification by flash column chromatography (pentane:Et₂O = 95:5) the homologated boronic ester **18q** (72.0 mg, 81%) as a colourless oil.

[α]_D²⁴: +15 (*c* 1.0, CHCl₃)


¹H NMR (400 MHz, CDCl₃): δ 7.35 (d, *J* = 8.3 Hz, 2H, ArH), 7.09–7.04 (m, 4H, ArH), 6.81 (d, *J* = 8.0 Hz, 2H, ArH), 3.78 (s, 3H, OCH₃), 2.74–2.47 (m, 4H, H), 1.78–1.58 (m, 2H, CH₂), 1.37 (quint, 1H, *J* = 7.5 Hz, CH), 1.19 (s, 6H, CH₃ × 2), 1.17 (s, 6H, CH₃ × 2) ppm

¹³C NMR (101 MHz, CDCl₃): 157.9 (C) 141.2 (C), 134.8 (C), 131.2 (2 × CH), 130.8 (2 × CH), 129.4 (2 × CH), 119.5 (C), 113.8 (2 × CH), 83.3 (2 × C), 55.4 (CH₃), 36.7 (CH₂), 34.6 (CH₂), 33.4 (CH₂), 25.5 (CH), 25.0 (2 × CH₃), 24.9 (2 × CH₃) ppm

¹¹B NMR (96 MHz, CDCl₃): 33.5 ppm

IR (neat): 2982, 2935, 1511, 1379, 1244, 1142, 824 cm⁻¹

HRMS (ESI) calculated for C₂₃H₃₀BBrO₃Na: 467.1368, found 467.1381



[α]_D²⁴: +20 (*c* 1.0, CHCl₃)

¹H NMR (400 MHz, CDCl₃): δ 7.42 (d, *J* = 8.2 Hz, 2H, Ar-H), 7.10 (d, *J* = 8.6 Hz, 2H, Ar-H), 7.08 (d, *J* = 8.2 Hz, 2H, Ar-H), 6.83 (d, *J* = 8.5 Hz, 2H, Ar-H), 3.83–3.76 (m, 1H, CH), 3.79 (s, 3H, OCH₃), 2.81–2.76 (m, 2H, 2 × CHH), 2.69–2.61 (m, 2H, 2 × CHH), 1.84–1.74 (m, 2H, CH₂), 1.46 (br. d, *J* = 3.6 Hz, 1H, OH)


¹³C NMR (101 MHz, CDCl₃): 158.0 (C), 137.6 (C), 133.9 (C), 129.6 (2 × CH), 131.7 (2 × CH), 131.3 (2 × CH), 129.4 (2 × CH), 120.5 (C) 114.0 (2 × CH), 71.9 (CH), 55.4 (CH₃), 43.6 (CH₂), 38.8 (CH₂), 31.3 (CH₂)

IR (neat): 3320, 2945, 1512, 1247, 1012, 802 cm⁻¹


HRMS (ESI) calculated for C₁₇H₁₉BrO₂Na: 357.0461, found 357.0456

M.P. 72–74 °C


Chiral HPLC: (Daicel Chiralcel-IB column (25 cm) with guard, hexane:isopropanol = 96:4, 1.0 mL/min, room temperature, 210.8 nm): t_R = 16.4 minutes (minor), 19.8 minutes (major), e.r. = 97:3 (Li), e.r. > 99:1 (Mg)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.445	BB	0.3317	4534.43652	210.19647	49.9442
2	19.768	VB	0.4021	4544.57178	175.48772	50.0558




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.241	VV	0.2975	320.99515	15.76789	3.2428
2	18.836	VV	0.3924	9577.67090	369.48154	96.7572



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.137	MM	0.2931	77.56490	4.41115	0.5705
2	19.275	MM	0.4509	1.35177e4	499.63275	99.4295

8.16 Preparation (*R*)-1-(4-methoxyphenyl)-6-(trimethylsilyl)hex-5-yn-3-ol (**18r**)



Following **GP3**, alkynyl sulfoxide *syn*-**14j** (112 mg, 0.22 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol), *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol), afforded after purification by flash column chromatography (pentane:Et₂O = 95:5) a mixture of the homologated boronic ester and starting boronic ester **17a**. Following **GP8**, oxidation of the mixture using NaBO₃•4H₂O (308 mg, 2.00 mmol) afforded after purification by flash column chromatography (pentane:EtOAc = 85:15) the alcohol **18r** (30.0 mg, 54%) as a colourless oil.

Following **GP4**, alkynyl sulfoxide *syn*-**14j** (133 mg, 0.26 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.14 M in THF, 210 μ L, 0.24 mmol) afforded after purification by flash column chromatography (pentane:Et₂O = 95:5) a mixture of the desired homologated boronic ester and starting boronic ester **17a**. Following **GP8**, oxidation of the mixture using NaBO₃•4H₂O (308 mg, 2.00 mmol) afforded after purification by flash column chromatography (pentane:EtOAc = 85:15) the alcohol **18r** (33.0 mg, 60%) as a colourless oil.

$[\alpha]_D^{24}$: +7 (*c* 1.0, CHCl₃)


¹H NMR (400 MHz, CDCl₃): δ 7.13 (d, *J* = 8.6 Hz, 2H, ArH), 6.84 (d, *J* = 8.6 Hz, 2H, ArH), 3.79 (s, 3H, OCH₃), 3.74 (app. br. quint, *J* = 6.0 Hz, 1H, CH), 2.74 (quint., *J* = 6.8 Hz, 1H, CHH), 2.64 (quint., *J* = 6.8 Hz, 1H, CHH), 2.47 (dd, *J*₁ = 17.1 Hz, *J*₂ = 4.8 Hz, 1H, CHH), 2.38 (dd, *J*₁ = 17.1 Hz, *J*₂ = 4.8 Hz, 1H, CHH), 2.00 (s, 1H, OH), 1.82 (dt, *J*₁ = 8.1 Hz, *J*₂ = 6.0 Hz, 2H, CH₂), 0.16 (s, 9H, Si(CH₃)₃) ppm

¹³C NMR (101 MHz, CDCl₃): 158.0 (C), 133.9 (C), 129.4 (2 \times CH), 114.0 (2 \times CH), 103.2 (C), 87.9 (C), 69.2 (CH), 55.4 (CH₃), 38.1 (CH₂), 31.1 (CH₂), 29.1 (CH₂), 0.2 (3 \times CH₃) ppm


IR (neat): 3389, 2954, 2173, 1512, 1246, 841 cm⁻¹

HRMS (ESI) calculated for C₁₆H₂₄O₂SiNa: 299.1546, found 299.1534

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm) with guard, hexane:isopropanol = 98:2, 0.5 mL/min, room temperature, 210.8 nm): t_R = 20.5 minutes (minor), 22.7 minutes (major), e.r. = 93:7 (Li), e.r. > 99:1 (Mg)



8.17 Preparation of (*R*)-6-chloro-1-(4-methoxyphenyl)hexan-3-ol (**18s**)



Following **GP3**, chloropropyl sulfoxide *anti*-**14k** (100 mg, 0.21 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol), *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol) and acetic acid (11 μ L), afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) a mixture of the desired homologated boronic ester and starting boronic ester **17a**. Following **GP7**, oxidation of the mixture using H₂O₂ (1 mL) afforded after purification by flash column chromatography (hexane:EtOAc = 80:20) the alcohol **18s** (20.3 mg, 42%) as a colourless solid.

Following **GP4**, chloropropyl sulfoxide *syn*-**14k** (124 mg, 0.26 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.14 M in THF, 210 μ L, 0.24 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) a mixture of the desired homologated boronic ester and starting boronic ester **17a**. Following **GP7**, oxidation of the mixture using H₂O₂ (1 mL) afforded after purification by flash column chromatography (hexane:EtOAc = 80:20) the alcohol **18s** (27.0 mg, 56%) as a colourless solid.

[α]²³_D: -8 (*c* 0.5, CHCl₃)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ : 7.12 (d, $J = 8.6$ Hz, 2H, Ar-H), 6.84 (d, $J = 8.6$ Hz, 2H, Ar-H), 3.79 (s, 3H, O- CH_3), 3.65 (m, 1H, 3-H), 3.57 (t, $J = 6.0$ Hz, 2H, 6-H), 2.73 (m, 1H, 1-H), 2.63 (m, 1H, 1-H), 1.96 (m, 1H, 5-H), 1.89–1.64 (m, 4H, 5-H + 2-H \times 2 + 4-H), 1.56 (m, 1H, 4-H), 1.48 (bs, 1H, OH) ppm


$^{13}\text{C NMR}$ (CDCl_3 , 101 MHz) δ : 157.8 (Ar-C), 133.8 (Ar-C), 129.3 (2C, Ar-C \times 2), 113.9 (2C, Ar-C \times 2), 70.7 (3-C), 55.3 (O- CH_3), 45.2 (6-C), 39.4 (2-C), 34.6 (4-C), 31.1 (1-C), 28.8 (5-C) ppm

IR (neat): 3675, 2988, 2972, 2901, 1394, 1074, 1066, 1057, 892, 879 cm^{-1}


HRMS (ESI) calculated for $\text{C}_{13}\text{H}_{19}\text{ClNaO}_2$: 265.0966, found: 265.0976

M.P. 37–39 $^\circ\text{C}$

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 95:5, 0.7 mL/min, room temperature, 210.8 nm): $t_R = 17.2$ minutes (major), 18.5 minutes (minor), e.r. = 98:2 (L), e.r. = 99:1 (M)



8.18 Preparation of (*R*)-6-azido-1-(4-methoxyphenyl)hexan-3-ol (**18t**)



Following **GP4**, sulfoxide *anti*-**14l** (59.6 mg, 0.120 mmol), boronic ester **17a** (22.0 mg, 0.084 mmol) and *i*PrMgCl•LiCl (1.2 M in THF, 90 μL , 0.110 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) a mixture of the desired homologated boronic ester and starting boronic ester **17a**. Following **GP8**, oxidation of the mixture using NaBO₃•4H₂O (146 mg, 0.950 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 80:20) the alcohol **18t** (11.7 mg, 56%) as a colourless oil.

$[\alpha]_D^{22}$: +16 (*c* 0.5, CHCl₃)


¹H NMR (CDCl₃, 400 MHz) δ : 7.12 (d, *J* = 8.6 Hz, 2H, Ar-H), 6.84 (d, *J* = 8.5 Hz, 2H, Ar-H), 3.79 (s, 3H, OCH₃), 3.64 (tt, *J*₁ = 8.9 Hz, *J*₂ = 4.8 Hz, 1H, CH), 3.31 (t, *J* = 6.7 Hz, 2H, CH₂), 2.73 (ddd, ²*J*₁ = 14.0 Hz, *J*₂ = 8.8 Hz, *J*₃ = 6.4 Hz, 1H, CH_{2a}), 2.63 (ddd, ²*J*₁ = 14.0 Hz, *J*₂ = 9.0 Hz, *J*₃ = 7.1 Hz, 1H, CH_{2b}), 1.83–1.46 (m, 6H, CH₂ × 3), 1.42 (br. s, 1H, OH) ppm

¹³C NMR (CDCl₃, 101 MHz) δ : 158.0 (Ar-C), 133.9 (Ar-C), 129.4 (2C, Ar-C), 114.0 (2C, Ar-C), 70.9 (CH), 55.4 (OCH₃), 51.7 (CH₂), 39.6 (CH₂), 34.7 (CH₂), 31.3 (CH₂), 25.3 (CH₂) ppm


IR (neat): 3446, 2918, 2097, 1512, 1246, 1036, 736 cm⁻¹

HRMS (ESI) calculated for C₁₃H₁₉N₃NaO₂: 272.1369, found: 272.1368

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 96:4, 0.8 mL/min, room temperature, 210.8 nm): tR = 18.8 minutes (minor), 20.6 minutes (major), e.r. > 99:1



8.19 Preparation of (R)-2-(1-(4-methoxyphenyl)pentan-3-yl)-4,4,5,5-tetramethyl-1,3-dioxaborolane (18u)



Following **GP3**, butyl sulfoxide *syn*-**14m** (95.5 mg, 0.21 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *t*BuLi (1.7 M in pentane, 235 μ L, 0.40 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 98:2) the homologated boronic ester **18u** (43.2 mg, 65%) as a colourless oil.

Following **GP4**, ethyl sulfoxide *syn*-**14m** (119 mg, 0.26 mmol), boronic ester **17a** (52.4 mg, 0.20 mmol) and *i*PrMgCl•LiCl (1.14 M in THF, 210 μ L, 0.24 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 98:2) the homologated boronic ester **18u** (46.2 mg, 70%) as a colourless oil.

$[\alpha]^{23}_D$: +6 (*c* 0.5, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ: 7.10 (dt, *J*₁ = 8.6 Hz, *J*₂ = 2.9 Hz, 2H, Ar-H), 6.81 (dt, *J*₁ = 8.6 Hz, *J*₂ = 2.9 Hz, 2H, Ar-H), 3.78 (s, 3H, O-CH₃), 2.61–2.48 (m, 2H, 1-H), 1.70 (m, 1H, 2-H), 1.62 (m, 1H, 2-H), 1.49–1.36 (m, 2H, 4-H), 1.32–1.23 (m, 4H, 5-H + 6-H), 1.26 (s, 12H, C-CH₃ × 4), 1.03 (m, 1H, 3-H), 0.88 (t, *J* = 7.0 Hz, 3H, 7-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ: 157.6 (Ar-C), 135.3 (Ar-C), 129.2 (2C, Ar-C × 2), 113.6 (2C, Ar-C × 2), 82.9 (2C, B-O-C × 2), 55.2 (O-CH₃), 34.7 (1-C), 33.8 (2-C), 31.5 (4-C), 30.9 (5-C), 24.9 (2C, C-CH₃ × 2), 24.8 (2C, C-CH₃ × 2), 23.0 (6-C), 14.1 (7-C) ppm (carbon attached to boron not observed due to quadrupolar relaxation)

¹¹B NMR (CDCl₃, 128 MHz) δ: 33.8 ppm


IR (neat): 2923, 2856, 1512, 1379, 1314, 1244, 1143, 1039, 967, 824 cm⁻¹

HRMS (ESI) calculated for C₂₀H₃₃BNaO₃: 355.241863, found: 355.242160


Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 95:5, 0.7 mL/min, room temperature, 210.8 nm): t_R = 11.4 minutes (minor), 12.6 minutes (major), e.r. = 97:3 (Li), e.r. = 98:2 (Mg)



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	11.372	SB	8426.9	611	0.2075	49.199	0.651
2	12.57	SVR	8701.2	553.2	0.2392	50.801	0.999




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.886	MM	133.7	9.7	0.2297	2.975	0.731
2	11.393	MM	4360.4	296.8	0.2468	97.025	0.697



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	10.648	MM	154.7	8.9	0.2906	1.937	1.111
2	11.595	MM	7831.9	531.7	0.2493	98.063	0.648

8.20 Preparation of ethyl (S)-9-(4-methoxyphenyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nonanate (18v)



Following **GP4**, ethyl sulfoxide *anti*-**14n** (70.6 mg, 0.13 mmol), boronic ester **17a** (26.2 mg, 0.10 mmol) and *i*PrMgCl•LiCl (1.14 M in THF, 105 μ L, 0.12 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 85:15) the homologated boronic ester **18v** (25.4 mg, 61%) as a colourless oil.

$[\alpha]_D^{23}$: -6 (*c* 0.8, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.08 (d, *J* = 8.6 Hz, 2H, Ar-H), 6.80 (d, *J* = 8.6 Hz, 2H, Ar-H), 4.10 (q, *J* = 7.1 Hz, 2H, 10-H), 3.77 (s, 3H, O-CH₃), 2.59–2.57 (m, 2H, 1-H), 2.26 (t, *J* = 7.5 Hz, 2H, 8-H), 1.74–1.66 (m, 1H, 2-H), 1.64–1.56 (m, 3H, 2-H + 7-H), 1.47–1.36 (m, 2H, 4-H), 1.31–1.21 (m, 19H, C-CH₃ \times 4, 5-H, 6-H, 11-H), 1.03 (m, 1H, 3-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 173.9 (CO), 157.6 (Ar-C), 135.1 (Ar-C), 129.2 (2C, Ar-C \times 2), 113.6 (2C, Ar-C \times 2), 82.9 (2C, B-O-C \times 2), 60.1 (10-C), 55.2 (O-CH₃), 34.7 (1-C), 34.3 (8-C), 33.7 (2-C), 31.0 (4-C), 29.4 (6-C), 28.8 (5-C), 24.9 (7-C), 24.8 (2C, C-CH₃ \times 2), 24.8 (2C, C-CH₃ \times 2), 14.2 (11-C) ppm (carbon attached to boron not observed due to quadrupolar relaxation)

¹¹B NMR (CDCl₃, 128 MHz) δ : 34.2 ppm


IR (neat): 2927, 1733, 1512, 1379, 1314, 1244, 1143, 1036, 967, 824 cm⁻¹

HRMS (ESI) calculated for C₂₄H₃₉BNaO₅: 441.278712, found: 441.279249

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 90:10, 0.7 mL/min, room temperature, 210.8 nm): t_R = 12.2 minutes (major), 13.8 minutes (minor), e.r. = 99:1




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	12.182	BB	3227.3	214.5	0.2508	48.898	0.722
2	13.817	BB	3372.8	188.2	0.2859	51.102	0.65



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	12.084	BB	8893.1	357.3	0.2412	98.548	0.611
2	13.974	BB	131.4	7.7	0.2415	1.456	0.769

8.21 Preparation of (*S*)-6,6,6-trifluoro-1-(4-methoxyphenyl)hexan-3-ol (**18w**)



Following **GP3**, sulfoxide *syn*-**14o** (62 mg, 0.12 mmol), boronic ester **17a** (31 mg, 0.12 mmol) and *t*BuLi (1.7 M in pentane, 141 μ L, 0.24 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) a mixture of the desired homologated boronic ester and starting boronic ester **17a**. Following **GP7**, oxidation of the mixture using H₂O₂ (1 mL) afforded after

purification by flash column chromatography (hexane:EtOAc = 80:20) the alcohol **18w** (11 mg, 35%) as a colourless solid.

Following **GP4**, sulfoxide *syn*-**14o** (79 mg, 0.16 mmol), boronic ester **17a** (32 mg, 0.12 mmol) and *i*PrMgCl•LiCl (1.3 M in THF, 100 μ L, 0.13 mmol) afforded after purification by flash column chromatography (hexane:Et₂O = 95:5) a mixture of the desired homologated boronic ester and starting boronic ester **17a**. Following **GP8**, oxidation of the mixture using NaBO₃•4H₂O (189 mg, 1.22 mmol) afforded after purification by flash column chromatography (hexane:EtOAc = 80:20) the alcohol **18w** (17 mg, 52%) as a colourless solid

$[\alpha]_D^{24}$: -11 (*c* 0.5, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.11 (d, *J* = 8.5 Hz, 2H, 4-H), 6.84 (d, *J* = 8.6 Hz, 2H, 3-H), 3.79 (s, 3H, 1-H), 3.66 (tt, *J*₁ = 8.4 Hz, *J*₂ = 4.3 Hz, 1H, 8-H), 2.73 (dt, *J*₁ = 15.0 Hz, *J*₂ = 7.6 Hz, 1H, 6-H_a), 2.64 (dt, *J*₁ = 13.8 Hz, *J*₂ = 7.9 Hz, 1H, 6-H_b), 2.40–2.24 (m, 1H, 10-H_a), 2.23–2.05 (m, 1H, 10-H_b), 1.82–1.71 (m, 3H, 7-H, 9-H_a), 1.65 (dddd, *J*₁ = 13.9 Hz, *J*₂ = 10.8 Hz, *J*₃ = 8.7 Hz, *J*₄ = 5.2 Hz, 1H, 9-H_b), 1.43 (br. s, 1H, OH) ppm

¹³C NMR (CDCl₃, 101 MHz) δ : 158.1 (2-C), 133.5 (5-C), 129.4 (2C, 4-C), 127.5 (q, ¹*J*_{CF} = 275.9 Hz, 11-C), 114.1 (2C, 4-C), 70.0 (8-C), 55.4 (1-C), 39.5 (7-C), 31.2 (6-C), 30.3 (q, ²*J*_{CF} = 29.1 Hz, 10-C), 29.7 (q, ¹*J*_{CF} = 2.5 Hz, 9-C) ppm


¹⁹F NMR (CDCl₃, 377 MHz) δ : -66.4 (t, *J* = 10.9 Hz, CF₃) ppm

IR (neat): 3415, 2936, 2846, 1512, 1246, 1135, 1034, 830 cm⁻¹


HRMS (EI) calculated for C₁₃H₁₇O₂F₃: 262.1175, found: 262.1184

M.P. 43–45 °C

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 98:2, 1.0 mL/min, room temperature, 210.8 nm): t_R = 15.6 minutes (major), 17.7 minutes (minor), e.r. = 99:1 (Li), e.r. > 99:1 (Mg)



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	15.603	PK	1550.8	76.3	0.3388	90.241	0.714
2	17.574	PK	1535.9	67.8	0.3777	49.759	0.709




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	15.589	PK	6540.6	325.7	0.3347	98.612	0.509
2	17.112	PK	52	4.5	0.3409	1.388	0.886



#	Time	Type	Area	Height	Width	Area%	Symmetry
1	12.534	MM	10141.3	474.5	0.3662	99.302	0.55
2	12.642	MM	71.3	4.2	0.285	0.698	0.871

8.22 Preparation of (S)-2-(4-(4-methoxyphenyl)-2-methyl-1-phenylbutan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (21a)



Following **GP6**, sulfoxide **20a** (195 mg, 0.39 mmol), boronic ester **17a** (78 mg, 0.30 mmol), *t*BuLi (1.6 M in pentane, 370 μ L, 0.60 mmol) and PMDTA (120 μ L, 0.60 mmol) afforded after purification by flash column chromatography (petroleum ether:EtOAc = 98:2 to 90:10) the desired homologated boronic ester **21a** (65 mg, 57%) as a colourless oil.

$[\alpha]^{22}_{\text{D}}$: +7 (*c* 1.0, CHCl₃)

¹H NMR (CDCl₃, 400 MHz) δ : 7.23–7.20 (m, 4H, 12-H and 13H), 7.18–7.14 (m, 1H, 14-H), 7.10 (d, *J* = 8.3 Hz, 2H, 4-H), 6.82 (d, *J* = 8.3 Hz, 2H, 3-H), 3.78 (s, 3H, 1-H), 2.84 (d, ²*J* = 13.1 Hz, 1H, 10-H_a), 2.63–2.53 (m, 3H, 10-H_b + 6-H), 1.75 (td, *J*_t = 12.5 Hz, *J*_d = 5.4 Hz, 1H, 7-H_a), 1.49 (td, *J*₁ = 12.5 Hz, *J*₂ = 5.7 Hz, 1H, 7-H_b), 1.26 (s, 6H, 16-H), 1.22 (s, 6H, 17-H), 0.98 (s, 3H, 9-H) ppm


¹³C NMR (CDCl₃, 101 MHz) δ : 157.7 (2-C), 140.1 (11-C), 135.7 (5-C), 130.5 (2C, 12-C), 129.3 (2C, 4-C), 127.8 (2C, 13-C), 125.9 (14-C), 113.9 (2C, 3-C), 83.4 (2C, 15-C), 55.4 (1-C), 44.9 (10-C), 42.1 (7-C), 31.8 (6-C), 25.3 (2C, 17-C), 25.0 (2C, 16-C), 21.4 (9-C) ppm (*carbon attached to boron (8-C) was not observed due to quadrupolar relaxation in ¹³C NMR but it correlates with 9-H at 26.9 ppm in HMBC*)

¹¹B NMR (CDCl₃, 128 MHz) δ : 32.1 ppm


IR (neat): 2976, 2929, 1511, 1310, 1244, 1038, 821, 703 cm⁻¹

HRMS (ESI) calculated for C₂₄H₃₃BNaO₃: 403.2419, found: 403.2414

Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 96:4, 0.9 mL/min, room temperature, 210.8 nm): tR = 12.2 minutes (minor), 12.8 minutes (major), e.r. = 97:3



8.23 Preparation of (*R*)-3-methyl-1-phenylhex-5-en-3-ol (**21b**)



Following **GP6**, sulfoxide **20b** (153 mg, 0.34 mmol), phenyl ethyl pinacol boronic ester **15** (60 mg, 0.26 mmol), *t*BuLi (1.6 M in pentane, 350 μ L, 0.59 mmol) and PMDTA (120 μ L, 0.59 mmol) afforded after purification by flash column chromatography (petroleum ether:EtOAc = 98:2 to 90:10) a mixture of the desired homologated boronic ester and the starting boronic ester **15**. Following **GP7**, oxidation of the mixture using H₂O₂ (1 mL) afforded after purification by flash column chromatography (hexane:EtOAc = 90:10 to 70:30) the alcohol **21b** (29 mg, 59%) as a colourless oil.

Spectral data matched that previously reported.³²

$[\alpha]_D^{25}$: +18 (*c* 0.8, CHCl₃) Lit. for (*R*):^{32a} +57 (*c* 1.0, CHCl₃, *er* 99:1); for (*S*):^{32b} -58 (*c* 1.0, CHCl₃, *er* 91:9)


¹H NMR (CDCl₃, 400 MHz) δ : 7.30–7.27 (m, 2H, 2-H), 7.21–7.16 (m, 3H, 1-H + 3-H), 5.89 (ddt, J_{trans} = 16.8 Hz, J_{cis} = 10.4 Hz, J = 7.5 Hz, 1H, 10-H), 5.19–5.13 (m, 2H, 11-H), 2.73–2.69 (m, 2H, 5-H), 2.30 (d, J = 7.5 Hz, 2H, 9-H), 1.80–1.76 (m, 2H, 6-H), 1.48 (br. s, 1H, OH), 1.26 (s, 3H, 8-H) ppm

¹³C NMR (CDCl₃, 101 MHz) δ : 142.7 (4-C), 133.9 (10-C), 128.6 (2C, 2-C), 128.5 (2C, 3-C), 125.9 (1-C), 119.1 (11-C), 72.2 (7-C), 46.6 (9-C), 43.9 (6-C), 30.4 (5-C), 26.9 (8-C) ppm

IR (neat): 3402, 2975, 2931, 1640, 1455, 915, 744 cm⁻¹

HRMS (ESI) calculated for C₁₃H₁₈NaO: 213.1250, found: 213.1255


Chiral HPLC: (Daicel Chiralcel-IB column (25 cm), hexane:isopropanol = 98:2, 0.7 mL/min, room temperature, 210.8 nm): t_R = 13.6 minutes (minor), 14.7 minutes (major), e.r. = 97:3




#	Time	Type	Area	Height	Width	Area%	Symmetry
1	13.766	VV R	6942	417.8	0.2507	50.133	0.69
2	14.994	VB	6905.3	386.5	0.271	49.867	0.706

#	Time	Type	Area	Height	Width	Area%	Symmetry
1	13.544	HM	276.9	17.9	0.2573	2.867	0.74
2	14.72	HM	31094.8	566.1	0.2975	97.333	0.793

8.24 Iterative homologation sequence



(2S, 3R, 4S)-3-Allyl-4-phenethylhept-6-en-2-ol (22)




1st homologation: According to **GP3** using allylic sulfonamide *syn-14f* (485 mg, 1.10 mmol), phenyl ethyl pinacol boronic ester **15** (233 mg, 1.00 mmol) and *t*-BuLi (1.7 M in pentane, 1.18 mL, 2.00 mmol). The resulting mixture was concentrated *in vacuo* and the residue was suspended in pentane:Et₂O = 95:5 (ca. 20 mL). The suspension was filtered (~ 6 cm depth of wetted silica), the silica was washed (180 mL, pentane:Et₂O = 95:5) and the filtrate was concentrated *in vacuo* to give the crude homologated boronic ester.

2nd homologation: The crude product from the first homologation was dissolved in toluene (4 mL) and transferred to an oven dried Schlenk tube. The solvent was removed *in vacuo* and the compound was dried on high vacuum for 1 h with stirring. The reaction was performed according to **GP3** using allylic sulfonamide *syn-14f* (485 mg, 1.10 mmol), the crude boronic ester obtained from the first homologation (assumed 1.00 mmol) and *t*-BuLi (1.7 M in pentane, 1.18 mL, 2.00 mmol). The resulting mixture was concentrated *in vacuo* and the residue was suspended in pentane:Et₂O = 95:5 (ca. 20 mL). The


suspension was filtered (~ 6 cm depth of wetted silica), the silica was washed (180 mL, pentane:Et₂O = 95:5) and the filtrate was concentrated *in vacuo* to give the crude homologated boronic ester.

3rd homologation (with sulfoxide): The crude product from the second homologation was divided into three batches (3 mL of a 9 mL solution in toluene was transferred to an oven dried Schlenk tube). The solvent was removed *in vacuo* and the compound was dried on high vacuum for 1 h with stirring. The reaction was performed according to modified **GP3** using methyl sulfoxide *syn-14b* (207 mg, 0.50 mmol), the crude boronic ester obtained from the second homologation (assumed 0.33 mmol), and *t*-BuLi (1.7 M in pentane, 583 μ L, 0.99 mmol). The resulting mixture was concentrated *in vacuo* and the residue was suspended in pentane:Et₂O = 95:5 (ca. 20 mL). The suspension was filtered (~ 6 cm depth of wetted silica), the silica was washed (180 mL, pentane:Et₂O = 95:5) and the filtrate was concentrated *in vacuo* to give crude boronic ester. Oxidation of the crude boronic ester was performed according to **GP8** using NaBO₃•4H₂O (508 mg, 3.30 mmol) for 3 h.



Purification by silica gel chromatography (58:35:5:2 hexane/toluene/diethyl ether/dichloromethane) gave **22** as a colourless oil (35.0 mg, 41% over 4 steps, d.r. >95:5).

3rd homologation (with stannane): The crude product from the second homologation was divided into three batches (3 mL of a 9 mL solution in toluene was transferred to an oven dried Schlenk tube). The solvent was removed *in vacuo* and the compound was dried on high vacuum for 1 h with stirring. The reaction was performed according to S. Balieu *et al.*³⁰ using (*S*)-stannane (*S*)-**3** (198 mg, 0.45 mmol), the crude boronic ester obtained from the second homologation (assumed 0.33 mmol), and *n*-BuLi (1.6 M in hexanes, 269 μ L, 0.43 mmol) in Et₂O (2.5 mL). The reaction mixture was filtered through silica (~10 mm depth of wetted (Et₂O) silica, using a filter frit connected directly to an oven dried receiving vessel) to give a pale yellow solution. The silica was washed with Et₂O (reagent grade, 20 mL) and the solvent was removed under reduced pressure to give the crude boronic ester. Oxidation of the crude boronic ester was performed according to **GP8** using NaBO₃•4H₂O (508 mg, 3.30 mmol) for 3 h.



Purification by silica gel chromatography (58:35:5:2 hexane/toluene/diethyl ether/dichloromethane) gave **22** as a colourless oil (44.0 mg, 52% over 4 steps, d.r. >95:5).

$[\alpha]^{22}_{\text{D}}$: -12 (c 1.0, CHCl₃)


R_f = 0.18 (55:35:5:5 hexane/toluene/diethyl ether/dichloromethane)

¹H NMR (400 MHz, CDCl₃): δ 7.32–7.25 (m, 2H, H-2), 7.21–7.15 (m, 3H, H-1 and H-3), 5.83–5.71 (m, 2H, H-9 and H-13), 5.08–4.95 (m, 4H, H-10 and H-14), 3.80 (app. sext, J = 6.2 Hz, 1H, H-15), 2.73 (ddd, J_1 = 13.8 Hz, J_2 = 10.0 Hz, J_3 = 4.9 Hz, 1H, H-5_a), 2.55 (ddd, J_1 = 13.8 Hz, J_2 = 9.4 Hz, J_3 = 7.2 Hz, 1H, H-5_b), 2.29–2.22 (m, 1H, H-8_a), 2.14–2.00 (3H, m, H-8_b and H-12), 1.86 (ddt, J_1 = 13.8 Hz, J_2 = 6.4 Hz, J_3 = 3.3 Hz, 1H, H-6_a), 1.81–1.73 (m, 1H, H-7), 1.58–1.52 (m, 1H, H-11), 1.48 (ddt, J_1 = 13.8 Hz, J_2 = 9.3 Hz, J_3 = 5.0 Hz, 1H, H-6_b), 1.14 (dd, J_1 = 6.2 Hz, J_2 = 0.8 Hz, 3H, H-16), 1.07 (d, J = 5.2 Hz, 1H, H-17) ppm


¹³C NMR (101 MHz, CDCl₃): 142.9 (C-4), 139.1 (C-13), 138.0 (C-9), 128.6 (2C, C-3 × 2), 128.5 (2C, C-2 × 2), 125.9 (C-1), 116.3 (C-10), 115.7 (C-14), 69.2 (C-15), 49.4 (C-11), 37.0 (C-7), 36.7 (C-8), 34.4 (C-5), 32.8 (C-6), 31.4 (C-12), 21.8 (C-16) ppm

IR (neat): 3397, 2920, 2851, 1455, 909 cm⁻¹

HRMS (ESI) calculated for C₁₈H₂₆ONa: 281.1876, found: 281.1865




(2*R*,4*R*,5*R*)-4-allyl-5-phenethyloct-7-en-2-ol 26



3rd and 4th homologation (with bromochloromethane and then *syn*-sulfoxide 14b): The crude product from the second homologation was divided into three batches (3 mL of a 9 mL solution in toluene was transferred to an oven dried Schlenk tube). The solvent was removed *in vacuo* and the compound was dried on high vacuum for 1 h with stirring. The reaction was performed according to S. Balieu *et al.*³⁰ using bromochloromethane (67 μ L, 0.99 mmol), crude boronic ester obtained from the second homologation (assumed 0.33 mmol), and *n*-BuLi (1.6 M in hexanes, 519 μ L, 0.83 mmol) in Et₂O (1.3 mL). The reaction mixture was filtered through silica (~10 mm depth of wetted (Et₂O) silica, using a filter frit connected directly to an oven dried receiving vessel) to give a pale yellow solution. The silica was washed with Et₂O (reagent grade, 20 mL) and the solvent was removed under reduced pressure to give the crude boronic ester.

The crude product from the homologation with bromochloromethane was dissolved in toluene (2 mL) and transferred to an oven dried Schlenk tube. The solvent was removed *in vacuo* and the compound was dried on high vacuum for 1 h with stirring. The reaction was performed according to **GP3** using methyl sulfoxide *syn*-**14b** (151 mg, 0.36 mmol), crude boronic ester obtained from the homologation with bromochloromethane (assumed 0.33 mmol) and *t*-BuLi (1.7 M in pentane, 389 μ L, 0.66 mmol). The resulting mixture was concentrated *in vacuo* and the residue was suspended in pentane:Et₂O = 95:5 (ca. 20 mL). The suspension was filtered (~ 6 cm depth of wetted silica), the silica was washed (180 mL, pentane:Et₂O = 95:5) and the filtrate was concentrated *in vacuo* to give crude boronic ester. Oxidation of the crude boronic ester was performed according to **GP8** using NaBO₃·4H₂O (508 mg, 3.30 mmol) for 3 h.



Purification by silica gel chromatography (pentane/EtOAc 100:0 → 75:25) gave **26** as the major component of a mixture with under-homologation product (37 mg, 41% over 5 steps, ca. 90% purity). Further purification using reverse phase HPLC (acetonitrile:water = 60:40 → 85:15) gave **26** as a colourless oil (25 mg, 24% over 5 steps, d.r. >95:5).

$[\alpha]_D^{22}$: -9 (*c* 0.5, CHCl₃)

R_f = 0.13 (55:35:5:5 hexane/toluene/diethyl ether/dichloromethane)

¹H NMR (400 MHz, CDCl₃): δ 7.31–7.25 (m, 2H, ArH), 7.21–7.14 (m, 3H, ArH), 5.83–5.66 (m, 2H, CH₂=CH), 5.07–4.96 (m, 4H, CH=CH₂), 3.71 (app. sext, *J* = 6.1 Hz, 1H, CH), 2.72–2.63 (m, 1H, CHH), 2.60–2.50 (m, 1H, CHH), 2.19–2.06 (m, 3H, CH₂ and CHH), 1.90 (dt, *J*₁ = 14.0 Hz, *J*₂ = 8.0 Hz, 1H, CHH), 1.70 (app. br. p, *J* = 6.6 Hz, 1H, CH), 1.63–1.47 (m, 3H, CH₂ and CH), 1.42–1.26 (m, 2H, CH₂), 1.13 (d, *J* = 6.7 Hz, 1H, CH₃) ppm (*OH* not observed)


¹³C NMR (101 MHz, CDCl₃): 142.7 (C), 138.2 (2 × CH), 128.5 (4 × CH), 125.9 (CH), 116.1 (2 × CH₂), 66.4 (CH), 40.5 (CH₂), 39.1 (CH), 36.1 (CH), 35.5 (CH₂), 35.4 (CH₂), 34.4 (CH₂), 32.2 (CH₂), 24.0 (CH₃) ppm

IR (neat): 3351, 2923, 2858, 1453, 908 cm⁻¹

HRMS (ESI) calculated for C₁₉H₂₈ONa: 295.2032, found: 295.2034

9. Trapping Experiments

To a solution of *t*BuLi (2 equiv) in THF were added a solution of sulfoxide **14b** (1 equiv) in THF at -78 °C dropwise. After 30 min, the reaction was quenched with CD₃OD (2 equiv) and it was stirred 5 min at the same temperature. The mixture was warmed to rt and diluted with EtOAc. H₂O was added and the layers were separated. The organic layer was dried over MgSO₄ and all volatiles were removed under reduced pressure. After adding 1,3,5-trimethoxybenzene as an internal standard, the mixture was analyzed by ¹H NMR measurements. By ¹H NMR spectrum of the crude mixture, it is clear that the deuteriated *p*-tolyl *tert*-butyl sulfoxide is one of the by-products of the reaction (Figure S2).







Figure S2. ^1H NMR (400 MHz, CDCl_3)

10. Determination of Absolute Configuration of Benzoates

The stereochemistry of sulfoxide–ligand exchange is well established in literature.³³ While inversion of configuration at sulfur occurs with sulfoxide–ligand exchange,³⁴ generated metal carbenoids reacts with boronic esters with retention of configuration. When ethyl TIB ester **1** was lithiated with *s*BuLi in the presence of TMEDA and trapped with racemic methyl tolylsulfinate after lithium–magnesium exchange, all four stereoisomers were obtained (Figure S3, A). Replacing racemic methyl tolylsulfinate with enantiopure Andersen’s sulfinate gave two major stereoisomers of benzoate **14b** with *S*-configuration at the sulfur atom (B). On the other hand, enantioselective lithiation of ethyl TIB ester using (+)-sparteine and trapping with racemic methyl tolylsulfinate after lithium–magnesium exchange gave two major stereoisomers of benzoate **14b** with *R*-configuration at the carbon centre (C). The less polar compound on TLC was therefore identified as the *syn* diastereomer *syn*-**14b**, while the more polar compound was revealed to be the *anti* diastereomer *anti*-**14b**.


































Figure S3. (A): Reaction using TMEDA and methyl sulfinate; (B) reaction using TMEDA and Andersen's sulfinate (*S*)-**9**; (C): reaction using (+)-sparteine and methyl sulfinate.

The same experiment using (+)-sparteine was done starting from homoallylic benzoate **28** and the opposite enantiomer of Andersen's sulfinate *ent*-**9** to generate *syn*-**14f** as the major diastereomer (less polar) with only minor amount of *anti*-**14f** (more polar).


After comparison of the chemical shifts for the α -sulfinyl proton (¹H NMR) and α -sulfinyl carbon (¹³C NMR), the trends, as highlighted in Figure S4, have been used to assign the stereochemistry of sulfoxides **14a-o** as *syn* or *anti*.

<i>syn</i> -14 (less polar)		<i>anti</i> -14 (more polar)		<i>syn</i> -14 (less polar)		<i>anti</i> -14 (more polar)	
	α_{H} 5.64 ppm α_{C} 92.0 ppm		α_{H} 6.08 ppm α_{C} 87.8 ppm		α_{H} 5.92 ppm α_{C} N.D.		α_{H} 6.31 ppm α_{C} 87.9 ppm
	α_{H} 5.79 ppm α_{C} 89.0 ppm		α_{H} 6.07 ppm α_{C} 85.0 ppm		α_{H} 5.84 ppm α_{C} 90.3 ppm		α_{H} 6.06 ppm α_{C} 89.0 ppm
	α_{H} 5.62 ppm α_{C} 93.8 ppm		α_{H} 5.93 ppm α_{C} 89.9 ppm		α_{H} 5.68 ppm α_{C} -		α_{H} 6.02 ppm α_{C} 87.6 ppm
	α_{H} 5.72 ppm α_{C} 95.8 ppm		α_{H} 5.89 ppm α_{C} 94.5 ppm		α_{H} 5.67 ppm α_{C} 92.1 ppm		α_{H} 6.01 ppm α_{C} 87.8 ppm
	α_{H} 5.61 ppm α_{C} 98.6 ppm		α_{H} 5.66 ppm α_{C} 95.7 ppm		α_{H} 5.67 ppm α_{C} 92.5 ppm		α_{H} 6.00 ppm α_{C} 88.5 ppm
	α_{H} 5.75 ppm α_{C} 91.3 ppm		α_{H} 6.07 ppm α_{C} 87.2 ppm		α_{H} 5.66 ppm α_{C} 92.5 ppm		α_{H} 5.99 ppm α_{C} 88.7 ppm
	α_{H} 5.78 ppm α_{C} 92.5 ppm		α_{H} 6.09 ppm α_{C} 88.4 ppm		α_{H} 5.68 ppm α_{C} 90.7 ppm		α_{H} 6.03 ppm α_{C} N.D.

■ most down-field ■ most up-field

Figure S4. Correlation between the chemical shifts α -proton and carbon of sulfinyl benzoates and the relative configuration of compounds **14**

Furthermore, four known compounds have been synthesized and optical rotation of each compound was compared with the literature values.



$[\alpha]_{\text{D}}^{23}$: -19 (c 0.7, CHCl_3)
for (*R*): -8.2 (c 0.98, CHCl_3)¹⁷
for (*S*): +7.6 (c 1.7, CHCl_3)¹⁶

$[\alpha]_{\text{D}}^{23}$: -9 (c 0.7, CHCl_3)
for (*R*): -9.6 (c 1.05, CHCl_3)¹⁷
for (*S*): +9.4 (c 1.6, CHCl_3)¹⁶

$[\alpha]_{\text{D}}^{23}$: -16 (c 0.8, CHCl_3)
for (*R*): +0.12 (c 1.05, CHCl_3)¹⁶

$[\alpha]_{\text{D}}^{22}$: +18 (c 0.8, CHCl_3)
for (*R*): +57 (c 1, CHCl_3)^{18a}
for (*S*): -58 (c 1, CHCl_3)^{18b}


11. References

1. Burchat, A. F.; Chong, J. M.; Nielsen, N. *J. Organomet. Chem.* **1997**, *542*, 281–283.
2. Krasovskiy, A.; Knochel, P. *Synthesis* **2006**, 890–891.
3. Lujan-Montelongo, J. A.; Estevez, A. O.; Fleming, F. F. *Eur. J. Org. Chem.* **2015**, 1602–1605.
4. Hoang, C. T.; Alezra, V.; Guillot, R.; Kouklovsky, C. *Org. Lett.* **2007**, *9*, 2521–2524.
5. Yao, L.; Smith, B. T.; Aubé, J. *J. Org. Chem.* **2004**, *69*, 1720–1722.
6. Hartman, T.; Šturala, J.; Cibulka, R. *Adv. Synth. Catal.* **2015**, *357*, 3573–3586.
7. (a) Tsushima, T.; Kawada, K.; Ishihara, S.; Uchida, N.; Shiratori, O.; Higaki, J.; Hirata, M. *Tetrahedron* **1988**, *44*, 5375–5387; (b) Karra, S. R. Novel Indole Derivatives and Their Use in Neurodegenerative Diseases. US2016/168090, 2016.
8. Scharfbier, J.; Oestreich, M. *Synlett* **2016**, *27*, 1274–1276.
9. Dudley, G. B.; Takaki, K. S.; Cha, D. D.; Danheiser, R. L. *Org. Lett.* **2000**, *2*, 3407–3410.
10. Burns, M.; Essafi, S.; Bame, J. R.; Bull, S. P.; Webster, M. P.; Balieu, S.; Dale, J. W.; Butts, C. P.; Harvey, J. N.; Aggarwal, V. K. *Nature* **2014**, *513*, 183–188.
11. Roesner, S.; Blair, D. J.; Aggarwal, V. K. *Chem. Sci.* **2015**, *6*, 3718–3723.
12. Chen, J. L. Y.; Scott, H. K.; Hesse, M. J.; Willis, C. L.; Aggarwal, V. K. *J. Am. Chem. Soc.* **2013**, *135*, 5316–5319.
13. Varela, A.; Garve, L. K. B.; Leonori, D.; Aggarwal, V. K. *Angew. Chem. Int. Ed.* **2017**, *56*, 2127–2131.
14. Smith, J. R.; Collins, B. S. L.; Hesse, M. J.; Graham, M. A.; Myers, E. L.; Aggarwal, V. K. *J. Am. Chem. Soc.* **2017**, *139*, 9148–9151.
15. Lee, J. C.; Oh, Y. S.; Cho, S. H.; Lee, J. D. *Org. Prep. Proced. Int.* **1996**, *28*, 480–483.
16. Pulis, A. P.; Aggarwal, V. K. *J. Am. Chem. Soc.* **2012**, *134*, 7570–7574.
17. Liu, Y.; Zhou, Y.; Wang, H.; Qu, J. *RSC Advances* **2015**, *5*, 73705–73713.
18. Aichhorn, S.; Bigler, R.; Myers, E. L.; Aggarwal, V. K. *J. Am. Chem. Soc.* **2017**, ASAP, DOI: 10.1021/jacs.7b05880.
19. Hesse, M. J.; Butts, C. P.; Willis, C. L.; Aggarwal, V. K. *Angew. Chem. Int. Ed.* **2012**, *51*, 12444–12448.
20. Stymiest, J. L.; Bagutski, V.; French, R. M.; Aggarwal, V. K. *Nature* **2008**, *456*, 778–782.
21. Rasappan, R.; Aggarwal, V. K. *Nat Chem* **2014**, *6*, 810–814.
22. Blakemore, P. R.; Marsden, S. P.; Vater, H. D. *Org. Lett.* **2006**, *8*, 773–776.
23. Yamamoto, Y.; Fujikawa, R.; Umemoto, T.; Miyaura, N. *Tetrahedron* **2004**, *60*, 10695–10700.
24. Corey, E. J.; Chaykovsky, M. *J. Am. Chem. Soc.* **1965**, *87*, 1345–1353.
25. Larouche-Gauthier, R.; Elford, T. G.; Aggarwal, V. K. *J. Am. Chem. Soc.* **2011**, *133*, 16794–16797.
26. Sandford, C.; Rasappan, R.; Aggarwal, V. K. *J. Am. Chem. Soc.* **2015**, *137*, 10100–10103.


27. Srihari, P.; Hari Krishna, N.; Sridhar, Y.; Kamal, A. *Beilstein J. Org. Chem.* **2014**, *10*, 3122–3126.
28. Bagutski, V.; French, R. M.; Aggarwal, V. K. *Angew. Chem. Int. Ed.* **2010**, *49*, 5142–5145.
29. Brondani, P. B.; Dudek, H.; Reis, J. S.; Fraaije, M. W.; Andrade, L. H. *Tetrahedron: Asymmetry* **2012**, *23*, 703–708.
30. Balieu, S.; Hallett, G. E.; Burns, M.; Bootwicha, T.; Studley, J.; Aggarwal, V. K. *J. Am. Chem. Soc.* **2015**, *137*, 4398–4403.
31. Matsuo, J.-i.; Hattori, Y.; Ishibashi, H. *Org. Lett.* **2010**, *12*, 2294–2297.
32. (a) Pulis, A. P.; Blair, D. J.; Torres, E.; Aggarwal, V. K. *J. Am. Chem. Soc.* **2013**, *135*, 16054–16057; (b) Tietze, L. F.; Schiemann, K.; Wegner, C.; Wulff, C. *Chem. Eur. J.* **1998**, *4*, 1862–1869.
33. Rayner, P. J.; O'Brien, P.; Horan, R. A. *J. Am. Chem. Soc.* **2013**, *135*, 8071–8077.
34. Andersen, K. K. *Tetrahedron Lett.* **1962**, *3*, 93–95.

12. NMR Spectra


^1H NMR of **27** (400 MHz, CDCl_3)




^{13}C NMR of **27** (101 MHz, CDCl_3)




^1H NMR of **28** (400 MHz, CDCl_3)




^{13}C NMR of **28** (101 MHz, CDCl_3)





^1H NMR of **29** (400 MHz, CDCl_3)





^{13}C NMR of **29** (101 MHz, CDCl_3)




^1H NMR of **30** (400 MHz, CDCl_3)




^{13}C NMR of **30** (101 MHz, CDCl_3)




^1H NMR of **17b** (400 MHz, CDCl_3)




^{13}C NMR of **17b** (101 MHz, CDCl_3)




¹H NMR of **19** (400 MHz, CDCl₃)




¹³C NMR of **19** (101 MHz, CDCl₃)




^1H NMR of *syn*-**14a** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14a** (101 MHz, CDCl_3)




¹H NMR of *anti*-**14a** (400 MHz, CDCl₃)




¹³C NMR of *anti*-**14a** (101 MHz, CDCl₃)




^1H NMR of *syn*-**14b** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14b** (101 MHz, CDCl_3)




^1H NMR of *anti*-**14b** (400 MHz, CDCl_3)




^{13}C NMR of *anti*-**14b** (101 MHz, CDCl_3)



^1H NMR of *syn*-**14c** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14c** (101 MHz, CDCl_3)




^1H NMR of *anti*-**14c** (400 MHz, CDCl_3)




^{13}C NMR of *anti*-**14c** (101 MHz, CDCl_3)




^1H NMR of *syn*-**14d** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14d** (101 MHz, CDCl_3)




^1H NMR of *anti*-**14d** (400 MHz, CDCl_3)




^{13}C NMR of *anti*-**14d** (101 MHz, CDCl_3)




^1H NMR of *syn*-**14e** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14e** (101 MHz, CDCl_3)




^1H NMR of *anti*-**14e** (400 MHz, CDCl_3)




^{13}C NMR of *anti*-**14e** (101 MHz, CDCl_3)




^1H NMR of *syn*-**14f** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14f** (101 MHz, CDCl_3)




^1H NMR of *anti*-**14f** (400 MHz, CDCl_3)




^{13}C NMR of *anti*-**14f** (101 MHz, CDCl_3)




^1H NMR of *syn*-**14g** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14g** (101 MHz, CDCl_3)




^1H NMR of *anti*-**14g** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14g** (101 MHz, CDCl_3)




¹H NMR of *anti*-**14h** (400 MHz, CDCl₃)




¹³C NMR of *anti*-**14h** (101 MHz, CDCl₃)




¹H NMR of *anti*-**14i** (400 MHz, CDCl₃)




¹³C NMR of *anti*-**14i** (101 MHz, CDCl₃)




^1H NMR of *syn*-**14j** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14j** (101 MHz, CDCl_3)




¹H NMR of *anti*-**14j** (400 MHz, CDCl₃)




¹³C NMR of *anti*-**14j** (101 MHz, CDCl₃)




^1H NMR of *anti*-**14k** (400 MHz, CDCl_3)




^{13}C NMR of *anti*-**14k** (101 MHz, CDCl_3)




^1H NMR of *syn*-**14I** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14I** (101 MHz, CDCl_3)




^1H NMR of *anti*-**14I** (400 MHz, CDCl_3)




^{13}C NMR of *anti*-**14I** (101 MHz, CDCl_3)




^1H NMR of *syn*-**14m** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14m** (101 MHz, CDCl_3)




^1H NMR of *anti*-**14m** (400 MHz, CDCl_3)




^{13}C NMR of *anti*-**14m** (101 MHz, CDCl_3)




^1H NMR of *syn*-**14n** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14n** (101 MHz, CDCl_3)




^1H NMR of *anti*-**14n** (400 MHz, CDCl_3)




^{13}C NMR of *anti*-**14n** (101 MHz, CDCl_3)




^1H NMR of *syn*-**14o** (400 MHz, CDCl_3)




^{13}C NMR of *syn*-**14o** (101 MHz, CDCl_3)




¹H NMR of **20a** (400 MHz, CDCl₃)




¹³C NMR of **20a** (101 MHz, CDCl₃)




^1H NMR of **20b** (400 MHz, CDCl_3)




^{13}C NMR of **20b** (101 MHz, CDCl_3)




^1H NMR of **18a** (400 MHz, CDCl_3)




^{13}C NMR of **18a** (101 MHz, CDCl_3)




^1H NMR of **18b** (400 MHz, CDCl_3)




^{13}C NMR of **18b** (101 MHz, CDCl_3)




^1H NMR of **18c** (400 MHz, CDCl_3)




^{13}C NMR of **18c** (101 MHz, CDCl_3)




^1H NMR of **18d** (400 MHz, CDCl_3)




^{13}C NMR of **18d** (101 MHz, CDCl_3)




^1H NMR of **18e** (400 MHz, CDCl_3)




^{13}C NMR of **18e** (101 MHz, CDCl_3)




^1H NMR of **18f** (400 MHz, CDCl_3)




^{13}C NMR of **18f** (101 MHz, CDCl_3)




^1H NMR of **18g** (400 MHz, CDCl_3)




^{13}C NMR of **18g** (101 MHz, CDCl_3)




^1H NMR of **18h** (400 MHz, CDCl_3)




^{13}C NMR of **18h** (101 MHz, CDCl_3)




^1H NMR of **18i** (400 MHz, CDCl_3)




^{13}C NMR of **18i** (101 MHz, CDCl_3)




^1H NMR of **18j** (400 MHz, CDCl_3)




^{13}C NMR of **18j** (101 MHz, CDCl_3)




^1H NMR of **18k** (400 MHz, CDCl_3)




^{13}C NMR of **18k** (101 MHz, CDCl_3)




¹H NMR of **181** (400 MHz, CDCl₃)




¹³C NMR of **181** (101 MHz, CDCl₃)




^1H NMR of **18n** (400 MHz, CDCl_3)




^{13}C NMR of **18n** (101 MHz, CDCl_3)




^1H NMR of **18p** (400 MHz, CDCl_3)




^{13}C NMR of **18p** (101 MHz, CDCl_3)




¹H NMR of **31** (400 MHz, CDCl₃)




¹³C NMR of **31** (101 MHz, CDCl₃)




^1H NMR of **18q** (400 MHz, CDCl_3)




^{13}C NMR of **18q** (101 MHz, CDCl_3)




^1H NMR of **32** (400 MHz, CDCl_3)




^{13}C NMR of **32** (101 MHz, CDCl_3)




^1H NMR of **18r** (400 MHz, CDCl_3)




^{13}C NMR of **18r** (101 MHz, CDCl_3)




^1H NMR of **18s** (400 MHz, CDCl_3)




^{13}C NMR of **18s** (101 MHz, CDCl_3)




^1H NMR of **18t** (400 MHz, CDCl_3)




^{13}C NMR of **18t** (101 MHz, CDCl_3)




^1H NMR of **18u** (400 MHz, CDCl_3)




^{13}C NMR of **18u** (101 MHz, CDCl_3)




^1H NMR of **18v** (400 MHz, CDCl_3)




^{13}C NMR of **18v** (101 MHz, CDCl_3)




^1H NMR of **18w** (400 MHz, CDCl_3)




^{13}C NMR of **18w** (101 MHz, CDCl_3)




¹H NMR of **21a** (400 MHz, CDCl₃)




¹³C NMR of **21a** (101 MHz, CDCl₃)




^1H NMR of **21b** (400 MHz, CDCl_3)




^{13}C NMR of **21b** (101 MHz, CDCl_3)




^1H NMR of **22** (400 MHz, CDCl_3)



^{13}C NMR of **22** (101 MHz, CDCl_3)



^1H NMR of **26** (400 MHz, CDCl_3)



^{13}C NMR of **26** (101 MHz, CDCl_3)

